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Epithelial ovarian cancer (EOC) is one of the most common gynaecological 
cancers and is a leading cause of death in women worldwide.  The current 
detection and prognostication protocols generally involve measuring serum  
CA-125 levels which have met with limited success.  The identification of proteins 
released into the cyst fluid of EOC could provide the basis for the discovery of 
possible candidate protein markers with diagnostic and prognostic potentials.  
 
Using the proteomics-based methods including surface enhanced laser 
desorption/ionisation time of flight (SELDI-TOF), two dimensional gel 
electrophoresis (2-DE) and matrix-assisted laser desorption/ionisation time of 
flight mass spectrometry (MALDI TOF/MS), the differentially expressed 
haptoglobin and ceruloplasmin were identified in cyst fluid from malignant when 
compared with benign ovarian tumours.  Validation of these biomarkers using 
traditional immunologic methods including sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE), Western analysis, 
immunocapture proteinChip analysis, immunohistochemistry and enzyme linked 
immunosorbent assay (ELISA) proved the validity of the two proteins as potential 
biomarkers.  Diagnostic and prognostic significance of haptoglobin in serum as 
well as in cyst fluid from patients presenting with various stages of EOCs were 
evaluated.  Although the serum haptoglobin had limited roles in pre-operative 
diagnosis of this disease, the study did provide evidence that pre-operative 
serum haptoglobin could serve as an independent prognostic factor in patients 
presenting with EOC.  Our data indicated that elevated serum haptoglobin levels 




The potential application in clinics using cyst fluid haptoglobin levels as an intra-
operative diagnostic method was also tested.  It showed that haptoglobin had an 
enhanced predictive performance when combined with CA-125 and ultrasound 
parameters as a preliminary study using 47 benign and 43 malignant ovarian 
tumours giving 88.4% sensitivity and 91.5% specificity with a PPV of 90.5% and 
NPV of 89.6% for EOCs.  Such intra-operative cyst fluid determination of 
haptoglobin levels using a simple test kit with a specific cut-off value has potential 
clinical significance in that it could be performed as an adjunct to frozen section 
and be utilised to triage women requiring frozen section or sub-specialist consult, 
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Chapter 1: Introduction 
 
1.1 Overview  
 
1 in 75 women will develop ovarian carcinoma sometime during their lifetime 
(Holschneider et al., 2000).  Worldwide there are 204 449 new cases of ovarian 
cancer diagnosed annually, and an estimated 124 860 disease-related deaths 
(IARC, 2006).  Epithelial ovarian cancer is now the leading cause of 
gynaecological cancer-related deaths in the UK and the USA (Bristow et al., 
2006).  In Singapore, ovarian cancer is the most common gynaecological 
malignancy and the fourth most common female cancer (Figure 1.1).  The 
incidence of this cancer saw a sharp rise from 222 cases in 1968-1972 to 1055 
cases in 1998-2002 (Seow. et al., 2004).  The age-adjusted rate of incidence for 
ovarian cancer was 6.0/100,000 in 1968-1972 and rose to 11.0/100,000 (1998-
2000, Table 1.1).   
 
Despite the progress in cancer therapy, ovarian cancer mortality has remained 
virtually unchanged over the past two decades.  This is attributed to the 
difficulties in early diagnosis and therefore, ovarian cancer has the highest 
mortality rate of all the gynaecological cancers (Kristensen et al., 1997).  The 
overall survival rate of ovarian cancer is about 50% over a 5-year period, and this 
is largely dependent upon the stage of the disease at the time of diagnosis.  
However, early diagnosis of this cancer results in a 5-year survival rate of about 
80% (Kristensen et al., 1997).  Regular pelvic examinations and CA-125 
measurements followed by radiological diagnosis on an individualised basis have 
been the current practice for detection of this enigmatic condition.  However, 
neither an elevated serum CA-125 level, nor the presence of an ovarian cyst 
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identified by clinical examination and ultrasonography, accurately predicts the 
occurrence of an ovarian malignancy (van Nagell et al., 2000).   
 
Recent development in genomic and proteomic technology has made it possible 
to apply high throughput methods to detect alterations in gene and protein 
expression and their association with disease processes (Welsh et al., 2001; 
Zhang et al., 2004).  In this context, many polypeptides have been identified to be 
highly expressed in tumours with potential clinical utilities.  However, there is still 
a dearth of clinically useful markers for the diagnosis as well as prognostication of 
ovarian cancer.   
  
In this thesis, I explore the possibility of identifying differentially expressed protein 
biomarkers in ovarian cyst fluid using combined proteomics-based methods.  This 
fluid represents a source of potential significance in the identification of target 
markers since the protein composition changes occurring in EOC cells will be 
probably reflected in the cyst fluid.  The exploration of secretion and expression 
of these polypeptides may revolutionise the way of diagnosis and prognostication 

































Figure 1.1     Ten most frequent cancers in females in Singapore, 1998-2002. 
Adapted from Seow, (2004) 
 
 
Table 1.1     Incidence of ovarian cancer in Singapore, 1968-2002 
Adapted from Seow, (2004) 
Year No. Age-standardised rate (per 100,000/year) 
1968-1972 222 6.0 
1973-1977 263 6.3 
1978-1982 411 8.6 
1983-1987 497 8.8 
1988-1992 702 10.5 
1993-1997 880 11.4 

















The exact aetiopathogenesis of ovarian cancer remains poorly understood.  
Current research studies have focused on the reproductive, genetic and 
environmental influences in the carcinogenesis of this insidious disease.  
 
1.2.1.1 Reproductive and endocrine factors 
 
Increasing epidemiological studies have indicated that reproductive/hormonal 
milieu could be responsible for the high risk of ovarian cancer in postmenopausal 
women.  The levels of follicle-stimulating hormone (FSH) and luteinising hormone 
(LH) reach the highest level in menopausal period.  These gonadotropins 
together with other steroid hormones such as oestrogen, progesterone and 
androgen are believed to be involved in the ovarian tumourigenesis (Risch, 1998; 
Ho, 2003).  Oestrogen has long been regarded as a causative factor with its level 
in ovarian tissue being at least 100 times higher than that in blood.  It is 
envisaged that the high hormone levels could enable a direct genotoxic effect on 
ovarian surface epithelial (OSE) cells (Ho, 2003).  In addition to the genetic 
damage, studies showed that oestrogen might increase the risk of ovarian cancer 
by oestrogen receptor–mediated growth stimulatory responses due to the fact 
that expression of oestrogen receptor has been observed in both OSE and 
ovarian tumour cells (Karlan et al., 1995; Lau et al., 1999; Syed et al., 2001).  
Binding of oestrogen to the receptor could result in cellular proliferation which has 
been demonstrated in several oestrogen positive ovarian cancer cell lines 
(Langdon et al., 1994).  Administration of a competitive agent such as tamoxifen 
could significantly inhibit this growth stimulatory effect (Nash et al., 1989).  
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Moreover, numerous oestrogen-regulated proteins have been studied in the 
multiple carcinogenesis process of ovarian cancer.  These proteins such as cyclin 
D1, kallikreins and cathepsin-D are involved in cellular growth, motility and 
invasion of the malignant cells (Clinton et al., 1997; Rochefort et al., 2001).    
 
The so called “incessant ovulation” mechanism is considered to be another main 
aetiological factor for ovarian carcinogenesis, which was firstly introduced in 1971  
due to relatively high risk of ovarian cancer in nulliparous women (Fathalla, 1971).  
Most of ovarian cancers originate from OSE cells which cover the entire surface 
of ovary and present as a single layer of cuboidal, low columnar or flattened cells 
(Blaustein et al., 1979).  It was hypothesised that after repeated ovulation, the 
repairs of trauma in surface epithelium somehow resulted in aberrant proliferation 
and malignant transformation of the OSE cells.  This theory was also supported 
by the increased incidence of ovarian cancer in the patients subjected to 
hyperovulation by drugs (Fathalla, 1971) and protective effects of parity and oral 
contraceptive (Rodriguez et al., 1998).  Moreover, a study showed that there was 
a marked increase of the apoptotic epithelial cells after treatment with 
contraceptive in animal models (Rodriguez et al., 1998).  This finding suggested 
that oral contraceptive might prevent development of ovarian cancer by rendering 
the cells which are prone to be malignant to undergo apoptosis.   
 
1.2.1.2 Hereditary factors 
 
Although familial neoplasm only accounts for a small proportion of all ovarian 
cancers when compared with the sporadic form of the disease, a strong family 
history for malignancy indicates a genetic predisposition to ovarian cancer.  
Women with a first-degree relative with ovarian cancer may have as high as 50% 
chance of developing this familial disease compared to only 1.4% chance for 
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those without a family history (Schildkraut et al., 1988).  For patients with breast 
cancer, the relative risk of developing ovarian cancer varies from 0.6 to 6.1 
(Hildreth et al., 1981; Cramer et al., 1983a; Koch et al., 1988).  Inheritance of 
mutated tumour suppressive genes BRCA1 and BRCA2 is believed to have an 
important role in development of familial ovarian cancer.  Mutations such as point 
mutation, gene amplification and chromosomal translocation in these genes 
result in loss of function of tumour-suppressive abilities, which is considered as 
the first somatic genetic event driving the development of ovarian cancer 
(Auersperg et al., 1998).  The proteins encoded from these genes function in 
transcriptional activation and DNA repair, some of which are key regulators in 
maintaining the balance of cellular proliferation and apoptosis (Auersperg et al., 
1998).   
 
For sporadic ovarian cancer, which accounts for more than 95% of the cases, few 
mutations of BRCA1 and BRCA2 have been detected, indicating the presence of 
genetic changes in other oncogenes and tumour-suppressor genes (Gallion et al., 
1995).  Hence, substantial efforts have been directed to determine the altered 
region in genome and abnormal genes with lost functions based on mutation or 
differential expression study in tumour specimens.  More than 60 deregulated 
genes have been found in ovarian cancer including HER-2/neu, K-ras, c-myc with 
varying frequency (Aunoble et al., 2000), most of which encode proteins that are 
involved in growth stimulatory pathways in malignant as well as normal cells.  
Activation of these genes due to amplification or mutations has been regarded as 
a causative factor in the carcinogenesis of ovarian cancer.  For example, It was 
reported 32% of ovarian cancer overexpressed HER-2/neu, a gene which 
encodes cell membrane receptors involved in transmitting growth stimulatory 
signals when compared with normal ovary (Berchuck et al., 1990).   
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1.2.1.3 Environmental factors 
 
The relatively high incidence of ovarian cancer in industrialised countries 
suggests that environmental factors or diet may be involved in its aetiology.  
Excessive dietary intake of animal fat or red meat have been reported to increase 
the risk of EOC (Byers et al., 1983; Shu et al., 1989), while dietary fish and 
vegetables have been suggested to have a protective role (La Vecchia et al., 
1987; Shu et al., 1989).  The case-control study conducted in 1990 indicated a 
positive correlation of increasing consumption of milk with high risk of ovarian 
cancer (Mettlin et al., 1990).  Moreover, the reports on the association of mumps 
infection and risk of ovarian cancer have been conflicting.  Cramer and 
colleagues found an close relation between childhood mumps and subsequent 
ovarian cancer (Cramer et al., 1983b).  However, another group from Israel  
observed low titres mumps antibody in ovarian cancer patients indicating a weak 
aetiological association of this virus with this neoplasm (Menczer et al., 1979).  
 
1.2.2 Pathology classification 
 
Epithelial ovarian tumours account for approximately 60% of all ovarian tumours 
and their malignant forms account for more than 90% of all ovarian cancers 
(Russell, 1979).  According to histologic differentiation, the EOC is classified into 
four major groups: serous, mucinous, endometrioid and clear cell tumours.  The 
malignant tumours usually have the similar histologic architecture of the 
endocervix for mucinous cancer, the endometrium for endometrioid cancer and 
the fallopian tubes for serous cancer (Russell, 1979).  They are also classified as 
benign tumours, tumours of low malignant potential (LMP) and malignant tumours 
based on cytological features and clinical behaviour.  Tumours of low malignant 
potential are also named as borderline tumours.  This group of tumours is 
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characterised by the morphologic features intermediate between benign and 
malignant forms of ovarian tumours.  More than 70% of borderline tumours show 
localised disease at presentation which favours a better prognosis compared to 
malignant diseases.   
 
Serous cancers are the most common histologic type of ovarian malignancies, 
accounting for approximately 50% of all EOCs (Russell, 1979).  These tumours 
are usually bilateral and present as large, uni or multilocular cyst with the 
diameter greater than 5 cm in majority of cases.  Most tumours are partially cystic 
and partially solid.  The solid area with haemorrhage or necrosis is the general 
feature indicating malignant potential of the tumours.  Microscopically well-
differentiated serous cancer is characterised by presence of papillae covered with 
stratified epithelial cells. However, it is only focally present in poorly differentiated 
serous malignancies.  Borderline and malignant mucinous tumours represent the 
second most common type, accounting for 10% to 20% of all EOCs (Russell, 
1979).  They are usually large, cystic and multiloculated tumours with viscous 
mucin filled inside, the outer surface of which are generally smooth with 
occasional papillae projection, although some EOCs present as solid masses or 
predominantly solid tumours which disseminate widely throughout the peritoneal 
cavity.  Endometrioid cancer has the same histologic appearance as a typical 
endometrial cancer, accounting for 10% to 25% of all EOCs (Czernobilsky et al., 
1970).  Most endometrioid cancers are cystic, frequently with papillary structures 
filling the lumen.  Clear-cell cancer is the most chemoresistant type and accounts 
for about 5% of epithelial ovarian carcinoma (Kurman et al., 1972).  Most tumours 
are partially cystic.  Microscopically it is characterised by hobnail-shaped tumour 
cells with cleared-out cytoplasm (Kurman et al., 1972). 
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There are two important prognostic factors for ovarian cancer—stage and grade.  
The tumour stage describes how far the tumour has spread from where it starts in 
the ovary.  Staging is explained in detail by FIGO in 1985 (Gynecol Oncol, 1986; 
Table 1.2).  Clinical studies indicate that staging of ovarian cancer has significant 
impact on the survival of this disease.  The five-year survival rate shows a 
dramatic increase from 15 to 20% in late stage cancers to 90% for stage I 
patients (Young et al., 1990).  Histologic grade is also an important prognostic 
factor for ovarian cancer.  The grade is on a scale of 1, 2, or 3 representing well, 
moderate and poor differentiation respectively.  Grade 1 epithelial ovarian 
carcinomas more closely resemble normal ovarian tissue in contrast with those 
from grade 3.  Studies indicated that well-differentiated (G1) ovarian cancer tends 
to have a better prognosis compared to poorly-differentiated (G3) ones (Einhorn 


















Table 1.2     FIGO staging for primary carcinoma of the ovary 
 
Stage                                            Description 
I  Growth limited to the ovaries. 
IA Growth limited to one ovary; no ascites.  No tumour on the 
external surface; capsule intact. 
IB  Growth limited to both ovaries; no ascites.  No tumour on the 
external                       surface; capsule intact 
IC Tumour either Stage IA or IB but with tumour on surface of one or 
both ovaries; or with capsule ruptured; or with ascites present 
containing malignant cells or with positive peritoneal washings. 
II  Growth involving one or both ovaries with pelvic extension. 
 IIA Extension and/or metastases to the uterus and/or tubes. 
 IIB Extension to other pelvic tissues 
IIC Tumour either Stage IIA or IIB, but with tumour on surface of one 
or both ovaries; or with capsule ruptured; or with ascites present 
containing malignant cells or with positive peritoneal washings 
III Tumour involving one or both ovaries with peritoneal implants 
outside the pelvis and/or positive retroperitoneal or inguinal nodes.  
Superficial liver metastasis equals Stage III.  Tumour is limited to 
the true pelvis but with histologically proven malignant extension to 
small bowel or omentum. 
IIIA Tumour grossly limited to the true pelvis with negative nodes but 
with histologically confirmed microscopic seeding of abdominal 
peritoneal surfaces 
IIIB Tumour of one or both ovaries with histologically confirmed 
implants of abdominal peritoneal surfaces not exceeding 2 cm in 
diameter. Nodes are negative. 
IIIC Abdominal implants greater than 2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes.  
IV Growth involving one or both ovaries, with distant metastases.  If 
pleural effusion is present, there must be positive cytology to allot 




1.2.3 Pre-operative Diagnosis of EOCs 
 
A key challenge in cancer control and prevention is the detection of the disease 
at an early stage, which could result in effective intervention and contribute to 
reduction in mortality and morbidity.  Unfortunately, the early diagnosis of ovarian 
cancer is difficult because of the physically inaccessible location of the ovaries, 
the lack of specific symptoms in the early stage of disease, and the limited 
understanding of ovarian carcinogenesis (Cannistra, 2004).  Because currently 
available screening tests do not achieve high enough levels of sensitivity and 
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specificity to be useful for the detection of this low prevalent disease, screening is 
not recommended for the general population (Jacobs et al., 2004).   
 
1.2.3.1 Signs and symptoms 
 
The early diagnosis of ovarian cancers is difficult because symptoms arising from 
neoplasm are often absent or vague until the tumours become large and have 
metastasized.  Retrospective studies indicated that women with ovarian cancer 
presented with non-specific symptoms including pelvic or abdominal discomfort, 
urinary frequency, and alterations in gastrointestinal functions (Flam et al., 1988; 
Goff et al., 2000; Olson et al., 2001).  There are no specific symptoms indicating 
early stage of ovarian cancer and patients with non-specific symptoms are 
always misdiagnosed as diseases from other systems.  Ovarian tumours are 
usually palpable in pelvic examinations of postmenopausal women, while 
palpable tumours in premenarchal girls could indicate the presence of 
malignancy (Shankar et al., 2001).  
 
1.2.3.2 Blood testing 
 
Measurement of serum cancer antigen 125 (CA-125) levels in blood has been 
widely employed in the detection of ovarian cancer.  Concentrations of CA-125 
were elevated in approximately 80% of patients presenting with advanced 
ovarian cancer whereas only in 50% of patients presenting with stage I disease 
(Bast et al., 1985).  Moreover, elevated concentration of CA-125 was associated 
with various kinds of malignancies such as pancreas, breast and ovary cancers 
(Bast et al., 1983).  It was also observed to be elevated in benign conditions such 
as endometriosis and pelvic inflammatory disease (PID) (Daoud et al., 1991).  
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Despite the poor sensitivity and specificity, CA-125 is mainly useful in monitoring 
therapeutic effects and recurrence of this insidious disease (Jacobs et al., 1989).  
 
1.2.3.3 Ultrasonography evaluation 
 
Ultrasonography may be used to differentiate malignant from benign ovarian 
tumours. Malignant ovarian tumours are generally multiloculated and have more 
solid areas with thick septa.  Ascites and metastasis present in malignancies are 
also easily identified by ultrasound assessment.  Several attempts have been 
made to distinguish early stage ovarian cancers from questionable ovarian cyst 
accurately based on greyscale ultrasound and colour Doppler features (Kurjak et 
al., 1993; Fleischer et al., 1996).   
 
The risk of malignancy index (RMI) scoring systems was developed from a 
combination of ultrasound and CA-125 concentrations (Table 1.3).  It is the 
method of choice for predicting whether or not an ovarian mass is likely to be 
malignant.  There are three scoring systems, RMI1, RMI2 and RMI3 which are 
shown in Table 1.3 (Jacobs et al., 1990; Tingulstad et al., 1996; Tingulstad et al., 
1999).  The modified RMI 2 and RMI 3 scoring methods are more sensitive 
compared with RMI 1 method, resulting in a better sensitivity and specificity in 
diagnosis of ovarian malignancies (Tingulstad et al., 1996; Tingulstad et al., 1999; 










Table 1.3     The RMI scoring system 
 




• solid areas 
• bilateral lesions 
• ascites 
• metastases 
0 = none 
1 = one 
abnormality 
3 = two or more 
abnormalities 
1 = none or one 
4 = two or more 
abnormalities 
 
1 = none or one 











CA-125 U/ml U/ml U/ml 
 
 
1.2.4 Management of ovarian cancer patients 
 
In ovarian cancer, surgery usually involves total abdominal hysterectomy, 
bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic 
lymphadenectomy (Cannistra, 2004).  In borderline tumours, a fertility sparing 
approach can be used, particularly in patients who desire fertility preservation 
(Robinson et al., 1992).  Accurate differential diagnosis between malignant and 
benign ovarian tumours is therefore crucial, and has important implications for 
both the intra-operative and post-operative management of every case.  
Appropriate staging and surgery for all stages of EOC has been shown to have a 
direct impact on patient survival.  A population-based study done by Engelen et al 
(2006) showed that the risk of dying for patients who did not undergo appropriate 
surgery was twice the risk of those who underwent adequate and appropriate 
surgery.  However, definite histopathologic diagnosis is usually revealed at least 
a few days after surgical removal, using the standard technique of paraffin 
section.  As a result, inadequate surgical removal of the tumour and surrounding 
tissue is a potential problem in ovarian cancer patients.   
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1.2.5 Intra-operative diagnosis of EOCs 
 
Intra-operative diagnosis for the presence or absence of malignancy in an 
ovarian cyst is important in determining the choice and extent of surgical 
procedures.  Intra-operative suspicion of malignancy is particularly important in 
younger patients wanting to preserve fertility (Palomba et al., 2007), and in 
patients undergoing laparoscopic surgery for ovarian pathology (Chapron et al., 
1998).  An ovarian malignancy is unexpectedly encountered in up to one percent 
of cases undergoing laparoscopy (Wenzl et al., 1996; Muzii et al., 2005).  Neither 
an elevated serum CA-125 level, nor the presence of an ovarian cyst identified by 
clinical examination and ultrasonography, accurately predicts the occurrence of 
an ovarian malignancy (van Nagell et al., 2000).  Benign and malignant tumours 
cannot always be accurately and easily distinguished visually (Lim et al., 1997) 
and even the absence of solid areas or septae within ovarian cysts, and negative 
findings from intra-operative video-laparoscopic surveillance cannot entirely 
exclude the possibility of ovarian malignancy (Wenzl et al., 1996). 
 
Currently, frozen section examination of tumour tissue is the mainstay of intra-
operative diagnosis for the benignity or malignancy of an ovarian cyst.  The 
accuracy of frozen-section results is a determinant in the selection of the 
appropriate surgical procedure to prevent under- and over-treatment for ovarian 
cancer patients and provides important information on patient prognosis (Yeo et 
al., 1998).  Unfortunately, frozen section services are not universally and 
uniformly available. It requires a trained pathologist to be on site and on standby.  
Besides being expensive and resource intensive, many centres do not offer this 
service after office hours, while in many emerging economy countries most 
centres do not offer it at all.  Frozen section analysis is also limited by the 
selection of sampling location.  It is affected by the large size of some tumours, 
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the heterogeneous composition, and an often focal nature of the malignancy 
(Rose et al., 1994; Yeo et al., 1998; Pinto et al., 2001).  In comparison with other 
gynaecologic conditions, frozen section diagnosis of ovarian tumours has also 
been reported to be most problematic in terms of its accuracy, achieving a 
sensitivity of 85.7 %, specificity of 87.2 %, positive predictive value (PPV) of 89.4 
% and negative predictive value (NPV) of 82.9 % (Boriboonhirunsarn et al., 2004). 
Such levels of diagnostic accuracy fall short of the ideal in cancer diagnostics. An 
alternative method for intra-operative diagnosis, which is easier, cheaper, faster, 
and at least as accurate as frozen section would clearly be very useful. 
 
Identification of a specific protein biomarker within biological materials that can be 
obtained during surgery such as ovarian cyst fluid would be useful.  This may 
help to either diagnose or create a high level of suspicion for malignancy.  It could 
allow the development of a rapid intra-operative identification test for women with 














1.3 Biomarkers for ovarian cancer 
 
At present, there is a dearth of clinically useful markers for the diagnosis as well 
as prognostication of ovarian cancer.  The currently used serum marker CA-125 
has limited sensitivity and specificity for detecting small volume, early stage 
disease, with a PPV of less than 10% (Jacobs et al., 2004).  
 
The malignant transformation of a normal ovarian epithelial cell is caused by 
genetic alterations that disrupt the regulation of proliferation and apoptosis, in 
turn leading to altered protein expression and modification (Boyd et al., 1990; 
Weinberg, 1996).  Genetic alterations and changes in protein levels could prove 
to be vital for detection of subjects at risk of developing cancers as a normal cell 
progresses through the complex process of transformation to a cancerous state.  
The changes which occur exclusively in cancer but not in the surrounding non-
malignant cells, can be detected within the cancer cells and in the peripheral 
blood or body fluids (Srinivas et al., 2001) (Figure 1.2).  Such genetic and 
proteomic biomarkers can serve as molecular signposts of the pathophysiologic 
state of a cancer cell, as well as for the diagnosis, prognostication and 














Figure 1.2     Molecular marker detection from cancer cells  
Cancer cells may enter into blood and other body fluid as an epithelial tumour 
grows.  They may also secrete proteins directly into body fluids.  This makes it 
possible to detect genetic and protein biomarkers with diagnostic and prognostic 
potential for this cancers.  There are different types of biomarkers which could be 
detected.  DNA can be analysed for changes in gene copy number, mutation, 
loss of heterozygosity (LOH), microsatellite instability, and promoter 
hypermethylation.  RNA can be analysed for expression levels, and proteins can 










1.3.1 The genetic markers 
 
All cancers are genetic in origin, in the sense that the driving force of malignant 
transformation is genetic variation (Boyd et al., 1990; Weinberg, 1996).  The 
sequential mutations of cancer-related genes, with the subsequent selection and 
accumulation in a clonal population of cells, are the main factors determining 
whether a tumour develops and the time required for its development and 
progression (Boyd et al., 1990; Vogelstein et al., 1993).  The most compelling 
evidence is that for human epithelial tumours, the incidence rate increases at 
fourth to eighth power in an age-specific manner, suggesting the presence of four 
to eight rate-limiting genetic alteration process in the development of cancers 
(Renan, 1993).  
 
Genetic modifications, which are generally identified in early stages of cancers 
could lead to investigations on their role in the detection of human neoplasms.  
Identification of free circulating DNA provides the good source for searching 
genetic biomarkers for molecular diagnosis.  Free DNA was initially identified 50 
years ago in the serum or plasma from patients with cancers, and elevated levels 
of DNA were found in the serum of patients with metastatic diseases (Leon et al., 
1977; Shapiro et al., 1983).  The mechanism by which the DNA is released and 
survives in the circulation is not well understood.  Plasma or serum DNA from 
cancer patients is being used to detect suitable tumour markers such as 
oncogene mutations and hypermethylation of the promoter regions (Ramirez et 
al., 2003; Gautschi et al., 2007).  However, the specificity of serum or plasma 
DNA is not satisfactory since genetic changes of circulating DNA have also been 
observed in patients with other diseases (Lo et al., 2000; Chang et al., 2003).  
DNA can also be easily isolated from other body fluids such as saliva, urine and 
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stools, which could be useful in detecting specific tumour types (Lichtenstein et 
al., 2006; Quinque et al., 2006; Zou et al., 2006).  
 
1.3.1.1 Gene mutations 
 
Cancer-associated mutations were initially studied in solid tumours in the early 
1990s, when TP53 mutations were identified in the urine from patients presenting 
with bladder cancer (Sidransky et al., 1991) and ras mutations in the stools from 
patients with colorectal cancer (Sidransky et al., 1992).  This led researchers to 
search for other gene mutations that could be of use in cancer detection and 
prognostication.   
  
The breast cancer susceptibility genes BRCA1 and BRCA2 are the most 
important ones known to predispose ovarian cancer.  Various functions have 
been attributed to the BRCA tumour suppressor genes including regulation of cell 
cycle progression, induction of apoptosis, involvement in DNA repair and the 
maintenance of genomic integrity (Powell et al., 2003).  Mutations in BRCA genes 
cause a high lifetime risk of both breast and ovarian cancer; the risk of ovarian 
cancer in BRCA1 mutation carriers is 40% by age 70, with the corresponding risk 
in BRCA2 carriers being about 10%.  Mutations in these genes account for 5–
13% of ovarian cancer cases in Western countries (Takahashi et al., 1995; 
Stratton et al., 1997; Rubin et al., 1998; Risch et al., 2001).  Somatic mutations in 
BRCA1 are rarely identified in the sporadic tumours (Geisler et al., 2002).  On the 
other hand, decreased expression of BRCA1 in sporadic ovarian and breast 
tumours has been observed and may contribute to the pathophysiology of this 
disease (Russell et al., 2000; Zheng et al., 2000).  
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While there exists clear evidence of mutation associated tumour characteristics 
such as histology, grade and stage for breast cancer, reports on sporadic ovarian 
carcinomas are conflicting.  Some studies reported that papillary serous 
adenocarcinoma was the prominent BRCA1 mutation associated ovarian cancer 
type, while others report no such association (Chang et al., 1995; Rubin et al., 
1996; Johannsson et al., 1997; Pharoah et al., 1999; Chen et al., 2003; Lakhani 
et al., 2004).  There has been further suggestion that the BRCA1 status may 
influence patient survival (Rubin et al., 1996; Boyd et al., 2000; Cass et al., 2003).   
 
Another genetic lesion that has been implicated in the genesis and development 
of ovarian cancer involves p53 tumour suppressor gene.  The p53 gene located 
on chromosome 1; its various types of mutations have been observed in many 
human cancers (Soussi et al., 1994).  In ovarian cancer, it has been observed to 
be mutated in about 30—50% of the patients (Marks et al., 1991; Okamoto et al., 
1991; Tsao et al., 1991).  The translational product of the p53 gene is a nuclear 
phosphoprotein involved in the regulation of normal cellular growth and 
development.  The loss of normal p53 function, due to mutation, overexpression 
or deletion of the gene, is often associated with a malignant phenotype (Basset-
Seguin et al., 1993; Soussi et al., 1994).  It has been reported that P53 gene 
mutation is useful not only in detecting cancer, but also in monitoring therapeutic 
effects and determining disease prognosis (Laframboise et al., 2000; Havrilesky 
et al., 2003).   
 
1.3.1.2 Loss of heterozygosity (LOH) 
 
All cells contain two copies of autosomal genes inherited from each parent.  
According to Knudson’s ‘two kit’ theory, both alleles of a growth-regulatory 
‘tumour suppressor’ gene have to be altered either by mutation or deletion in 
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order to inactivate it (Knudson, 1971).  If a cell develops a mutation in one allele 
of a tumour-suppressor gene, loss of the remaining wild-type allele — LOH — 
can initiate tumourigenesis (Obata et al., 2000).  LOH can be detected by various 
PCR based approaches in most neoplasm including ovarian cancer.  For 
example, chromosomal 17 was subjected to LOH in 50% to 80% of all ovarian 
cancer (Presneau et al., 2005).  LOH was related with many tumour suppressive 
genes.  High frequency deletion on the short arm of chromosome 17 was often 
associated with TP53 mutation (Phillips et al., 1996).  Moreover, studies indicated 
that on 17q 78% of the deletion occurred at 17q 21 intragenic to BRCA1, 58% at 
17q11.2 including NF1, and 46% at a locus distal to BRCA1, suggesting that 
multiple tumour suppressor genes involved in ovarian cancer on 17q (Tangir et 
al., 1996).  The other well-established LOH studies on ovarian cancer included 
chromosome 5q and 18.  The analysis of 49 ovarian tumours for LOH on 
chromosome 5q showed 47% of them had loss at 5q13.1-21 region proximal to 
APC.  The losses were also observed in 33% of stage I tumours indicating 
involvement of genes within this region in the early carcinogenetic process of 
ovarian cancer (Tavassoli et al., 1996).  On chromosome 18, LOH and mRNA 
expression of the DCC gene have been examined in ovarian tumours.  It was 
envisaged that the significant loss or reduction of DCC expression in malignant 
tissues suggested a role for this tumour suppressor gene in tumour development 
(Enomoto et al., 1995).  Hence, the characteristic LOH are valuable clonal 
markers for ovarian cancer.  
 
1.3.1.3 DNA methylation 
 
Methylation status in promoter regions of cancer-related genes has been 
reported to be another type of biomarker (Esteller et al., 2002).  Loss of 
methylation in promoter region has two consequences in tumourigenesis.  Firstly, 
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a weakening of transcriptional repression in normally silent regions of the 
genome could result in overexpression of the potentially harmful viral genes and 
normally silenced genes (Walsh et al., 1998).  Secondly, losses of methylation 
would affect nuclear structures leading to chromosome instability in cancer.  
Specific PCR assay was developed to detect methylation status of cancers.  This 
assay could identify one cancer cell out of 1,000 normal cells and is sensitive 
enough to detect tumour DNA in most of the body fluid (Herman et al., 1996).   
 
On the other hand, hypermethylation of CpG islands in gene promoter regions is 
associated with aberrant silencing of transcription and regarded as a contributing 
factor in inactivation of tumour suppressor genes (Esteller et al., 2001).  Groups 
of hypermethylated genes have been reported to be associated with ovarian 
cancer.  For example, the hypermethylation profiles of several tumour suppressor 
and cancer-related genes (p16, RARbeta, E-cadherin, H-cadherin, APC et al.) in 
ovarian epithelial neoplasms were investigated with a view to better understand 
the role of epigenetic silencing in carcinogenesis (Makarla et al., 2005).  It was 
found that all of these genes were hypermethylated in invasive ovarian cancers at 
a frequency of 9% to 30%.  Three genes exhibited higher methylation frequencies 
in invasive tumours including RASSF1A (30%), H-cadherin (22%) and APC (22%) 
(Makarla et al., 2005).  The frequent occurrence of aberrant methylation in 
invasive epithelial ovarian carcinomas therefore suggests that an accumulation of 
events at specific genes may trigger malignant transformation of benign and 
borderline tumours.  Aberrant DNA methylation was also recognised as 
biomarkers in predicting disease free survival for ovarian cancer (Wei et al., 
2002).  Using specified microarray techniques, a panel of candidate methylated 
loci demonstrated the capability of predicting disease free survival with 95% 
accuracy (Wei et al., 2006).   
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1.3.1.4 Changes in gene expression 
 
The most common mechanisms for mutational activation of human oncogene are 
gene amplification, typically resulting in overexpression of otherwise normally 
expressed protein products.  On the other hand, the protein products of tumour 
suppressor genes functioning to inhibit cell proliferation are inactivated through 
loss-of-function mutations. 
 
cDNA microarray has been used as a tool to study the mRNA expression profile 
in tumours as well as in normal tissues.  A key emphasis in many of these studies 
has been the identification of gene products that could act as ovarian cancer 
specific biomarkers (Ismail et al., 2000; Wang et al., 2000; Welsh et al., 2001; 
Bonome et al., 2005).  Using Affymetrix, U95 A Chip containing 12,000 genes, 
Warrenfeltz S and coworkers have come up with a genetic profile of ovarian 
cancer which could serve as a useful prognostic tool (Warrenfeltz et al., 2004).  
The profile, consisting of 115 genes, was found from 68 patient samples 
presenting with advanced ovarian cancer.  The 115 genes were also biologically 
interesting, as many of the genes were previously shown to be involved in cancer 
growth, angiogenesis and many of them encode growth factors or their specific 
receptors.  Another interesting study was conducted by Wong and colleagues.  In 
their investigation, 30 differentially expressed genes in ovarian cancer were 
identified, among which osteopontin was detected as a putative biomarker (Wong 
et al., 2001).  In a follow-up study, osteopontin was shown to be elevated at the 
protein level in plasma of ovarian cancer patients (Kim et al., 2002) indicating a 





1.3.2 The protein markers 
 
Cancer, although often classified as a genetic abnormality, is in a functional 
sense, a proteomic disease (Bishop, 1995).  Genetic mutations can modify 
protein signalling pathways and thereby create a survival advantage for the 
cancer cells due to suppression of the inhibitory signals.  While studies involving 
genomics and mRNA expression will continue to contribute substantially to 
medicine, there are limits to the type and amount of information such 
investigations can provide.  Expression of mRNA and protein are not highly 
correlated by comparison of gene transcripts and the corresponding translational 
products (Celis et al., 2000; Steiner et al., 2000).  In addition to providing 
quantitative data, the proteomics technology can provide additional qualitative 
information which includes post-translational modification and protein-protein 
interaction.  
  
1.3.2.1 Protein markers in cyst fluid 
 
Calgranulins 
Calgranulins A and B, both low molecular weight proteins, were found to be 
overexpressed in the cyst fluid of malignant epithelial ovarian cysts (Ott et al., 
2003). These two proteins are members of the S100 Calcium-binding protein 
family. They function as inhibitors of casein kinases I and II that are essential for 
phosphorylation of various molecules necessary for normal transcription and 
translation. The amount of detectable calgranulins was also found to correlate 
with tumour progression, i.e. early-stage ovarian carcinomas express much less 
calgranulins than advanced carcinomas, based on differences in the intensity of 
spots corresponding to the calgranulins on two-dimensional gel electrophoresis 
(Ott et al, 2003). However, no published studies to date have quantitatively 
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studied the intracystic expression of calgranulins or looked at its accuracy and 
usefulness in diagnosing ovarian malignancy in the clinical setting. 
 
Growth factors and cytokines 
Vascular endothelial growth factor (VEGF) has also been reported to be 
significantly over-expressed (p<0.001) in cyst fluid of malignant epithelial ovarian 
cysts compared to benign ovarian cysts (Demirkiran et al., 2003).  VEGF is an 
important modulator of angiogenesis; it increases microvascular permeability and 
endothelial cell growth.  However, no statistically significant correlation between 
cyst fluid VEGF levels and cancer grade and stage has been reported (Boss et 
al., 2001).  Insulin-like growth factor-1 and IGF-binding protein-2, which are 
expected to have a mitogenic effect on the epithelial ovarian cancer cells, have 
also been found to be over-expressed in the cyst fluid of malignant ovarian cysts 
(Karasik et al., 1994). 
 
A number of cytokines have also been studied for their expression in cyst fluid. 
Tumour necrosis factor (TNF), interleukin-6 (IL-6) and interleukin-8 (IL-8) have all 
been shown to be elevated in the cyst fluid of malignant epithelial ovarian cysts 
(Darai et al., 2003).  The levels of IL-8 in malignant cyst fluid were, in a study, 
shown to be 13-fold higher than in benign cyst fluid (Ivarsson et al., 1998). IL-8 is 
known to influence proliferation and angiogenesis of several non-ovarian tumours. 
 
Soluble cell-cell adhesion molecules 
Adhesion molecules are important in carcinogenesis, as their abnormal 
expression by neoplastic cells may be an important determinant of local invasion 
and metastatic dissemination (Darai et al., 1998), A study by Sundfeldt et al 
showed, using an ELISA method, that there were significantly higher levels of the 
soluble form of the cellcell adhesion molecule E-cadherin in malignant ovarian 
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cyst fluid compared to fluid from benign ovarian cysts (Sundfeldt et al., 2001).  
This result was supported by another study done by Darai et al (1998), which 
also showed that soluble ICAM-1 and CD44 were elevated in the cyst fluid of 
borderline and malignant tumours compared with benign cystadenomas.  
Elevated concentrations of such cell-cell adhesion molecules in biological fluids in 
contact with neoplastic cells have also been found to be of diagnostic and 
prognostic use in cancers of the bladder (Jackson et al., 1993) and stomach 
(Matsuura et al., 1992). 
 
Gonadotropins 
Gonadotropins like follicular stimulating hormone (FSH) and luteal hormone (LH) 
were found to be highly expressed in the cyst fluid of malignant serous ovarian 
cysts, while they had very low expression or were absent in benign ovarian cysts 
(Kramer et al,1998, Chudecka-Glaz et al, 2003). Gonadotropins can stimulate 
ovarian cancer growth in cell cultures. Cell lines expressing gonadotropin 
receptors are also more resistant to chemotherapy (Chudecka-Glaz et al, 2003) 
 
Proteolytic enzymes 
For the dissemination of malignant cells and cancer progression, the dissolution 
of the basement membrane and the extracellular matrix surrounding the tumour 
is critical.  A study by Koivunen et al reported increased concentrations of a 
tumour associated trypsinogen isoenzyme (TAT-2; a 28 kDa protein as 
determined by SDSPAGE) in the cyst fluid of malignant serous and mucinous 
ovarian cysts compared to benign ovarian cysts (Koivunen et al., 1990).  The 
level of TAT-2 in cyst fluid was also found to correlate with the degree of 
malignancy of the tumour. Increased levels of protease inhibitor in association 
with cancer have also been observed, which may reflect a defence mechanism of 
the host against tumour invasion (Chawla et al., 1984). 
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Tissue polypeptide specific antigen (TPS) 
Levels of TPS, a marker that is used to measure tumour cell activity in many 
cancers, have also been reported to be higher in cyst fluid from patients with 
ovarian carcinoma compared with the levels in patients who had benign cysts (p 
< 0.001) (Sedlaczek et al., 2002).  However, there was no significant correlation 
between TPS levels and FIGO cancer stage. 
 
Cancer antigens 
A number of studies have also looked at CA-125 to examine whether its over-
expression in the serum of patients with EOC is mirrored in cyst fluid. 
Interestingly, no correlation between CA-125 levels in cyst fluid and whether the 
cyst was benign or malignant was found (Sedlaczek et al., 2002).  Other proteins 
that were found to be over-expressed in the cyst fluid of malignant epithelial 
ovarian cysts include CA 19-9 and carcinoembryonic antigen (CEA), although 
there are conflicting reports for these markers (Cherchi et al., 2002).  Alterations 
in the plasminogen activation system have also been described in the cyst fluid of 
ovarian tumours (Boss et al., 2002). 
 
Use of intracystic biomarkers in the clinical setting 
The search for protein biomarkers of ovarian cancer has for many years focused 
primarily on serum biomarkers for the early diagnosis of the cancer.  It is only 
fairly recently that there has been growing interest in cyst fluid protein biomarkers, 
which can be used for the intra-operative diagnosis of ovarian cancer.  
Unfortunately, none of the intra-cystic biomarkers that have so far been proposed 
as useful in differentiating between benign and malignant ovarian cysts are 
currently used in the clinical setting.  In general, this is because these biomarkers 
have not been studied extensively enough, especially in terms of the sensitivity 
and specificity that can be achieved by using them to differentiate between a 
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benign and a malignant ovarian cyst.  VEGF is one of the most promising cyst 
fluid biomarkers that have been reported.  The study by Demirkiran et al found 
that by using a cut-off value of 16 ng/ml for VEGF concentration in ovarian cyst 
fluid, a sensitivity and specificity of 98% and 80% respectively could be achieved 
for the intra-operative diagnosis of EOC (Demirkiran et al., 2003).  Whether, by 
using cyst fluid VEGF levels as an adjunct to frozen section, the accuracy of 
intra-operative diagnosis can be improved to what is achieved by frozen section 
alone needs to be studied.  
 
The adhesion molecules seem to be plausible potential biomarkers for ovarian 
malignancy since these molecules play an important role in allowing malignant 
cells to spread locally and also to metastasize.  Soluble E-cadherin, in particular, 
has been studied more than the other adhesion molecules, especially in terms of 
its clinical relevance as a cyst fluid biomarker.  Using a threshold for the 
intracystic concentration of E-cadherin as 10,000 ng/ml, sensitivity of 69% with a 
positive predictive value of 100% and a negative predictive value of 92% was 
obtained (Darai et al., 1998).  These results, although promising, need to be 
verified in a larger sample size than was used in this preliminary study by Darai et 
al (1998). 
 
Many of the intra-cystic biomarkers reported to be of potential use in diagnosing 
ovarian malignancy have not been studied further in terms of their clinical 
relevance. Such biomarkers include a number of inflammatory cytokines e.g. IL-8, 
gonadotropins, proteolytic enzymes e.g. TAT-2 and TPS.  Without knowing the 
sensitivity and specificity that can be achieved by using an appropriate cut-off 
concentration, it is difficult to assess whether these markers are likely to be of 
any use in the future in the clinical setting.  Of these biomarkers, however, TAT-2 
could potentially be of the most interest, as its levels in cyst fluid were found to 
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correlate with the degree of malignancy of the tumour (Koivunen et al., 1990).  
This makes TAT-2 of potential use in not only creating a high index of suspicion 
for malignancy and to triage for frozen section, but also as a marker for the 
tumour grade which may affect surgical management. 
 




The most thoroughly assessed ovarian cancer biomarker is CA-125.  The 
discovery of CA-125 dates back to the early 70’s when attempts were made to 
obtain monoclonal reagents for serotherapy of patients with ovarian cancer 
(Order et al., 1973).  In animal model studies,  the intraperitoneal injection of a 
heteroantiserum from rabbits raised against a purified tumour-associated antigen 
could inhibit the growth of intraperitoneal ovarian cancer transplants in mice 
(Order et al., 1973).  With the advent of the monoclonal technology by Kohler and 
Milstein in 1975 (Kohler et al., 1975), attempts were made to develop antibodies 
reactive with ovarian cancer cells (Knapp et al., 1977; Bast et al., 1981).  After 
repeated injection of a human ovarian cancer cell line in mice, the hybridomas 
were prepared from spleen cells and the P3NS-1 plasmacytoma.  The clones 
producing antibodies that bound to the cancer cell line were then isolated and an 
IgG1 antibody generated with desired specificity was designated OC-125.  This 
antibody was found to bind the CA-125 antigens using immunohistochemical 
techniques, which was found to be expressed by approximately 80% of EOCs as 
well as by other carcinomas (Knapp et al., 1977; Bast et al., 1981).  Mucinous 
cystadenocarcinomas were less frequently positive when compared with serous 
and endometrioid adenocarcinomas (Kikkawa et al., 1996).  
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The characterisation of CA-125 began in the mid-1980s.  CA-125 was found to 
interact with a family of high molecular weight glycoproteins which contain 
multiple CA-125 antigenic determinants.  It differed from classical mucins by the 
percentage of carbohydrate conversion and presence of both N-and O-linked 
carbohydrate residues (Davis et al., 1986).  The biologic function of these CA-125 
antigenic determinants was unknown, but studies indicated that they might be 
positively stained in a wide range of normal adult tissues including pleura, 
pericardium and peritoneum but not in the normal adult ovary (Kabawat et al., 
1983).  A serum CA-125 level of 35 U/ml is usually accepted as the upper limit of 
normal range (Bast et al., 1985).  The mechanisms by which serum CA-125 
levels are elevated remains obscure at present but perhaps relates to disruptions 
of tumour-vascular interface (Bast et al., 1985).   
 
There are three major roles of CA-125 in the diagnosis and management of 
ovarian cancer (Bast et al., 1985): 
1. Evaluating the therapeutic effectiveness in patients diagnosed with ovarian 
cancer. 
2. Monitoring therapy of women known to have EOCs following cytoreductive 
surgery. 
3. Detecting the recurrent disease during post-treatment surveillance. 
 
The use of CA-125 as a screening tool was initiated due to the fact that 83% of 
patients with EOCs had a CA-125 level of more than 35 U/ml (Bast et al., 1985).  
This elevation of CA-125 was found in 50% of patients with stage I cancer and 
>90% of women with more advanced stages, though mucinous and borderline 
tumours were likely to be present with lower levels of CA-125 than serous 
cancers (Bast et al., 1985).  Regular pelvic examinations and CA-125 
measurements followed by radiological diagnosis on an individualised basis have 
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been the current practice for detection of this enigmatic condition (Mackey et al., 
1995).  One of the earliest attempts to use the CA-125 assay as a screening tool 
was reported by Jacobs et al in 1998,  who evaluated 1010 apparently healthy 
postmenopausal women by pelvic examination and serum CA-125 measurement 
(Jacobs et al., 1988).  Participants with abnormal findings underwent abdominal 
ultrasonography and those with abnormal CA-125 examinations were referred to 
a gynaecologist for surgical evaluation.  The specificity of this assay was 
calculated to be 97%, which was below the estimated specificity of 99.6% 
necessary to keep the positive predictive value of ≥ 10%.  Although current early 
detection protocols generally involve a combination of ultrasound and serum CA-
125 levels, these criteria have met with limited success (Karlan et al., 1999).  The 
largest randomised screening trial to date evaluating more than 20,000 women 
indicated a survival benefit in such women, the cancer was however undetected 
at an early stage and mortality rates were not significantly different between the 
screened and control groups of women (Jacobs et al., 1999).  As a marker for 
screening test, the data on serum CA-125 alone are disappointing, due both to 
the relatively high incidence of false-positive findings and also to the fact that only 
50% or fewer of patients with stage I disease have elevated CA-125 levels.   
 
Even though high CA-125 level was observed in serum of malignant ovarian 
tumours, the false-positive rate of remains high in part due to its elevation in 
benign gynaecology conditions such as ovarian cysts, endometriosis and uterine 
fibroids (Fisken et al., 1993; Mackey et al., 1995; Cannistra, 2004) and conditions 
in other systems such as hepatic disease, renal failure and pancreatitis (Bastani 
et al., 1995; Devarbhavi et al., 2002).  Although a combination of tumour markers 
could be one method to overcome this problem, there is currently no evidence 
that any such biomarker combination could improve the detection rate of EOC 
when compared with CA-125 alone.  Screening with additional serum markers 
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including CA-199 and lysophosphatidic acid as adjuncts to CA-125 have not 
enhanced its diagnostic value (Xu et al., 1998; Woolas et al., 1999).   
 
1.3.2.2.2 Other EOC-associated molecules 
 
Although serum CA-125 levels have consistently proved to be the most useful 
tumour marker for evaluation and monitoring of patients with known or suspected 
EOC, a number of additional tumour-associated molecules have been extensively 
evaluated as well. 
  
Cancer Antigens 
Alpha-fetoprotein (AFP) is an oncofetal glycoprotein normally present in the fetal 
circulation and re-expressed in adults who have germ cell or hepatic tumours as 
well as in some benign medical conditions (Gillespie et al., 2000).  The serum 
half-life of AFP is 4 to 6 days, and its levels are usually measured prior to 
administration of chemotherapeutic drugs (Schwartz, 1984).  Although mild 
elevations in AFP have been observed in EOC (Chumas et al., 1984), the main 
clinical utility of serum AFP levels in gynaecologic oncology is in the monitoring of 
patients with germ cell malignancies (von Eyben, 2003).  it was reported to be 
correlated with increasing stage of germ cell tumours, with degree of resection of 
primary tumour following cytoreductive surgery, and most importantly with 
response of residual disease to chemotherapy (von Eyben, 2003).   
 
Carcinoembryonic antigen (CEA) is another oncofetal glycoprotein that has been 
extensively studied in a wide variety of neoplasms (Wahlstrom et al., 1979).  
Unfortunately, the role of serum CEA levels in monitoring therapy of patients with 
EOC remains to be established.  Elevated serum CEA levels are more likely to be 
associated with mucinous adenocarcinomas.  Some patients with mucinous 
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tumours show rising serum CEA levels during disease progression, but little 
correlation exists between clinical response to therapy and decline in CEA 
because the initial elevations of CEA in many of these patients are modest (Bast 
et al., 1984). 
 
Cancer antigen 19-9 (CA19-9) and 153 (CA-153) like CA-125 are both 
monoclonal antibody-defined tumour markers.  CA19-9 is a carbohydrate 
determinant recognised by a monoclonal antibody originally developed against a 
human colon carcinoma cell line (Koprowski et al., 1979).  CA-153 is a breast 
cancer-associated antigen identified by two monoclonal antibodies, 115D8 and 
DF3.  The first antibody reacts with the high-molecular-weight glycoprotein MAM-
6 expressed by most carcinomas, whereas the second antibody recognises an 
antigen with a molecular-weight of 260 kDa present in a membrane-enriched 
fraction of metastatic breast cancer cells (Kufe et al., 1984; Hilkens et al., 1986).  
CA19-9 is elevated primarily in patients with carcinomas of the gastro-intestinal 
tract and CA-153 is recommended in the monitoring of the course and response 
to therapy of breast cancer (Pronk et al., 1997; Wolfrum et al., 2005).  However, 
both of them are elevated in ovarian cancer and reported as adjunct biomarkers 
to CA-125 in monitoring therapy and detecting recurrence of this disease (Bast et 
al., 1984; Scambia et al., 1988).  
 
Cancer antigen 72-4 (CA72-4) or tumour-associated glycoprotein 72 (TAG 72) is 
a mucin-like, glycosylated surface antigen found in colon, gastric, and ovarian 
cancer with a molecular weight greater than 1000 kDa.  It is recognised by the 
two murine IgG monoclonal antibodies: B72.3, isolated using a metastatic breast 
cancer cell membrane component from liver and CC49, isolated using the LS-
174-T colon cancer cell line (Colcher et al., 1981).  CA72-4 is expressed by a 
wide range of human adenocarcinomas and is regarded as a serum marker for 
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the postoperative monitoring of patients with colon and gastric cancers (Klug et 
al., 1986; Gangopadhyay et al., 1998).  As for ovarian cancer, CA72-4 is more 
frequently elevated in mucinous tumours (Kikkawa et al., 2006).  However, there 
is no significant improvement in the diagnosis of ovarian cancer using 
combination of CA72-4 and CA-125 when compared with CA-125 alone (Negishi 
et al., 1993).  
 
Lysophosphatidic acid (LPA) 
LPA is a bioactive phospholipid with mitogenic and growth factor-like activities.  It 
mediates a number of biological responses through activation of G protein-
coupled plasma membrane receptors (LPA1, LPA2, and LPA3) (Moolenaar et al., 
1997) and is involved in many biological processes, such as transient elevation of 
cytosolic free calcium, phosphorylation of specific cellular proteins including focal 
adhesion kinase, activation of mitogen-activated protein kinases, and formation of 
focal adhesions (Chrzanowska-Wodnicka et al., 1994; Xu et al., 1995).  Plasma 
LPA levels may represent a potential biomarker for ovarian cancer and other 
gynaecologic cancers.  Studies (Xu et al., 1998) showed that elevated LPA levels 
were detected in 90% patients with stage I and 100% patients with stage II–IV 
ovarian cancer.  In comparison, only less than 60% patients had elevated CA-125 
levels, including 2 out of 9 patients with stage I disease.  In another study LPA 
and other lysophospholipids were found to be useful markers for diagnosis and 
prognostication of ovarian cancer in a controlled setting (Sutphen et al., 2004).  
The combination of the above mentioned lysophospholipids yielded the best 
discrimination between pre-operative case and control samples, with 91.1% 






Chemically, prostasin is a trypsin-like serine proteinase secreted by the prostate 
gland with a molecular mass of 40 kDa (Yu et al., 1994).  Like the enzymatic 
activity of other serine proteinases, the activity of prostasin depends upon a 
catalytic triad of the amino acids histidine, aspartic acid, and serine (Yu et al., 
1995).  It was identified as a potential biomarker following discovery of its mRNA 
overexpression in ovarian cancer patients when compared with normal human 
ovarian surface epithelial cell lines using microarray technology (Mok et al., 2001).  
The use of a combination of prostasin and CA-125 in 37 patients with 
nonmucinous neoplasms and 100 control subjects resulted in improved sensitivity 
(92%) and specificity  (94%) for detection of ovarian cancer (Mok et al., 2001).  
 
Osteopontin (OPN) 
OPN is another biomarker that has been identified by exploiting gene expression 
profiling techniques.  It exhibited a 184-fold overexpression in pooled ovarian 
cancer cell lines when compared with human OSE (Wong et al., 2001).  As a 
secreted phosphorylated glycoprotein, OPN is abundant in bone mineral matrix 
and accelerates bone regeneration and remodelling.  It is also produced in 
tumour tissues and involves in the regulation and progression of many cancers 
by enhancing the invasive and proteolytic capabilities of tumour cells (Agrawal et 
al., 2002).  In a study conducted by Kim and coworkers, OPN was observed to be 
significantly elevated (P <0.001) in sera from EOC patients when compared with 
healthy controls (Kim et al., 2002). 
 
Growth factors and cytokines 
Cytokines and growth factors have been observed to play important roles in the 
development of various kinds of neoplasms (Aaronson, 1991; Cross et al., 1991) 
and it has been proposed that EOC may be a cytokine propelled disease (Malik 
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et al., 1991).  Involvement of these molecules in the tumourigenesis of ovarian 
cancer opens a door for researchers to assess their expression in tissue, serum, 
plasma and the potential roles in diagnosis, prognostication as well as in the 
evaluation of therapeutic effectiveness.  
 
Several growth factors have been examined in ovarian cancer including 
transforming growth factor-β (TGF-β), vascular epidermal growth factor (VEGF) 
and inhibin (Sewell et al., 2005; Inan et al., 2006; Zeineldin et al., 2006).  TGF-β 
is a 24 kDa glycoprotein acting as an autocrine growth inhibitory factor for normal 
ovarian epithelial cells.  It may act in a similar fashion for some ovarian cancer 
cells (Bartlett et al., 1992).  Therefore, the loss of the ability to produce active 
TGF-β or to respond to this factor may have occurred in some ovarian cancers.  It 
was reported that patients with malignant ovarian tumours expressing TGF- β 
and its receptors in blood vessels had longer survival rate than those with 
negatively expressed tumours (Henriksen et al., 1995).  The aberrant levels of 
TGF- β and the significant correlations between this ligand and patient survival 
indicate the prognostic significance of this biomarker for ovarian cancer. 
 
VEGF is a growth factor responsible for proliferation of vascular endothelial cells 
and vascular permeability.  It acts through two specific tyrosine-kinase receptors 
termed flt and KDR (Neufeld et al., 1994).  This growth factor is secreted by 
several normal cell types as well as different tumour cells.  For instance the 
expression of mRNA for VEGF and its receptors were detected in ovarian cancer 
cell lines (Boocock et al., 1995) and surgical samples from primary and 
metastatic ovarian carcinomas (Mattern et al., 1997; Lee et al., 2006).  Moreover, 
elevated serum VEGF levels were observed in ovarian cancer patients (Rosen et 
al., 2005).  It was reported in a study including 53 ovarian cancer patients that 
pre-operative serum VEGF levels were significantly higher in patients with 
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advanced neoplasm (P = 0.027), but not in those with early cancers (Gadducci et 
al., 1999).  Among patients with advanced disease, VEGF levels were 
significantly higher in women with ascites (Gadducci et al., 1999).  These data 
indicate that VEGF has a definite biological role in tumour progression and in the 
pathogenesis of ascite formation.  It was also reported using multivariate analysis 
that elevated pre-treatment serum VEGF could serve as a independent 
prognostic factor since it was significantly correlated with poor disease-free 
survival and overall survival of ovarian cancer patients (Cooper et al., 2002; 
Hefler et al., 2006). 
 
Inhibin A or B is a hetero-dimer consisting of α and either βA or βB subunits 
linked by disulphide bond.  It is produced primarily by the gonads with an 
essential role in regulating pituitary FSH secretion by a negative feedback 
mechanism (Knight, 1996).  Serum inhibin is a product from ovary and it 
decreases to non-detectable levels after menopause.  However, mucinous 
carcinomas and some sex cord stromal tumours continue to produce inhibin, 
which provides a basis for a serum diagnostic test (Knight, 1996).  Available data 
indicated that when used in combination with CA-125 inhibin had an increased 
sensitivity (95%) and specificity (95%) for detection of ovarian cancer (Robertson 
et al., 2002).   
 
Various cytokines, including tumour necrosis factor- α (TNF- α), 
macrophage/monocyte colony stimulating factor (M-CSF),  and interleukin 6 (IL-6) 
may also play important roles in ovarian cancer pathogenesis (Scambia et al., 
1996; Chen et al., 2001; van Haaften-Day et al., 2001; Wang et al., 2005; 
Muthukumaran et al., 2006).  In an Italian study, raised IL-6 concentrations 
(>6pg/ml) were detected in 50% of 114 patients with malignancies.  However, the 
sensitivity of diagnosis using serum IL-6 was lower than that of CA-125 and the 
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combination of both assays showed no improvement when compared with CA-
125 alone (Scambia et al., 1995).  It was noteworthy that ovarian cancer patients 
with high IL-6 levels had a significantly worse survival outcome than those with 
low IL-6 levels (P = 0.0009)(Scambia et al., 1995).  
 
Tumour necrosis factor-α (TNF-α) was originally identified as an agent that was 
selectively cytotoxic for some tumour cell lines (Old, 1985) and caused necrosis 
of certain murine tumours (Palladino et al., 1987).  However, this cytokine has a 
number of biological activities that could promote the growth and invasive 
capacity of tumours (Fiers, 1991).  TNF-α was found expressed by the tumour 
epithelium and infiltrating macrophages using in situ hybridisation and the 
expression levels were correlated with increasing tumour grade in serous ovarian 
carcinoma (Naylor et al., 1993).  Others have shown that TNF-α mRNA is 
expressed by ovarian carcinoma as well as OSE cells, with the function to 
promote growth in both cell types (Takeyama et al., 1991; Wu et al., 1993).  
 
Macrophage colony-stimulating factor (M-CSF) is a cytokine produced 
constitutively by normal as well as neoplastic ovarian epithelium.  Many ovarian 
cancer cells express both M-CSF and fms, the M-CSF receptor (Ramakrishnan et 
al., 1989).  M-CSF is a homodimeric 90 kDa glycoprotein.  It has been postulated 
that M-CSF by stimulating macrophages could produce other cytokines, such as 
IL-I or IL-6 that can further stimulate tumour cell growth (Ziltener et al., 1993).  
Diagnostic and prognostic potential of M-CSF and its receptor was also 
investigated in ovarian cancer.  Levels of fms transcripts were strongly 
associated with ovarian tumours in high histological grade and advanced clinical 
stage with a poor clinical outcome (Chambers et al., 1997).  Moreover, elevated 
plasma levels of M-CSF were observed in 70-80% of patients with ovarian cancer 
(Kacinski et al., 1990).  Combination of M-CSF with other biomarkers had 
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achieved a better sensitivity in discriminating malignant ovarian tumours from 
benign pelvic masses (Woolas et al., 1995).   
 
Based on previous studies, it could be surmised that growth factors and cytokines 
could potentially act as autocrine or paracrine stimulatory factors which modify 
the tumour cell environment, resulting in enhanced proliferation and metastatic 
characteristics of ovarian cancer.  The potential role of cytokines and other 
immunomodulatory agents in the diagnosis, prognosis and management of 
ovarian cancers could provide a better understanding of the gamut of these 
factors in the microenvironment of the tumours and the malignant behaviour of 
the tumour itself.   
 
1.3.2.2.3 Multiplex platform for biomarker application 
 
It has been suggested that the multi-parametric analyses could increase 
sensitivity and seem to be a logical approach for early diagnosis of ovarian 
cancer, although increased sensitivity is usually associated with decreased 
specificity (Diamandis, 2002).  Important progress has been achieved by the use 
of the combination of CA-125 and ultrasound.  The specificity of screening using 
CA-125 alone was improved by the addition of pelvic ultrasound as a secondary 
test to assess morphology of the ovary (Kupesic et al., 2002).  It was further 
improved by combination of sequential CA-125 and pelvic ultrasound resulting in 
a specificity of 99.9% for detection of ovarian cancer (Jacobs et al., 1988).  It was 
also observed in the same study that CA-125 levels in healthy women were static 
or decreased while levels in malignancies were significantly elevated with time.  A 
more sophisticated approach therefore would be to interpret serial CA-125 results 
other than a fixed absolute cut-off level.  The algorithm developed from this serial 
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CA-125 profile increased the sensitivity in diagnosis when compared with a single 
cut-off value and it improved the specificity at the same time (Jacobs et al., 1988).  
 
Panels of protein markers were also investigated in detection of ovarian cancer.  
Based on cDNA microarray analysis in normal OSE and 42 ovarian cancers of 
different stage, grade, and histology, a panel of biomarkers have been identified 
as the potential candidates for the diagnosis of ovarian cancer (Lu et al., 2004).  
Using immunohistochemistry method, a combination of CLDN3, CA-125, and 
MUC1 could result in a sensitivity of 99.4% in detecting 158 cancers from normal 
ovarian samples, and 100% with a combination of CLDN3, CA-125, MUC1, and 
VEGF (Lu et al., 2004).  Another study using a panel of eight different markers 
(CA-125, M-CSF, OVX1, LASA, CA15-3, CA72-4, CA19-9, CA54/61) achieved a 
better sensitivity in differentiation of malignant from benign adnexal masses 
(Woolas et al., 1995).  The same group later demonstrated that a prototype 
artificial neural network developed from four markers might dramatically improve 
sensitivity compared to CA-125 alone (87.5% versus 68.4%) while maintaining 
the specificity.  In addition, application of multiple markers may increase the 
specificity when serial cut-off values were employed (Zhang et al., 1999).  In a 
preliminary study using a panel of five tumour markers (CA-125, HER-2/neu, 
urinary gonadotropin peptide, lipid-associated sialic acid, and Dianon marker 
70/K), a population specific pool of markers could be obtained to improve the 
early diagnosis of EOC from 1,257 high-risk women (Crump et al., 2000).  
 
Studies also demonstrated that the use of panel of multiple cytokines,  which 
individually may not be useful clinically, might proved to be of highly diagnostic 
value (Gorelik et al., 2005).  A novel multianalyte profiling technology was 
designed which allowed simultaneous measurement of multiple cytokines and 
growth factors.  Concentrations of 24 cytokines and CA-125 were measured in 
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sera from patients presenting with ovarian cancer and healthy controls.  Six of 
them including IL-6, IL-8, EGF, VEGF, monocyte chemoattractant protein-1 
(MCP-1), and CA-125 demonstrated significant different serum concentrations 
between ovarian cancer and control groups.  The classification tree analysis 
designed from these cytokines resulted in 84% sensitivity and 95% specificity 
compared with 74% sensitivity and 80% specificity using CA-125 alone.  This 
study indicated that simultaneous testing of a panel of serum cytokines and CA-
125 might provide a promising approach for ovarian cancer detection.  A more 
recent report indicated that using three markers (IL-18, FGF-2, and CA-125) the 
sensitivity in detection ovarian cancer was similar compared to that of CA-125 
alone.  However, the specificity was significantly improved in detection of ovarian 
cancer (20/25 patients) compared to that from individual assessement of each 
marker (Le Page et al., 2006).  
 
Although endeavours have been made in the quest for candidate biomarkers for 
ovarian cancer, the above mentioned proteins have not been fully evaluated with 
randomised clinically controlled trials or tested in a multicentre study.  A more 
thorough investigation of these biomolecules is needed before they can be used 
in screening the general population.  The ideal tumour marker should be a 
substance unique to a particular neoplasm and distinct from the normal tissue.  It 
should also be detectable and quantifiable with consistency and reproducibility, 
sensitive enough to detect cancer at an early stage and be specific enough to 
distinguish the benign and malignant forms.  In order to develop a suitable 
diagnostic test, several criteria are needed which includes the important 
characteristics such as sensitivity, specificity, and predictive values.  Most clinical 
researchers in this area of investigation concur that in order to be acceptable in 
this context an ovarian cancer test must achieve a minimum PPV of 10% (Jacobs 
et al., 2004).  Considering the low abundance of ovarian cancer, a test for ovarian 
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cancer is required with a view to achieve a minimum of 99.6% specificity which 
possess a challenge to the efforts for the appropriate identification of additional 


























1.4 Application of proteomics on biomarker discovery 
 
Development of high throughput biotechnology and bioinformatics are making it 
possible to simultaneously analyse the entire components of proteins expressed 
in a particular type of cell or tissue.  These advances have created unique 
opportunities in the field of medicine, where the results of gene and protein 
expression studies are expected to help identify cellular alterations associated 
with disease aetiology, progression, outcome, and response to therapy.  As we 
enter into the post genomic era, development of proteomics promises to 
revolutionise and provide high throughput approaches for biological studies 
(Figure 1.3).  
 
The term “proteomics” was coined in 1995 as global analysis of the proteins 
expressed in a cell, tissue or body fluid (Wasinger et al., 1995).  Recent 
advances in proteomic profiling technology have made it possible to apply 
computational methods to detect changes in protein expression profiles and their 
association to disease processes.  In the past 5 years, significant effort has been 
made in identifying reliable novel protein markers for early detection and 
prognostication of ovarian cancer using proteomics based methods.  Such 
information will be crucial in our understanding of cancer prognosis, diagnosis 
and therapeutics with the ultimate goal being in the identification of potential 
markers for early detection and prognostication of this insidious disease.  
 
1.4.1 Principle of mass spectrometry 
 
The mass spectrometry determines the mass-to charge (m/z) ratio or a property 
related to m/z.  A mass spectrum is the curve of ion abundance versus m/z, 
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although in most cases the x-axis is simply labelled as ‘mass’ rather than m/z 
(Glish et al., 2003).  Mass spectrometers consist of three basic components: an 
ion source, a mass analyser and an ion detector (Figure 1.4).  For analysis of 
biological samples by MS, molecules must be converted into gas phase ions 
using the laser energy.  A mass analyser measures these ions according to their 
m/z ratios.  The motion of such ions is then recorded based on the number of 
events or electrical currents created (Glish et al., 2003).  This sequence of events 




Figure 1.3     Time line indicating the development of proteomics 
technology.   
With the advances in mass spectrometry, large nucleotide sequence dataset 
information, coupled to computational algorithms and bioinformatics resources 









Figure 1.4     Illustration of mass spectrometer  
(a) A single-stage mass spectrometer.  The instrument consists of three 
components: an ionisation source, mass analyser and ion detector.  The mass 
analyser shown in the figure is a time-of-flight (TOF) mass spectrometer.  The 
mass-to-charge ratio (m/z) of ions was measured.  A mass spectrum of a protein 
digest is shown to the right of the figure.  (b) The components of one type of 
tandem mass spectrometer. The instrument consists of an ion source, first mass 
analyser, gas-phase collision cell, second mass analyser and ion detector.  The 
first mass analyser can be used to scan and isolate a parent ion for dissociation 
in the collision cell.  The dissociation products are then analysed in the second 








1.4.1.1 Ionisation techniques 
 
The electrospray ionisation (ESI) (Whitehouse et al., 1985; Fenn et al., 1989) and 
MALDI (Karas et al., 1988) are two primarily used ionisation techniques.  These 
ionisation techniques are ‘soft’ procedure, which will not significantly change the 
integrity of large molecules ionised.  
 
ESI operates at atmospheric pressure and passes a continuous stream of 
charged droplets in a solution-based environment when a high electric potential is 
set between a capillary and the inlet to a mass spectrometer.  As the droplets 
evaporate in a drying gas or heat atmosphere, the charged droplets become free 
of the surrounding solvent and eventually ions are formed (Fenn et al., 1989).  
The introduction of microelectrospray and nanoeclectrospray (Emmett et al., 
1994; Wilm et al., 1996), coupled with high performance liquid chromatography 
(HPLC) (McCormack et al., 1997), allows analysis of a very small amount of 
sample mixture.  In addition, multiply charged ions which are generated by ESI 
could lower the m/z values in order to analyse higher molecular weight molecules 
and thus allow no limitations to the size of molecules subjected to analysis.  
Multiple protonation of peptides and proteins could further dissociate under 
activation with ESI.  The features of this technique have been effectively utilised 
in proteomics research. 
 
In the MALDI technique, however, samples are co-crystallised with a matrix and 
ionisation occurs with absorption of energy from the laser source.  The formation 
of singly charged ions resulting from proton transfer from the sample to matrix is 
generally observed in the gaseous phase.  Usually, small UV absorbing 
molecules such as 2, 5-dihydroxybenzoic acid and alpha-cyano-4-
hydrozycinnamic are employed as matrix.  Ions in MALDI are generated by 
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pulsed-laser beam rather than in a continuous process.  In contrast to ESI, 
MALDI has a relatively good tolerance to salts and buffers which makes sample 
preparation more readily with this technique. Furthermore, ions generated are in 
batches coincident with a pulsed laser beam rather than a continuous mist, which 
allows customised MS/MS analysis (Yates, 2004). The comparison of ESI and 
MALDI ionisation is listed in Table1.4.  
 
Table 1.4     Comparison of ESI and MALDI ionisation methods 
 
Adapted from Yates, (2004) 
 
1.4.1.2 Mass analyser 
 
The mass analyser is responsible for separating ions by their mass-to-charge 
(m/z) ratios.  Mass analysers use electric and/or magnetic fields to manipulate 
ions in a mass-dependent manner.  There are four principal types of mass 
analysers in use today (Table 1.5) and they could be further divided into beam 
analysers, in which ions enter the analysers in a beam and trapping analysers in 
ESI MALDI 
Pros Cons Pros Cons 
Multiple charging give 
low m/z for high MW 
samples - use small 
mass spectrometer 
Multiple charging can 
give confusing spectra 
Singly charged ions 
Sample in solid state 
Singly charged 
ions 
Direct coupling of LC 
to MS for on-line 
separations 
Low tolerance for 
mixtures -on-line LC 
separation 
recommended 






Relative tolerance to 
salts and buffers 
Sample 
preparation 
Mass range up to 
70kDa, Better mass 
accuracy via multiple 
charging 
Intolerant to salts,  Ion 
suppression 




except at low 
mass 
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which ions are trapped in the magnetic field and subsequently isolated in the 
analyser.  
 
Table 1.5     Comparison of performance characteristics for tandem mass 
spectrometers  
 
Instrument Resolution Mass accuracy MS scan rate MS/MS scan rate 
Linear Ion Traps 2–15,000 100–300 ppm Moderate to fast Moderate to fast 
Q-QIT 2000 300-500 ppm Moderate Moderate 
TOF-TOF 20-25,000 10-20 ppm Fast  Slow 
FTMS 50-100,00 1-2 ppm Moderate Moderate 
ppm = parts per million 
Adapted from Yates, (2004) 
 
The most commonly used mass analysers in proteomics are TOF and Ion trap, 
which produce similar mass spectrum and database matching scores.  A TOF 
spectrometer can separate ions based on their velocity, which is inversely 
proportional to the square root of m/z.  Hence, by measuring the time the ions 
reach the detector, the m/z value could be estimated.  The newly developed 
TOF/TOF instrument coupled a collision induced dissociation (CID) cell provides 
a better resolution and mass accuracy by obtaining MS/MS spectrum for both 
parent and fragment ions.  The other type of spectrometer Ion-trap has three 
dimensional electrical fields which can trap ions inside.  The mass selective mode 
of operation in ion trap makes the ion trajectories in an unstable condition for MS 
analysis.  It preferentially detects a larger number of high-mass fragments than 
the TOF/TOF.  Alternatively, the TOF/TOF detects the low-mass sequence 





1.4.1.3 Database searching 
 
The purpose of mass spectral database search is to investigate the best 
sequence match to the spectrum.  The approaches for database search using 
bioinformatics methods are generally uniform.  The experiment data are either 
peptide molecular weight digested from a protein by enzyme or MS/MS 
information from peptides subjected to further fragmentation.  The data are then 
compared with the theoretical peptide mass or ion mass value in a sequence 
database.  The corresponding mass values are counted and scored in such a 
way that the best matched protein is identified (Steen et al., 2004; Figure 1.5).  
For the unknown proteins which are not in the database, identification is 
performed using the closest homology in the related mammalian species.  Four 
basic algorithms have been developed in the database searching, namely the 
descriptive, interpretative, stochastic and probability-based modelling.  
Descriptive models use mathematical methods such as correlation analysis to 
evaluate the quality of the peptide fragments in the spectrometer and SEQUEST 
is an example using a two-tiered scoring system to assess the quality of the 
peptide spectrum from a database (Sadygov et al., 2004).  Interpretative methods 
including that of Peptide Search interpret the sequence from mass spectrum 
using probabilities or correlation analysis (Mann et al., 1994).  Stochastic 
approaches such as SCOPE, one of the earliest algorithms in the category, 
create likelihood of a correct match based on probability models for the 
generation of tandem mass spectra and the fragmentation of peptides (Bafna et 
al., 2001).  Statistical and probability models are used to determine the peptide 
identification based on empirically generated fragment probabilities (Perkins et al., 
1999).  Mascot is one of the most commonly used methods incorporating the 
probability-based scoring.  There are several advantages for the probability-
based scoring system.  Firstly, it is useful to avoid false positive results by a 
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simple cut-off score.  Secondly, comparison with other scoring methods is 
available such as sequence homology.  Thirdly, the searching parameters can be 
readily adjusted by iteration (Perkins et al., 1999).  
 
 
Figure 1.5     Diagram indicating the database searching for protein 
identification.   
Tryptic digested peptides are subjected to mass spectrometry and the mass 
spectrum from the protein using enzyme or fragmented MS/MS information are 
compared with the theoretical peptide mass or ion mass value in a sequence 
database.  The corresponding mass values are counted and scored so that the 
best matched protein is identified. 
 
1.4.2 Approaches for biomarker discovery 
 
The standard proteomic approach for biomarker research comprises protein 
isolation from clinical samples (tissues or biological fluids), digestion with 
proteases such as trypsin, separation of the resulting mixtures by gel based or 
solution based techniques, and identification of potential targets using MS based 
methods.  The various techniques include 2-DE, two dimensional differential in 
gel electrophoresis (2-D-DIGE), SELDI-TOF, protein microarrays, MudPIT and 
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ESI/MALDI TOF-MS for qualitative and quantitative determination of the 
biomarkers (Figure 1.6). 
 
 
Figure 1.6     Proteomics based methods for biomarker identification 
 
1.4.2.1 2-DE based research 
 
1.4.2.1.1 Technical consideration of 2-DE 
 
Conventional 2-DE using IPG strips and SDS-PAGE, combined with MS analysis 
has been widely utilised since the 1970s (Ballal et al., 1973).  2-DE comprising of 
isoelectric focusing (IEF) and SDS-PAGE enables the separation of complex 
protein mixtures according to pI, molecular weight, solubility, and relative 
abundance.  Depending on the gel size and the pH gradient used, 2-DE can 
resolve more than 5000 proteins simultaneously, and can detect 1 nanogram of 
protein per spot (Gorg et al., 2004).  Moreover, it generates a map of intact 
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proteins, which indicates the changes of protein expression levels.  This is in 
contrast to liquid chromatography mass spectrometry (LC-MS/MS) based 
methods for peptide analyses in which molecular weight and pI information are 
not available.  One of the greatest strengths of 2-DE is its capability to study 
proteins that have PTM including phosphorylation, glycosylation or even limited 
proteolysis (Table 1.6).  These PTM can be identified by their specific location in 
2-DE gels since they appear as distinct spot trains in the horizontal and/or vertical 
axis of the gels.  Moreover, 2-DE not only provides information on protein 
modifications and/or changes in their expression levels, but also permits the 
isolation of proteins in milligram amounts for further structural analyses by MALDI 
TOF-TOF/MS, ESI-MS or Edman microsequencing (Gorg et al., 2004).  In this 
context, 2-DE has been utilised to identify proteins that are differentially 
expressed between normal and tumour tissues in various malignancies, such as 
cancers of the cervix, stomach, pancreas, head and neck, and vagina (Ahmed et 
al., 2004; Chen et al., 2004a; Chen et al., 2004b; Fountoulakis et al., 2004; 
Hellman et al., 2004; Shen et al., 2004). 
 
1.4.2.1.2 2-DE in ovarian cancer 
 
Extensive 2-DE studies have been carried out using ovarian cancer cells, serum 
and plasma proteins.  A recent report of serum proteome in 38 ovarian cancer 
patients at different pathological grades compared with healthy women indicated 
that six upregulated protein spots occurred in all groups of ovarian cancer 
patients which were subsequently identified as isoforms of haptoglobin-1 
precursor, a liver glycoprotein present in human serum (Ahmed et al., 2004).  In 
this study, the high abundance proteins (e.g. immunoglobulin and albumin) were 
removed using a mixture of Affigel-Blue and protein A (5:1) in order to recover 
possible biomarkers present in low concentrations.  It was later demonstrated 
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that this protein could be secreted by ovarian cancer as the strong expression of 
it was observed in cytoplasma of the cancer cells.  In a follow-up study from the 
same group, IPG strips of a narrow range (pH 5.5–6.7) for the first dimension 
were used to improve the resolution of the spots in this region (Ahmed et al., 
2005).  It was observed that haptoglobin expression in sera of cancer patients 
decreased following chemotherapy (six cycles of taxol/carboplatin).  Changes in 
serum expression of haptoglobin also correlated with that of CA-125 levels before 
and after chemotherapy.  This data indicates that haptoglobin may serve as an 
additional biomarker in the monitoring of therapeutic intervention in women with 
ovarian cancer.  
 
Plasma has also been used in the search for potential protein biomarkers.  In a 
recent publication (Lomnytska et al., 2006), plasma proteomic profiles from 
ovarian cancer patients were compared to those from healthy women using 2-DE.  
A cohort of 39 ovarian cancer patients and 31 healthy individuals were studied.  
Truncated forms of cytosolic serine hydroxymethyl transferase (cSHMT), T-box 
transcription factor 3 (Tbx3) and utrophin were aberrantly expressed in samples 
from cancer patients when compared with those from healthy women (Lomnytska 
et al., 2006).  Such studies have indicated that increased expression of the three 
polypeptides in plasma samples from EOC could be used as components of a 
multi-parameter monitoring scheme of this disease.  
 
Primary and secondary ovarian tumour cell lines are other targets for biomarker 
identification as well as studying aetiological factors in the malignant 
transformation of the ovarian surface epithelium (OSE) to ovarian carcinoma.  
Using platinum sensitive and resistant ovarian cancer cell lines, researchers were 
able to investigate the protein signatures involved in chemoresistance (Yan et al., 
2007).  Reproducible and consistent deregulated protein spots on 2-DE were 
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identified including annexin A3, destrin, cofilin 1.  These proteins demonstrated 
distinct functional roles in the regulation of platinum resistance and therefore use 
of these protein signatures in matching the right therapeutic regimen in the 
appropriate patient could lead to better prognosis.   
 
Several studies have utilised a proteomic approach based on 2-DE and MS to 
investigate the pattern of protein expression associated with a predisposition to 
develop ovarian cancer (He et al., 2005; Smith-Beckerman et al., 2005).  Protein 
profiles of ovarian surface epithelium (OSE) from women with a history of familial 
ovarian cancer (FH-OSE), i.e., at least two first-degree relatives with such cancer 
and/or testing positive for BRCA1 mutations, were compared to the OSE protein 
profiles from normal women (NFH-OSE).  The studies illustrated differentially 
expressed proteins in the FH-OSE cells, in which increased expression of 
mesoderm induction early response gene and several chaperone proteins 
including BiP and GRP94 were observed (He et al., 2005; Smith-Beckerman et 
al., 2005).  The simultaneous analysis of these proteins may have useful 
diagnostic and prognostic value in the high-risk women. 
 
However, the 2-DE procedure is limited by the heterogeneous cell types of the 
tumour tissues.  The contamination from surrounding tissue represents a 
significant obstacle in the search for biomarkers, especially for early-stage 
ovarian cancers.  Recently the invention of Laser Capture Microdissection (LCM) 
has greatly improved the identification of diagnostic and prognostic markers due 
to its ability to produce pure cell populations from the surrounding tissues.  LCM 
was firstly introduced in 1996, when it provided a more easy, precise and efficient 
method of tissue microdissection compared to the previous techniques (Kovach 
et al., 1991; Shibata et al., 1992; Emmert-Buck et al., 1996).  Incorporating LCM 
into proteomics study could result in enrichment of candidate protein markers as 
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observed in the profiles of cervical, oesophageal and prostate epithelial cells 
(Banks et al., 1999; Emmert-Buck et al., 2000; Ornstein et al., 2000).  In the 
report using LCM on ovarian cancer, microdissected cells from 3 patients with 
invasive ovarian cancer revealed thirteen spots that were uniquely present in all 
three invasive ovarian cancers while it was absent or under-expressed in two 
cases with low malignant potential (Jones et al., 2002).  Mass spectrometry 
identification coupled with Western blotting analysis indicated three possible 
diagnostic markers, the 52 kDa FK506 binding protein, Rho G-protein 
dissociation inhibitor (RhoGDI) and glyoxalase I were specifically expressed by 
ovarian cancer cells (Jones et al., 2002).  However, questions regarding the use 
of LCM to simplify comparative analyses of EOC cells in a bid to reduce false 
positives between normal and diseased samples require further investigations.  
 
The new benchmark for protein analysis developed from 2-DE is 2-D DIGE.  This 
technique was originally developed by Minden and coworkers (Unlu et al., 1997).  
Proteins from cancer cases and controls are differentially labelled with 
fluorescent dyes Cy3 and Cy5 and the mixed proteins are separated in the same 
2-DE.  The gel is then scanned to generate a map for the two groups of samples, 
and differences in intensities for a given spot can be compared (Unlu et al., 1997).  
Due to the fact that the same protein from different samples is run simultaneously 
in the same gel, the reproducibility is significantly improved compared with 
conventional 2-DE (Unlu et al., 1997).  The 2-D DIGE method has helped in the 
search for biomarkers in human cancers such as oesophageal, colon, 
hepatocellular and pancreatic cancers (Zhou et al., 2002; Friedman et al., 2004; 
Fujii et al., 2005; Yu et al., 2005).  This technique has also been applied to 
identify potential diagnostic biomarkers and therapeutic targets for clear cell 
adenocarcinoma, the highly malignant subtype of ovarian cancer.  In the study 
described by Morita and colleagues, eighteen up-regulated and thirty-one down-
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regulated spots were observed in two clear cell adenocarcinoma cell lines when 
compared with those from mucinous adenocarcinoma cell lines.  The proteins 
identified included annexin, purine nucleoside phosphorylase and prohibitin, 
which were implicated in various functions of carcinogenetic process such as cell 
cycle regulation, transcription and cell adhesion (Morita et al., 2006).  The results 
of this study indicate the potential for proteomic approach to identify these 
disease-associated proteins, which may eventually serve as diagnostic markers 




1.4.2.2.1 Technical consideration of SELDI-TOF 
 
SELDI-TOF mass spectrometry is a high-throughput, affinity-based MS 
technique.  It represents a novel proteomic approach for the exploration and 
measurement of cancer-associated biomarkers and proteomic patterns in 
biological tissues and body fluids (Merchant et al., 2000).  Crude protein extracts 
are spotted on a specific protein chip surface with definite protein chemistry 
where selective adsorption takes place, resulting in the binding of the specific 
proteins (Merchant et al., 2000).   
 
The distinct advantages of SELDI-TOF is that it requires only tiny amounts of 
sample (5-10 µg) making it ideal for limited quantity of samples as evidenced in 
early stage cancers (Melle et al., 2005) (Table 1.6).  The system uses chip arrays 
with different chemical properties to capture groups of proteins that are distinctly 
present in different samples.  The commonly used ProteinChips include normal 
phase (NP20), reverse phase (H4), strong anion-exchange (SAX2), weak cation-
exchange (WCX2), and immobilised affinity capture (IMAC3) chips.  NP20 chips 
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generally bind to hydrophilic proteins while the H4 chips are suitable for their 
hydrophobic counterparts. The SAX2 and WCX2 chips are used to analyse 
proteins that have negative and positive charges on the surface, respectively.  
IMAC3 chips are used to capture proteins that bind divalent cationic metals such 
as nickel, copper and zinc (ProteinChip System Users Guide, Ciphergen).  
SELDI-TOF technology provides very good resolution of small proteins and 
peptides, as well as low-abundance proteins or proteins with extreme isoelectric 
points, and thus may complement 2-DE analysis.  
 
1.4.2.2.2 SELDI-TOF in ovarian cancer 
 
SELDI-TOF technology provides complicated patterns of mass spectrometry 
peaks, which could be eluted and identified individually with conventional gel-
based techniques (Moshkovskii et al., 2005).  Alternatively, the patterns 
themselves could serve as diagnostic markers on the basis of distinct protein 
profiles.  With the aid of bioinformatics data-mining systems a unique 
combination of mass spectra patterns are generated (Figure 1.7).  The data thus 
obtained could be used to discriminate disease states from normal controls 
(Figure 1.7).  The first study combining the mass spectrometry patterns and 
bioinformatics recognition algorithms applied this method to the early diagnosis of 
ovarian cancer (Petricoin et al., 2002).  In this study, a discriminatory mass 
spectrum pattern derived from sera of women diagnosed with ovarian cancer or 
from healthy women was developed from a training set of mass spectra.  The 
pattern was then applied to another set of blinded samples from both ovarian 
cancer and normal cases.  The power of this diagnostic test was observed to 
produce 100% sensitivity and 95% specificity in the detection of ovarian cancers.  
Interestingly, this technique seemed to possess the ability to detect patients with 
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early stage cancer, thus increasing the chances of early diagnosis for this 
insidious disease (Petricoin et al., 2002).  Protein pattern profiling has also been 
widely used to differentiate other cancers such as breast, prostate, and liver 
cancer from corresponding controls (Adam et al., 2002; Li et al., 2002; Poon et al., 
2003).  However, the data published by Petricoin’s group was re-examined by 
other investigators who reported that the peptide fingerprinting may have 
represented experimental artifacts instead of real biological differences (Erika, 
2004).  Due to the fact that overwhelming disputes occurred using this high 
throughput technology, further studies are warranted to improve the potential for 
identifying such malignancies which could be eventually used to screen the 
general population (Erika, 2004).  
 
 
Figure 1.7     Disease diagnostics using proteomic patterns 
Patents’ samples are applied to a protein chip, which is made up of a specific 
chromatographic surface.  After several washing steps and the application of an 
EAM, the proteins that are retained on the surface of the chip are analysed using 
mass spectrometry and sophisticated bioinformatics software.  Specific patterns 
for disease versus healthy controls are generated and used to diagnose the 
source of the biological sample.  Adapted from Rapkiewicz et al., (2004) 
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However, the multi-parametric analyses of Petricoin and colleagues are a logical 
approach to protein fingerprinting.  It is generally accepted that a single 
biomarker may not possess the potential for the early diagnosis of ovarian and 
other malignancies (Zhang et al., 1999; van Haaften-Day et al., 2001; Zhang et 
al., 2004).  Efforts should therefore be focused on the identification of a panel of 
novel biomarkers which are synthesised and secreted by the ovarian tumour cells.  
In this regard, SELDI-TOF is one of the more appropriate quantitative techniques 
to enable such analytical approaches required to identify specific proteins which 
could discriminate EOCs from normals. 
 
A few single and multiple disease-related protein biomarkers for the diagnosis of 
ovarian cancer have already been identified from differential SELDI-TOF protein 
patterns.  For example, a novel molecule—serum amyloid A1 (SAA1) was 
identified from SELDI-TOF protein profiles of serum obtained from 27 women 
presenting with EOC (Moshkovskii et al., 2005).  Certain panels of protein 
markers have also been identified recently using a similar approach.  Kozak et al. 
(2003) reported the identification of four ovarian cancer biomarker panels 
including transthyretin, beta-haemoglobin, apolipoprotein AI and transferrin from 
SELDI-TOF protein peaks.  This panel demonstrated improvement in the 
detection rate of early stage ovarian tumours (ROC 0.933) when compared with 
cancer antigen CA-125 alone (ROC 0.833) (Kozak et al., 2003).  More recently, 
Zhang et al. (2004) conducted a multicentre case-control study of serum 
proteomics to eliminate possible bias by cross comparison and independent 
validation.  These investigators identified three specific biomarkers including 
apolipoprotein A1, a truncated form of transthyretin and a cleavage fragment of 
inter-trypsin inhibitor heavy chain H4.  A multivariate model combining the three 
biomarkers and CA-125 was constructed and the sensitivity in detecting early 
stage invasive EOC was 74% compared with that of CA-125 alone (65%) at a 
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matched specificity of 97% (Zhang et al., 2004).  These results suggest that the 
biomarkers derived from SELDI-TOF technology may add to the list of potential 
markers which may have the ability of detection and prognostication for ovarian 
cancer in the general population.  
 
1.4.2.3 Protein microarray analysis 
 
1.4.2.3.1 Technical consideration 
 
Microarray analysis has a principal advantage of being a high throughput 
technology and offers greater precision than conventional blotting techniques 
(Schena et al., 1995).  Such arrays possess the advantage of high-density 
microscopic array elements, planar glass substrates, low reaction volumes, 
multicolour fluorescent labelling, high binding specificity, high-speed 
instrumentation for manufacture and detection, and sophisticated software for 
data analysis and modelling (Stears et al., 2003).  The development of antibody-
based protein microarray technologies represents a great advancement over the 
conventional ELISA method (Espejo et al., 2002; Templin et al., 2002).  Although 
the protein microarray technologies are limited by their requirement for highly 
specific, high-affinity antibodies as well as sensitive detection and signal 
amplification systems, they possess the advantages of being excellent means for 
simultaneous analyses of hundreds of analytes in a wide variety of disease 
conditions (Table 1.6) (Espejo et al., 2002; Templin et al., 2002).  Microarray 
analysis is therefore a fundamental technology with broad applications in genetic 





1.4.2.3.2 Protein microarray in ovarian cancer 
 
Recently, protein microarrays have been widely utilised for identification of 
potential protein biomarkers for cancers (Miller et al., 2003; Huang et al., 2004; 
Hudelist et al., 2004; Sanchez-Carbayo et al., 2006).  Using this method, a recent 
study reported that four out of 169 candidate protein biomarkers including leptin, 
prolactin, OPN and insulin-like growth factor-II were consistently deregulated in 
serum from patients with EOCs (Mor et al., 2005).  Using a combination of these 
four protein markers, this study demonstrated a sensitivity of 95%, specificity of 
95%, positive predictive value of 95% and negative predictive value of 94% in the 
diagnosis of EOCs (Mor et al., 2005).  It is noteworthy that the biomarkers 
identified in this study were well verified by other researchers (Mok et al., 2001; 
Kim et al., 2002; Lu et al., 2006).  In another study, Davidson and colleagues 
obtained cancer effusions to evaluate the biochemical status in such cancers in a 
bid to search biomarkers of prognostic or therapeutic significance.  Using a new 
lysate protein array, they found that proteins involved in signal transduction and 
transcription regulation were deregulated in effusions from cancer patients when 
compared with controls (Davidson et al., 2006).  Analysis of multiple serum 
biomarkers using a protein microarray technology appears to be a more 




1.4.2.4.1 Technical consideration 
 
Gel-based proteomics strategies are rapidly being replaced by techniques that 
involve peptide separation using high efficient nano-column liquid 
chromatography techniques linked to a mass spectrometer.  In particular, 
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multidimensional protein identification technology now allows the simultaneous 
“shotgun” analysis of hundreds of proteins in a single experiment (Washburn et 
al., 2002; Wu et al., 2002).  There are several advantages of MudPIT.  Firstly, it 
avoids the tedious process of 2-DE and can run in a fully automated system.  
Secondly, MudPIT can identify less abundant proteins from protein mixtures just 
by one or two good quality MS/MS spectra.  Thirdly, it is a more suitable 
technique for the study of hydrophobic proteins when compared with 2-DE (Link 
et al., 1999; Washburn et al., 2001).  However, the clinical implication of these 
high-throughput methods has not been well defined (Hanash, 2003), in part due 
to problems associated with the reproducibility of the LC-MS method (Wang et al., 
2003; Washburn et al., 2003).  Moreover, the limited number of samples that can 
be analysed in reality result in difficulties in obtaining clinically relevant 
information from a large number of samples (Boguski et al., 2003) (Table 1.6).  
 
MudPIT separates peptides using two-dimensional liquid chromatography. This 
technique requires columns consisting of strong cation exchange (SCX) and  
reversed phase (RP) material inside fused silica capillaries (Washburn et al., 
2001).  The chromatography proceeds in cycles, each comprising of an increase 
in salt concentration to "bump" peptides off the SCX, followed by a gradient of 
increasing hydrophobicity, to progressively elute peptides from the RP into the 
ion source (Link et al., 1999).  All peptides eluted from the nano-separation 
column are ionised and then subjected to MS/MS analysis.  Protein identity can 
be obtained by searching the MS/MS spectra against an appropriate database 
such as NCBI, Swissprot or the International Protein Index (IPI) human protein 
database (Link et al., 1999). 
 
MudPIT has been successfully applied in the quantitative comparison of protein 
expression (Steen et al., 2004).  In most circumstances, it is not only the identity 
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of the peptide that is of interest, but also its quantity in samples of different status. 
Unfortunately, the intensity of the signal of a peptide ion does not directly indicate 
the amount of protein present (Gygi et al., 1999).  There are generally two kinds 
of quantification methods in MudPIT: absolute quantification and relative 
quantification.  Absolute quantification is a laborious, but precise way of 
quantification by incorporating isotopically labelled peptides as ‘internal 
standards’.  The internal standards are to be mixed with the sample before 
digestion and loading onto the column.  Absolute quantification has been applied 
in small-molecule MS as well as in proteomic studies of a larger scale (Barr et al., 
1996; Gerber et al., 2003).  On the other hand, relative quantification using stable 
isotopes is the accurate way of measuring the relative amounts of a protein 
present in two samples.  The only difference in the several forms of molecules 
results from the substitution of the stable isotopes and there will only be a mass 
difference between them.  Therefore, the ratio of the two peaks, which can be 
determined quite accurately indicates the relative amounts of a protein that is 
present in the two subjects (Gygi et al., 1999; Ross et al., 2004).  Isotope-coded 
Affinity Tags (ICAT) technology is one of the widely used relative quantification 
methods.  Originally described by Gygi et al. (Gygi et al., 1999), this technology 
allows the systematic study of the proteome and can be used to measure the 
abundance of particular proteins in samples from cancer versus healthy controls 
(Li et al., 2004; Pawlik et al., 2006).  
 
1.4.2.4.2 Application of MudPIT 
 
The power of MudPIT for protein identification was first shown in the analysis of 
total cell lysate of Saccharomyces cerevisia (Washburn et al., 2001).  This study 
established that MudPIT is a powerful and unbiased method in protein 
identification, since large or small proteins, of high or low abundance, or 
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extremes in pI were identified with equal sensitivity.  There have been several 
studies in cancer proteomics using the MudPIT method, but the samples used 
were limited due to constraints of cost and time (Chen et al., 2006).  Using 
MudPIT technique coupled with ICAT labelling, Stewart and collaborators 
(Stewart et al., 2006) investigated the proteins associated with cisplatin 
resistance in ovarian cancer cells.  The huge number of novel identified proteins 
involving in different metabolic pathways may confer novel insights into the 
mechanisms of cisplatin resistance and allow researchers to generate new 
strategies in chemotherapy.   
 
The advent of proteomic technologies has provided clinician-scientists with a 
powerful analytical tool to investigate human diseases.  The application of 
proteomics in studying ovarian cancer, however, is still in its early stage and 
remains challenging.  These technologies are able to provide important 
information, and will have an increasing role in biomarker identification and 
validation in EOCs.  Due to the pros and cons in each proteomics technique, only 
single proteomics-based method obviously limits the chances in searching 
suitable biomarkers which could have been identified by alternative ways.  
Combination of different methods therefore opens new avenues in biomarker 
identification for ovarian cancer.  With the increased sensitivity of mass 
spectrometers and vigilant bioinformatics pattern-recognition tools, critical 
biomarker panels to be used in screening for this insidious cancer in women will 










Table 1.6     Comparison of proteomics technology in clinical application 
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1.5 Experiment aims and hypotheses 
 
Ovarian Cancer is one of the most lethal gynaecologic malignancies with a long 
asymptomatic course often presenting at an advanced stage at diagnosis.  
Despite advances in surgery and chemotherapy, the overall 5-year survival rate 
is about 50% (Kristensen et al., 1997).  Although current detection and 
prognostication protocols generally involve a combination of regular pelvic 
examinations and CA-125 measurements followed by radiological diagnosis, 
these criteria have met with limited success.   
 
The search for protein biomarkers of ovarian cancer has for many years focussed 
primarily on serum biomarkers for the diagnosis and prognostication of the 
cancer.  However, the cyst fluid represents an ideal source for biomarker 
identification in that it forms a continuous compartment surrounded by an 
epithelial cyst wall and the protein composition changes occurring in EOC cells 
will be reflected in the cyst fluid (Demirkiran et al., 2003).  Hence, studies 
involving cyst fluid proteins are of potential significance in the identification of 
target markers.   
 
The present study aims to identify useful diagnostic and/or prognostic protein 
markers with the potential use of cyst fluid as a model.  Moreover, an intra-
operative cyst fluid determination based on the differentially expressed protein 
levels with a specific cut-off value is developed to identify women who may 
require further pathological assessment with frozen section and hence, a more 
complex operative procedure by a cancer surgeon as opposed to a general 
gynaecologist.   
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Considering the pros and cons in each proteomics technique, the combination of 
two proteomics-based methods are utilised in this study in searching 
complimentary biomarkers.  The investigations were conducted in three stages:  
(a) to identify candidate biomarkers by combining various proteomics-based 
methods including SELDI-TOF, 2-DE, MALDI-TOF, and traditional immunological 
methods.  (b) to evaluate diagnostic and/or prognostic potential of candidate 
biomarkers in clinical settings and (c) to develop a portable diagnostic kit to 
detect EOC intra-operatively using cyst fluid.  
 
Accordingly, the main objectives and hypotheses of these projects are as follows: 
 
Objectives: 
1. To identify a series of disease related protein markers by comparing the 
protein difference in cyst fluid between benign and malignant ovarian tumours 
using a combination of SELDI-TOF, 2-DE based proteomics methods and 
conventional immunological techniques. 
2. To evaluate the pre-operative diagnostic and/or prognostic values of candidate 
protein markers in serum from patients presenting with EOC. 
3. To develop a simple, portable and fast intra-operative diagnostic kit using cyst 
fluid as a complementary diagnostic procedure to the use of frozen section 
technique to differentiate malignant from benign ovarian tumours.   
 
Hypotheses: 
1. Differential disease related proteins may be present in cyst fluid from benign 
and malignant ovarian tumours and could be identified using a combination of 
SELDI-TOF, 2-DE and conventional immunological techniques.  
 68
2. Similar protein patterns may also be observed in sera from benign and 
malignant ovarian tumours and they may have potential roles as diagnostic 
and/or prognostic markers.  
3. An intra-operative diagnostic assay based on the differentially expressed 
protein levels in cyst fluid may be developed to enable the differentiation between 




























2.1.1 Human samples 
 
2.1.1.1 Ethical approval for use of human samples 
 
Cyst fluid, blood and tissue collection for this research was approved by the 
National Healthcare Group Domain Specific Review Board, National University 
Hospital, Singapore (DSRB Ref: D/00/856).  All patients participating in this study 
gave written informed consent for the collection and use of human tissues and 
fluid samples.  
 
2.1.1.2 Cyst fluid samples 
 
Women aged 20 to 72 years with benign tumours (n=47), borderline tumours 
(n=10), early stage (n=13) and late stage (n=20) EOCs were enrolled for open 
surgical or laparoscopic treatment in the Department of Obstetrics & 
Gynaecology, National University Hospital, Singapore.  The histologic type of 
ovarian cancer was classified as defined by FIGO staging (1986).  Fluid samples 
from benign and malignant ovarian cysts were collected during surgery without 
intra-operative spillage.  The cyst fluids were then centrifuged at 1500 g for 10 
min at 4 °C and the supernatants were divided into aliquots of 1 ml each and 
snap frozen in liquid nitrogen for storage at -80 °C until analysis. 
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2.1.1.3 Peripheral blood 
 
Peripheral blood samples (n=126) were collected by venepuncture from patients 
presenting with epithelial ovarian tumours at the time of diagnosis or prior to the 
operative procedure.  Peripheral blood samples were also collected from healthy 
volunteers without any evidence of tumours (n=10).  
 
2.1.1.4 Tissue samples 
 
Tissue samples were collected intra-operatively from patients presenting with 
benign and malignant epithelial ovarian tumours.  Samples were rinsed using 
sterile saline and aliquots were snap frozen in liquid nitrogen and stored at -80 °C 
until analysis.  
 
2.1.1.5 Cell lines 
 
Ovarian carcinoma cell lines TOV-112D, SKOV-3 and Caov-3 were obtained from 
the American Type Culture Collection (ATCC, Manassas, VA, USA).  
 
2.1.2 Antibodies, reagents, media, solutions and kits 
 





Polyclonal rabbit anti-human haptoglobin and ceruloplasmin antibodies 
(Dakocytomation, Glostrup, Denmark); polyclonal goat anti-human haptoglobin 
 71
antibody (Biodesign, Saco, ME, USA); horse radish peroxidase (HRP) labelled 
anti-rabbit secondary antibody (Pierce Biotechnology, Rockford, IL, USA); 
biotinylated anti-rabbit secondary antibody (Vector Laboratories, Burlingame, CA, 
USA);  Polyclonal rabbit antibody against haptoglobin α-subunit was generated 
using the following amino acid sequence, CKNYYKLRTQGDGVY (BioGenes, 




Methanol, ethanol, acetone, chloroform, acetic acid, formic acid, hydrochloric acid, 
citrate, formaldehyde, isopentane (Merck, Darmstadt, Germany); dimethyl 
sulfoxide (DMSO), bovine serum albumin (BSA), glycerol,  bromophenol blue, 
thiourea, potassium ferricyanide, sodium thiosulphate, HPLC grade acetonitrile, 
triton X-100, ammonium sulphate, purified human haptoglobin, penicillin and 
streptomycin, haematoxylin and eosin (Sigma-Aldrich, St. Louis, MO, USA); 
N,N,N',N'-tetramethylethylenediamine (TEMED), 30% acrylamide/bis solution 
19:1 (5% C), SDS, Bradford assay dye reagent, ammonium persulphate, carrier 
ampholytes, overlay agarose, CHAPS, iodoacetamide (IAA), ethidium bromide, 
precision plus protein all blue® standards, mineral oil (Bio-Rad Laboratories, 
Hercules, CA, USA); modified sequencing grade trypsin, 6X DNA loading buffer, 
100bp DNA ladder (Promega, Southampton, UK); urea, tris base (Merck, 
Whitehouse Station, NJ, USA);  ethylenediaminetetraacetic acid (EDTA), trypsin 
(GIBCO, Invitrogen, Carlsbad, CA, USA); Tween 20; complete Mini® protease 
inhibitor cocktail (Roche diagnostics, Mannheim, Germany); dithiothreitol (DTT; 
Sigma-Aldrich, Oakville, Canada); 4700 proteomics analyser calibration mixture 
(des-Arg-Bradykinin, Angiotensin I, Glu-Fibrinopeptide B, angiotensin I and 
adrenocorticotropic hormone (ACTH) (1-17 clip), ACTH (18-39 clip) and ACTH 
(7-38 clip)) (Applied Biosystems, Framigham, MA, USA); ultra v block reagent 
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(BioGen Medical Instruments Inc, Turkey);  non fat dry milk (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA); alkaline phosphatase streptavidin (Vector 
Laboratories, Burlingame, CA, USA); fetal calf serum (Hyclone, Utah, USA).  
 
2.1.2.3 Water and Solutions 
 
Pure water (Milli-Q system, 18 MΩ/cm at 25 °C, with removal of organics) 
(Millipore, Bedford, MA, USA); 20 mM, 50 mM and 100 mM ammonium 
bicarbonate solution, 1x phosphate-buffered saline (PBS), 5x SDS/glycine 
electrophoresis buffer (15.1 g tris base, 72 g glycine and 5 g SDS, NUMI, NUS); 
5 x sample loading buffer (pH 6.8; 0.313 M Tris-HCl, 10%SDS, 0.05% 
bromophenol blue, 50% glycerol, 0.5 M DTT) coomassie blue destaining solution 
(5% methanol, 7% acetic acid and 88% water); sinapinic acid solution (50% 
acetonitrile, 0.5% TFA); transfer buffer for Western blotting [pH 8.3; 25mM tris 
base; 150 mM glycine; 10%(v/v) methanol]; TBST buffer (pH 7.5; tris base; 500 
mM NaCl; 0.05% Tween 20); PBST buffer (0.05% Tween 20 in PBS buffer); tris 
lysed buffer (pH 8.0; 50 mmol/L tris, 150 mmol/L NaCl, 5 mmol/L EDTA with 
protease inhibitor cocktail); proteinChip washing buffer (0.5% triton X-100 in PBS); 
rehydration buffer [pH 4–7; 7 M urea, 2 M thiourea, 100 mM DTT, 4% CHAPS, 
0.5% carrier ampholytes, 0.01% bromophenol blue (BPB) and 40 mM tris]; 
equilibration buffer I and II (pH 8.8; 50 mM Tris, 6 M urea, 30% glycerol, 2% SDS, 
0.01% BPB, 2 mM DTT/2.5 mM IAA); 10 x MOPS buffer [pH 7.0; 2 M MOPS 
(morpholinopropanesulphonic acid); 50 mM sodium acetate; 5 mM EDTA]; RNA 
denaturing buffer (10 ml 100% deionised formamide; 3.5 ml 40% formaldehyde; 
1.5 ml 10 x MOPS buffer); TBE buffer (pH 8.3; 0.89 M tris; 0.02 M EDTA; 0.89 M 




2.1.2.4 Cell culture media and supplements 
 
Standard culture medium contained RPMI 1640 (Invitrogen Corporation, 
Carlsbad, CA, USA) supplemented with 2 mM L-glutamine, 50 U/ml penicillin, 50 
µg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA) and 10% fetal calf serum 
(Hyclone, Utah, USA).  The cell freezing medium was supplemented with 10% 




RC® detergent compatible (DC) protein assay kit, silver stain plus kit, Aurum 
Serum Protein Mini kit, ReadyPrep 2-D Starter kit, ReadyPrep 2-D Cleanup kit 
(Bio-Rad Laboratories, Hercules, CA, USA); PHASE RANGE haptoglobin assay 
kit (Tridelta Development Ltd, Kildare, Ireland); SuperSignal West Pico 
chemiluminescent substrate kit (Pierce Biotechnology, Rockford, IL, USA); 
peroxidase ABTS and TMB substrate kit (Vector Laboratories, Burlingame, CA, 
USA); RNeasy mini kit,  one-step RT-PCR kit (Qiagen GmbH, Hilden, Germany); 
ovarian cancer (CA-125) ELISA kit (Alpha Diagnostic International, San Antonio, 
TX, USA); human C reactant protein (CRP) ELISA kit (Chemicon International, 









2.1.3.1 Pipettes, centrifuge tubes, filters 
 
Positive-pressure pipettes (Gilson, Villiers-le-Bel, France); pipette-aid motorised 
(BD Diagnostics, Franklin Lakes, NJ, USA); 1.5 ml conical-bottom polypropylene 
tubes, 0.2 µm and 70 µm filters, 70 µm cell strainers and Falcon 25 cm2 culture 
flasks (BD Biosciences, Bedford, MA, USA); 1.5 polyallomer tubes (Beckman 
coulter, Fullerton, CA, USA). 
 
2.1.3.2 Blood collection tubes, needles, slides, coverslips 
 
VACUETTE® serum tubes containing the clot-activating factor (Greiner Bio-One, 
Kremsmuenster, Austria); needles, uncoated microscope slides, cover slips (BDH 




Bench top centrifuge for 15- and 50 ml polypropylene tubes (Beckman GS-6R, 
Beckman coulter, Fullerton, CA, USA); bench top microcentrifuge for 0.5- and 1.5 
ml polypropylene tubes (Sanyo Gallenkamp PLC, Loughborough, UK); 
cytocentrifuge (Shandon, Cheshire, UK); Savant speedvac (Model SC110, Global 
Medical Instrumentation, Minnesota, USA). 
 
2.1.3.4 Water bath and thermocycler 
 
Standard water bath (GFL, INNOV Solutions, Milan, Italy); ALB64 thermo bath 
(ESEL TechTra Inc, Korea); Pχ2 programmable thermocycler (Thermo Hybraid, 





Misonix sonicator (ultrasonic processor)-XL2020 (Misonix incorporated, 
Farmingdale, NY, USA). 
 
2.1.3.6 Proteomics work station 
 
MP3 electrophoresis system, two dimensional gel electrophoresis systems, ready 
strips (7cm and 11 cm, pH 3-10 and 4–7), 4-20% tris-HCl precast criterion gel, 
GS-800 calibrated densitometer, Tran-Blot ® semi-dry transfer cells, electrode 
wicks, Protean IEF system, UltraRocker rocking platform (Bio-Rad Laboratories, 
Hercules, CA, USA); nitrocellulose membrane (Amersham Biosciences, 
Piscataway, NJ, USA);  CL-XPosure film (Pierce Biotechnology, Rockford, IL, 
USA);  Ciphergen proteinChip,  SELDI-TOF-MS system (Ciphergen Biosystems, 
Fremont, CA, USA); Voyager-DE STR MALDI-TOF/MS system and ABI 4700 
proteomics analyser mass spectrometer with a MALDI source and TOF/TOF™ 
optics (Applied Biosystems, Framigham, MA, USA), PVC plates (NUNC, Roskilde, 
Denmark), ELISA reader (Tecan, Salzburg, Austria). 
 
2.1.3.7 Microscope, spectrophotometers and transilluminator 
 
Microscope (Zeiss, Carl Zeiss, Oberkochen, Germany); Beckman DU 650 
spectrophotometer (Beckman Coulter, Fullerton, CA, USA); UV transilluminator 




IBM R40 (IBM, Armonk, NY, USA). 
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2.1.3.9 Computer software 
 
Adobe Photoshop graphics software (Adobe Systems UK, Middlesex, UK); 
Ciphergen software (version 3.0, Ciphergen biosystems, Fremont, CA, USA); 
Quantity one software, PDQuest version 7.2 software package (Bio-Rad 























2.2.1 Sample preparation 
 
2.2.1.1 Cyst fluid sample preparation 
 
The cyst fluid proteins were purified using three different protein precipitation 
methods namely acetone precipitation, chloroform/methanol precipitation and 
ammonium sulphate precipitation.  For acetone precipitation, four volumes of ice-
cold acetone were added into one volume of cyst fluid samples.  The mixtures 
were vortexed and incubated overnight at -20 °C.  For the chloroform/methanol 
precipitation method, five volumes of chloroform/methanol solution (70:30 v/v) 
mixtures were mixed with one volume of cyst fluid samples.  The solution was 
incubated in ice for 2 hours and the lower organic layer was discarded.  For the 
ammonium sulphate precipitation protocol, ammonium sulphate powder (13.2 mg) 
was added into 20 µl of cyst fluid and the mixtures were gently vortexed for 10 
min.  The samples were then incubated in ice for 2 hours.  After centrifugation at 
10, 000 rpm at 4 °C for 30 min, the supernatant was removed.  The pellet was 
washed using 20 µl of 90% ice-cold acetone and incubated in ice for another 15 
min.  The samples in all three above mentioned procedures were centrifuged at 
13,000 rpm, 4 °C for 30 min.  The pellet was air dried for maximum of 5 min and 
resuspended in millipure water.  The purified cyst fluid samples were kept at -80 





2.2.1.2 Blood sample preparation 
 
The venous blood samples were collected in 8 ml VACUETTE® serum tubes 
containing the clot-activating factor (Greiner Bio-One).  All samples were 
transported in ice to the laboratory and centrifuged immediately at 4 °C for 10 min 
at 1500 g.  The supernatant serum aliquots were stored at -80 °C until analysis 
according to the method described previously (Maccio et al., 2005).   
 
2.2.1.3 Tissue sample preparation 
 
Frozen section slides of tissue were stained using H & E solution and cancer 
cells with large and irregular nuclei and hyperchromasia were carefully counted 
under microscope in five randomly selected fields following consultation with the 
histopathologist wherein the cancer cells should be more than 60% of all cells in 
the field.  Proteins were extracted from tissue using tris lysis buffer for Western 
blotting procedures. 
 
2.2.2 Cell culture 
 
2.2.2.1 Thawing of frozen cell lines and culture 
 
Three ovarian cancer cell lines were included in this study.  TOV-112D, Caov-3 
and SKOV-3 cells sent on dry ice or stored in liquid nitrogen were resuscitated by 
leaving at 37 °C until completely defrosted.  The cell suspensions were 
transferred into 15 ml polypropylene tubes containing 10 ml pre-warmed RPMI 
culture medium (Invitrogen) supplemented with 10% fetal calf serum, 100 IU/ml 
penicillin and 100 µg/ml streptomycin (Sigma).  After centrifugation at 1000 rpm 
at room temperature to separate the cells from freezing media containing DMSO 
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(Sigma), the pellets were resuspended in 10 ml culture media and maintained as 
monolayers in 75 cm2 culture flasks (Falcon) at 37 °C in a humidified atmosphere 
of 5% CO2 in air.  The cells were passaged every 48-72 hours and maintained at 
an approximate density of 80% confluence.  
 
2.2.2.2 Cryopreservation of cell lines 
 
Immediately before and after cryopreservation (10-14 days) the possible 
contamination from bacteria, fungi, mycoplasma, and viruses should be checked.  
If contamination is confirmed, then the frozen material is destroyed.  Confluent 
cells were digested using 0.25% trypsin, collected using gentle centrifugation (10 
min at 1000 rpm) and resuspended in the freeze medium (RPMI with  5% DMSO) 
at a concentration of 1 × 106 to 5 × 106 viable cells/ml.  Aliquots of 1.5 ml of 
solution containing cells were transferred into cryopreservation tubes (Corning).  
The cells were allowed to equilibrate in the medium at room temperature for a 
minimum of 15 min and the tubes were transferred into a controlled-rate freeze 
chamber and placed in a –70 °C mechanical freezer for at least 24 hours. The 
cells were deposited into the liquid nitrogen bank the following day.  
 
2.2.3 Protein quantification 
 
The cyst fluid protein concentration of each sample was determined using the 
Bradford method (Bio-Rad Laboratory).  For the standards, 10 µl to 80 µl of BSA 
solution of 1 µg/µl was added to 390 µl, 380 µl, 370 µl, et al. of autoclaved water 
respectively.  Samples were diluted 1:10 before quantification.  Ten µl of sample 
was added to 390 µl of autoclaved water.  Both the standards and the samples 
were mixed with 100 µl of Bradford dye (Bio-Rad Laboratory) according to the 
manufacturer’s instructions.  The total volume in each cuvette is 500 µl.  The 
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samples were then analysed at 595 nm using a spectrophotometer (Beckman 
Coulter).  
 
Protein concentrations of tissue proteins were determined using Bio-Rad RC® DC 
protein assay kit (Principle of Lowry method) following the manufacturer’s 
instructions with slight modifications.  Twenty-five µl of BSA standards (0.2 µg/µl, 
0.6 µg/µl, 1 µg/µl and 1.4 µg/µl) or samples were mixed with RC® DC reagent I 
and II, and the mixtures were centrifuged at 13,000 rpm for 10 min.  The 
supernatants were discarded and the pellets were dissolved in 127 µl of working 
reagent A (20 µl of reagent S to each ml reagent A).  After incubation with 1 ml of 
reagent B for 15 min, the absorbance of the solution was read at 750 nm.  Protein 
concentrations were calculated using the equation deduced from the standard 
curve.  
 
2.2.4 SELDI-TOF-MS Analysis 
 
SELDI-TOF profiling for hydrophilic cyst fluid proteins was obtained using normal 
phase (NP20-hydrophilic surface) proteinChips (Ciphergen Biosystems).  The 
proteinChips were pre-incubated with 5 µl of Millipure water for 5 min.  5 µl of 
sample was then added to the NP20 proteinChip spots and incubated for 1 hour.  
Immunocapture experiments were performed using a PS20 ProteinChip array 
(Ciphergen Biosystems) precoated with anti-haptoglobin antibody 
(Dakocytomation).  Samples (10 µl) were incubated with 90 µl binding buffer 
(0.5% Triton X-100 in PBS) and allowed to bind the chips for 2 hours.  After two 
washes with binding buffer, the above mentioned arrays were treated with 
saturated sinapinic acid in 0.5% trifluoroacetic acid and 50% acetonitrile and 
analysed using the Ciphergen proteinChip Reader (model PBSII; Ciphergen 
Biosystems).  The mass spectra of proteins were generated using an average of 
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80 laser shots at each sample.  For low molecular weight proteins, data collection 
was optimised between 8-25 kDa.  The detector intensity was set at 10, and the 
laser intensity was set at 240 V.  For middle size proteins, data collection was 
optimised between 25-50 kDa.  The detector sensitivity and laser intensity was 10 
and 260 V, respectively.  The mass to charge ratio (m/z) of each of the proteins 
captured on the array surface was determined according to externally calibrated 
standards (Ciphergen Biosystems): bovine insulin (5,733.6 Da), human ubiquitin 
(8,564.8 Da), bovine cytochrome c (12,230.9 Da), equine myoglobin (16,951.5 
Da), bovine β-lactoglobulin A (18,363.3 Da) and horse-radish peroxidase (43,240 
Da).  Mass spectra were processed using the Ciphergen proteinChip software 
version 3.0 for baseline correction and peak detection in the auto mode.  
Baseline subtraction was performed on spectra to eliminate any baseline signal 
that was due mainly to chemical noise caused by EAM.  Peak was identified as 
areas of the mass spectrum by comparing the signal to neighbouring valley 




2.2.5.1 Assembly of apparatus before casting the polyacrylamide gels 
 
For preparation of casting the polyacrylamide gel, the 0.75 mm spacer and short 
plates from Bio-Rad Laboratories are cleaned with 70% ethanol.  The cleaned 
0.75 mm spacer and short plates are inserted into the casting frame, placed on 





2.2.5.2 Preparation of SDS-PAGE 
 
SDS-PAGE gels with different acrylamide concentrations ranging from 8 to 15% 
were used in the present study.  Compositions for the mini-size (7 cm) gels were 
described in Table 2.1.  Resolving gel mixture was prepared by mixing the 
reagents listed in Table 2.1 and loaded into the space between the glass plates.  
Next, stacking solution was loaded above the polymerised resolving gel by 
adding slowly at the side to the brim of the short plate.  The comb was then 
Inserted (Bio-Rad Laboratories) and the acrylamide in the stacking solution was 
allowed to polymerise for about 15 min.  The entire assembly was left overnight 
at 4 °C before usage. 
 
2.2.5.3 Running SDS-PAGE 
 
Protein samples were premixed with loading buffer and heated at 95 °C for 5 min.  
Once acrylamide was polymerised, protein standards and samples were loaded 
and electrophoresis was performed by applying a voltage of 120 V.  Enhanced 
resolution of low molecular weight protein bands was obtained by preparing high 











Table 2.1     Composition of mini size SDS-PAGE gel 
 
Separating gel mixture Components of single 
gel 
Stacking 
gel mixture 8% 10% 12% 15% 
H2O 1.75 ml 4.35 ml 3.75 ml 3.15 ml 2.25 ml 
4xTris(Upper/Lower) 625 µl 2.25 ml 2.25 ml 2.25 ml 2.25 ml 
30%AA 325 µl 2.4 ml 3 ml 3.6 ml 4.5 ml 
10%APS 30 µl 25 µl 25 µl 25 µl 25 µl 
TEMED 12 µl 12.5 µl 12.5 µl 12.5 µl 12.5 µl 
 
4x Lower tris (pH 8.8; 1.6 M tris, 0.4% SDS) 
4x Upper tris (pH 6.8; 0.5 M tris, 0.4% SDS) 
AA: acrylamide/bis solution 
APS: ammonium persulphate 
 
2.2.6 Native gel electrophoresis 
 
Native gel electrophoresis runs in the absence of SDS and the mobility of 
proteins depends on both the charge and hydrodynamic size of the proteins 
(Krause, 2006).  Native gels with different acrylamide concentrations ranging 
from 10 to 15% were used in the present study.  Compositions for the mini-size (7 
cm) gels are described in Table 2.2.  Protein samples were premixed with loading 
buffer (pH 6.8; 0.313M Tris-HCl, 0.05% bromophenol blue, 50% glycerol).  Once 
acrylamide is polymerised, protein standards and samples were loaded and 






Table 2.2     Composition of mini size native gel 
 





10% 12% 15% 
H2O 2.5 ml 5 ml 3.7 ml 2.5 ml 
Tris (Upper/Lower) 1 ml 2.8 ml 2.8 ml 2.8 ml 
30%AA 0.4 ml 3.7 ml 4.5 ml 5.7 ml 
10% APS 40 µl 40 µl 40 µl 40 µl 
TEMED 10 µl 10 µl 10 µl 10 µl 
 
Lower tris (PH 8.8; 1.5M tris-HCl) 
Upper tris (PH 6.8; 0.5M tris-HCl) 
AA: acrylamide/ bis solution 
APS: ammonium persulphate 
 
2.2.7 Silver staining 
 
The protein bands were visualised using silver stain plus kits (Bio-Rad 
laboratories) according to manufacturer’s instructions with modifications.  After 
electrophoresis, gels were taken out from the glass plates and placed with care 
into appropriate plastic containers.  The gels were then fixed in approximately 25 
ml of fixative solution containing 40% methanol and 10% acetic acid (v/v) for at 
least 30 min on an UltraRocker Rocking Platform (Bio-Rad Laboratories) at room 
temperature.  After washing by deionised distilled water for three times, gels were 
stained in developer solution until desired staining intensity was reached.  Next, 
the gels were placed in 5% acetic acid to stop the reaction (minimum 15 min) and 





2.2.8.1 Sample preparation 
 
2.2.8.1.1 Removal of high abundance protein 
 
The high abundance protein albumin was removed using Aurum Serum Protein 
Mini kits (Bio-Rad Laboratory).  The protein column was placed in a 12 x 75 mm 
test tube and the resin was allowed to settle for at least 5 min.  Gravity flow 
started after removal of caps and tips from the bottom of the columns and the 
residual buffer was allowed to drain from the column (approximately 2 min).  Next, 
the column was washed using 1 ml of protein binding buffer twice using gravity 
flow.  After centrifuging the column at 10,000 rpm for 20 sec in a microcentrifuge 
to dry the resin bed, 200 µl of the diluted cyst fluid sample in binding buffer (1:3, 
v/v) was added to the top of the resin bed and the sample was allowed to 
penetrate the column matrix.  This was followed by gentle vortexing for three 
times at 5 min intervals and the column was centrifuged at 10,000 rpm for 20 sec.  
The eluate in the collection tube was collected which contains the albumin 
depleted cyst fluid samples.  
 
2.2.8.1.2 Sample cleanup 
 
Protein samples were purified using ReadyPrep 2-D Cleanup Kit.  Proteins were 
mixed with three volumes of precipitating agent 1 in a 1.5 ml microcentrifuge tube 
and the tube was allowed to incubate on ice for 15 min.  The same volume of 
precipitating agent 2 was added to the mixture and the tubes were centrifuged at 
13,000 rpm for 5 min.  Next, the supernatant was discarded without agitating the 
pellet followed by brief centrifugation again to remove any residual liquid.  The 
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pellets were then washed using wash reagent 1, proteomic grade water and 
wash reagent 2 sequentially.  After centrifugation, the pellets were resuspended 
by adding an appropriate volume of 2-D rehydration/sample buffer. 
 
2.2.8.2 First-dimension separation 
 
In total, 100 µg of cyst fluid protein was mixed with rehydration buffer to a final 
volume of 200 µl and the mixtures were vortexed 4 times for 20 sec at 1 min 
intervals.  This mixture was then applied to Ready Strips (11 cm, pH 3-10, 4–7, 
Bio-Rad Laboratories) and the rehydration was conducted at room temperature 
for 16 hours.  Next, cyst fluid proteins were isoelectrically focused at 50 V for 2 
hours; 250 V for 1 hour; 500 V for 1 hour; 1000 V for 1 hour; 8000 V for 3 hours 
and then maintained at 8000 V for a total of  60000 Vhs.  Ready Strips were then 
stored at -80 °C until second dimensional electrophoresis.  
 
2.2.8.3 Second-dimension separation 
 
Ready Strips from the first dimensional separation were equilibrated in 3 ml of 
equilibration buffer I and buffer II for 15 min each.  Strips were rinsed in tris 
glycine SDS running buffer and then applied to the top of a 4-20% precast 
criterion gel (Bio-Rad Laboratories).  Low melting point agarose (0.5% in running 
buffer containing BPB) was layered on top of the strip and electrophoresis on the 
gel was carried out at 150 V for 1 hour.  
 
2.2.8.4 Gel staining and image analysis 
 
The protein spots were visualised using silver stain plus kits (Bio-Rad 
laboratories) Protein spots were scanned using a GS-800 calibrated densitometer 
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(Bio-Rad Laboratories) followed by spot detection, quantification, and matching 
with the PDQuest version 7.2 software package (Bio-Rad Laboratories).  The gel 
spots were automatically detected by the computer program and the expression 
levels of proteins were determined by averaging the normalisation volume of the 
spots.  The differentially expressed proteins between diseases and controls were 
selected and identified.  
 
2.2.9 MALDI TOF/MS and MALDI TOF-TOF/MS 
 
2.2.9.1 In-gel digestion for mass spectrometry 
 
In-gel digestion was performed as follows.  Finely cut gel pieces were ground and 
transferred into a 600 µl PCR tube.  Destaining was performed by the addition of 
1:1 ratio of 30 mM potassium ferricyanide and 100 mM sodium thiosulphate 
solution followed by vortexing.  The mixture was then washed and dehydrated 
sequentially in 100 mM ammonium bicarbonate, 50 mM ammonium bicarbonate 
and 50% acetonitrile (v/v).  After the sample was dried in a vacuum centrifuge it 
was reduced by adding a fresh solution of 10 mM DTT in 100 mM ammonium 
bicarbonate (incubated at 57 °C for 60 min), and alkylated by using 55 mM 
iodoacetamide solution in 100 mM ammonium bicarbonate (incubated at room 
temperature for 60 min).  Further procedures included gel washing in 100 mM 
ammonium bicarbonate (twice), dehydration in 100% acetonitrile (twice), re-
swelling in 100 mM ammonium bicarbonate (once), dehydration in 100% 
acetonitrile (twice), and drying in a vacuum centrifuge (once).  The dried sample 
was reconstituted by adding digestion solution (12.5 ng/µl trypsin in 50 mM 
ammonium bicarbonate solution), and kept at 4 °C for 30 min.  The excess 
digestion solution was removed and 50 mM ammonium bicarbonate solution was 
added to the sample before incubation in a thermo bath at 37 °C (12-15 hours).  
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After incubation, the solution was centrifuged at 6,000 rpm (10 min) and 
supernatant (“fraction A”) collected; to the pellet, 20 mM ammonium bicarbonate 
was added and spun at 6,000 rpm (10 min) and the supernatant (“fraction B”) 
was collected; to the pellet, 5% formic acid in 50% aqueous acetonitrile was 
added and centrifuged at 6,000 rpm (10 min) and supernatant (“fraction C”) was 
obtained.  The three fractions (“A”, “B” and “C”) were pooled and dried in a 
vacuum centrifuge. 
 
2.2.9.2 MALDI TOF analysis 
 
After in-gel digestion, the vacuum dried sample containing peptides was 
dissolved in 0.1% TFA and diluted in 50% acetonitrile.  0.4 µl of the extracted 
sample was dispensed onto a MALDI sample plate along with 0.4 µl of matrix 
solution consisting of 10 mg/ml α-cyano-4-hydroxycinnamic acid (CHCA), 0.1% 
TFA, and 50% acetonitrile.  Mass spectrometric analysis was performed using 
Applied Biosystems Voyager-DE STR MALDI-TOF mass spectrometer with the 
following specifications.  MS automatic data acquisition was performed in delayed 
extraction, reflectron mode, with the parameters set as follows: accelerating 
voltage of 20,500 V; grid voltage of 73.5%; guide wire voltage of 0.01% and 
extraction time of 380 ns.  Laser intensity was set at 2700 with 100 shots per 
spectrum.  The mass range was set between 800-3500 Da.  The mixture of 
ACTH peptides (1296.6835 Da and 2465.1989 Da (M+H+) ions) were used as 
internal calibration standards.  
 
2.2.9.3 MALDI TOF-TOF analysis 
 
Extracted peptides were resuspended in solution with 0.1% (v/v) TFA and 50% 
(v/v) acetonitrile.  0.5 µl of this peptide solution was mixed with an equal volume 
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of matrix solution containing saturated solution of CHCA in 0.1% (v/v) TFA and 
50% (v/v) acetonitrile and spotted onto a MALDI target plate.  The sample was 
analysed on the MALDI TOF/TOF 4700 Proteomics Analyser (Applied 
Biosystems).  Calibration of the instrument was performed externally with [M+H]+ 
ions of calibration mixture (4700 Cal Mix).  For MS analysis, the instrument was 
turned in a reflector mode with the laser intensity set at 5% higher than the 
threshold for ionisation.  MS spectra were obtained after accumulation of 5000 
consecutive laser shots.  For MS/MS analysis, the laser intensity was set at 15% 
higher than the threshold for ionisation.  Nitrogen was used as collision gas and a 
medium pressure was selected (approximately 8x10-7 torr as measured by the 
source 2 pressure gauge).  Data-dependent MS/MS analysis was performed in 
automatic mode with the highest twenty MS peaks in intensity selected for 
MS/MS analysis.  
 
2.2.9.4 Database search and bioinformatics analysis 
 
The search engine MASCOT was used for both peptide mass fingerprinting (PMF) 
and MS/MS based sequence query.  For MASCOT PMF search, parameters 
were set as follows: database was chosen with NCBI nonredundant database, 
taxonomy was selected as Homo sapiens, protein mass was set at 0-250 kDa, 
and one missing cleavage was allowed.  Methionine oxidation and cysteine 
carbamidomethylation were selected as variable modifications.  Peptide masses 
were stated to be monoisotopic and the mass tolerance was set as 50 ppm.  
 
For MASCOT sequence query search the parameters were set as follows: PMF 
data in combination with MS/MS spectra were submitted to the MASCOT 
database sequence query search engine using mass tolerance settings of 100 
ppm for PMF and 0.2 Da for MS/MS data, and 1 missing cleavage site.  The 
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protein mass was set at 0-250 kDa.  Taxonomy was chosen as Homo sapiens.  
Peptide masses were stated to be monoisotopic.  Methionine oxidation and 
cysteine carbamidomethylation were selected as variable modifications.  Trypsin 
autodigested peaks and keratin trypsin digested peaks were excluded from the 
submitted peaks.   
 
2.2.10 Western blotting analysis 
 
To perform Western blotting analysis, proteins were separated using SDS-PAGE 
as described in section 2.2.5.  The separated proteins in the acrylamide gel were 
transferred onto a nitrocellulose membrane using Tran-Blot ® semi-dry transfer 
cell (Bio-Rad Laboratories) at 15 V for an hour.  Next, the membrane was 
incubated with a blocking solution consisting of 5% non-fat dry milk in TBST 
solution at 37 °C for 1 hour followed by incubation with primary antibody 
overnight at 4 °C.  After washing the membrane 3 times (10 min each) with TBST, 
the membrane was incubated with a secondary antibody conjugated with HRP at 
a 1:5000 dilution for 1 hour at room temperature.  The membrane was briefly 
incubated with chemiluminescence HRP substrate (250 µl of peroxide solution 
and 250 µl of enhancer solution; Pierce) and exposed in the dark room to X-ray 
film for the appropriate time period (about 10 sec, 1 min and 3 min) to visualise 
the chemiluminescence signal corresponding to the specific antibody-antigen 
reaction.  Band intensities were measured using Quantity One® software (Bio-
Rad Laboratories) in order to obtain any quantitative difference of protein 






2.2.11 Antibody generation 
 
Polyclonal rabbit anti-human antibody was generated from Biogenes GmbH Pte 
Ltd (Biogenes).  Specific antigenic peptides were obtained by analyses of 
complete or partial protein sequences based upon the antigenicity, hydrophilicity, 
and accessibility parameters, which increases the likelihood of generating an 
antibody that recognises the full length protein.  A sequence representing 
haptoglobin α2-subunit was produced (CKNYYKLRTQGDGVY) based on these 
criteria and the specificity of this recommended antigenic peptide was confirmed 
using the Basic Local Alignment Search Tool (BLAST).  This procedure is very 
important since short peptides may have higher degree of amino acid homology 
with other proteins therefore creating unwanted antibody cross reactivity.  After 
generation of the specific peptide, the laboratory rabbits were inoculated with this 
peptide.  A first boost was made one week later and the trial bleeds were 
recovered from rabbits 10 days after each boost injection.  The titre evaluation of 
the antiserum was performed using an indirect immunoassay method.  Once the 
protocol of immunisation was found satisfactory to elicit the targeted antibodies, 
larger amounts of antiserum were produced using several immunisations in 
rabbits.  Antisera with similar characteristics (affinity, titre and crossreactivity) 




Polyclonal rabbit anti-human haptoglobin α-subunit antibody was generated using 
amino acid sequence, CKNYYKLRTQGDGVY (BioGenes).  The affinity-purified 
antibody developed for the haptoglobin α-subunit and two commercially available 
antibodies for the whole haptoglobin molecule were used for the sandwich ELISA 
analysis.  The total haptoglobin and haptoglobin α-subunit levels were quantified 
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using sandwich ELISA with rabbit anti-human polyclonal antibodies against 
haptoglobin (Dakocytomation) or haptoglobin-α subunit.  Goat anti-human 
haptoglobin antibody (Biodesign) diluted in 0.5% BSA in PBST buffer (1:200) was 
coated onto 96-well plates (NUNC) and the plate was incubated overnight at 4 °C.  
The plates were then blocked with 200 µl 3% non-fat dry milk in PBST for 2 hour 
at room temperature.  Next, diluted cyst fluid samples were individually mixed 
with 0.5% BSA in PBST buffer (1:100) and the mixture was incubated for 2 hour 
at room temperature.  The purified human haptoglobin (Sigma-Aldrich) or 
haptoglobin α-subunit (BioGenes) was used as standards.  The plate was then 
incubated with rabbit anti-human haptoglobin (1:400) (Dakocytomation) or 
haptoglobin-α subunit antibody (1:100) diluted in 0.5% BSA in PBST at room 
temperature for 2 hours followed by biotin-labelled anti-rabbit secondary antibody 
(1:400) and alkaline phosphatase streptavidin (1:400; Vector Laboratories).  p-
Nitrophenylphosphate (Vector Laboratories) was applied at 5 mM in 100 mM 
sodium bicarbonate solution at 37 °C for about 1 hour.  The protein 
concentrations were determined at 405 nm using an ELISA reader (Tecan). 
 
2.2.13 Measurement of haptoglobin using the PHASE RANGE haptoglobin 
assay kits 
 
A commercially available PHASE RANGE haptoglobin assay kit (Tridelta 
Development Ltd) was sourced that allowed a rapid, semi-quantitative 
assessment of total haptoglobin concentrations within body fluids.  This assay is 
based on the fact that the peroxidase activity of free haemoglobin is inhibited at a 
low pH environment. Binding of haptoglobin with haemoglobin will preserve the 
peroxidase activity of the bound haemoglobin.  Hence the peroxidase activity is 
proportional to the amount of haptoglobin present in the specimen.  We 
determined the accuracy and clinical usefulness of this kit in 90 cyst fluid samples.  
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Endometriotic and dermoid cysts were excluded from the study.  47 benign 
epithelial ovarian cysts, 13 borderline, 10 early stage and 20 late stage ovarian 
cancers were subjected to this analysis.  The assay was performed in a 96-well 
plate following the manufacturer’s instructions.  7.5 µl each of either prepared 
haptoglobin calibrators (0-2mg/ml), or the test specimens, were loaded in 
duplicate into the wells.  This was followed by the 100 µl of haemoglobin solution 
and mixed.  140 µl of a mixture of chromogen and substrate were next added and 
the plate was incubated for 5 min.  The colour reaction was recorded at the end 
of 5 min.   
 
2.2.14 Evaluation of ovarian tumour using ultrasonographic scoring system 
 
Transvaginal ultrasound examination was performed on an empty urinary bladder 
using a sector transducer (5-8 MHz) with a 210o /240 o image section (Acuson 
Sequoia Echo Ultrasound System, CA, USA).  Ultrasonographic evidence of 
metastasis and ascites are reported only if obvious, but we routinely report (1) the 
presence or absence of an ovarian tumour, (2) its solid or cystic nature, (3) the 
presence of septae and loculations within the tumour, (4) the presence of solid 
areas or papillary projections within the cyst, (5) whether the tumour is unilateral 
or bilateral, and (6) vascularity. 
 
2.2.15 Measurement of CA-125 level in serum and cyst fluid using sandwich 
ELISA method 
 
Serum and cyst fluid CA-125 levels were determined using a CA-125 ELISA kit 
(Alpha Diagnostic International).  The samples were diluted ten times using wash 
buffer and 25 µl of standards, control, and samples were pipetted into a 96-well 
plate in duplicate.  Next, 100 µl of biotinylated anti-CA-125 capture antibody was 
 94
loaded and the plate was incubated for 2 hours at room temperature.  After 
washing, 100 µl of HRP conjugated anti-CA-125 antibody was added and the 
plate was incubated for 1 hour at room temperature followed by addition of 
substrate and the stop solution.  The absorbance was read at 450 nm using the 
ELISA reader (Tecan).   
 
2.2.16 Histochemical and immunohistochemical studies 
 
The ovarian tumour tissues were frozen in liquid-nitrogen-cooled isopentane for 
histochemical examination.  Sections of 8 μm were cut from frozen slices and 
haematoxylin and eosin staining was performed to visualise sections containing 
the malignant ovarian cancer cells.  Briefly, in a slide rack, they were immersed in 
haematoxylin for 15 min, rinsed in running water, dipped in acid ethanol for 10 
sec and washed in running tap water for 5 min.  After 15 min in eosin, the slides 
were dehydrated in an ethanol series (70%, 100% x2), air-dried and mounted 
with coverslips over DPX mountant.  For immunohistochemistry study, after 8 min 
blockage with ultra v block reagent (BioGen Medical Instruments Inc), sections 
from ovarian cancer and benign ovarian tissue were immunostained for 1 hour 
using rabbit anti-human ceruloplasmin and haptoglobin antibody 
(Dakocytomation) at 37 °C followed by incubation with biotinylated anti-rabbit 
secondary antibody (1 hour at room temperature) and streptavidin alkaline 
phosphatase (30 min at room temperature) according to the manufacturer’s 
instructions.  Sections from formalin-fixed, paraffin-embedded tissues were also 
included in this study.  The slides were deparaffinised, treated with 3% hydrogen 
peroxide in phosphate-buffered saline and pretreated at 95 °C for 10 min in 10 
mol/l citrate buffer (pH 6.0).  Diaminobenzidine was used as the chromogen and 
haematoxylin as the nuclear counterstain.  IgG was used as negative control to 
replace the primary anti-haptoglobin antibody.  Tumours were considered positive 
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for ceruloplasmin and haptoglobin if definite cytoplasmic staining was present 
when observed under the microscope. 
 
2.2.17 Reverse transcription polymerase chain reaction (RT-PCR) 
 
2.2.17.1 Total RNA extraction 
 
Total RNA was isolated from cancer cells using an RNeasy Mini Kit (Qiagen) with 
minor modifications according to the manufacturer’s instructions.  Briefly, cancer 
cells (1x106) were mixed with 350 µl of Buffer RLT in 2 ml tubes.  After vortexing 
and homogenising the mixture, 350 µl of 70% ethanol was added to the 
homogenised lysates.  Next, 700 µl of this lysates containing any precipitate 
formed were applied to an RNeasy mini column placed in a 2 ml collection tube 
followed by centrifugation at 10,000 rpm for 15 sec.  After washing with 350 µl 
Buffer RW1, the samples were incubated with DNase for 30 min at room 
temperature.  The column was then washed using 700 µl Buffer RW1 and 500 µl 
Buffer RPE sequentially.  Thirty to fifty micro litre of Rnase-free water was added 
directly onto the Rneasy silica-gel membrane to dissolve the RNA.  After 
centrifugation, the eluate was collected and the quantity of RNA was estimated.  
 
2.2.17.2 Quantitative analysis of RNA products 
 
The concentration of RNA isolated was determined by measuring the absorbance 
at 260 nm (A260) and 280 nm (A280) in a spectrophotometer (Beckman). The ratio 
of absorbance at A260/A280 was taken as a measure of purity of total RNA.  2 µl of 
RNA was mixed with 78 µl of TE buffer (pH 7.0; 10 mM Tris, 1 mM EDTA).  After 
reading A260 blanked against TE buffer, the RNA recovered was determined by 
the following fomula: Total RNA (µg/ml) = (A260) x 40 µg /ml/ A260 x 40.   
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2.2.17.3 Qualitative analysis of RNA products 
 
The integrity and size distribution of total RNA purified was determined by 
denaturing agarose gel electrophoresis and ethidium bromide staining.  A 1.2% 
agarose gel was prepared by suspending appropriate amounts of agarose in 
DEPC treated water.  To the melted and cooled agarose, 1x MOPS buffer 
followed by 3 ml of 37% formaldehyde was added into 100 ml of gel solution.  
Next, the mixture was swirled and poured into the gel-casting unit and allowed to 
set.  The gel was covered with saran wrap in order to avoid evaporation of 
formaldehyde followed by immersion in 1x MOPS running buffer in the agarose 
gel electrophoresis apparatus.  
 
Two µl of the 10x loading buffer (2 µl 5x MOPS buffer, 3.5 µl formaldehyde and 
10 µl formamide) was added into 20 µl of RNA samples.  The mixture was 
denatured by heating at 65 °C for 15 min and applied to agarose gel 
electrophoresis at 50 V.  When electrophoresis was completed, the gel was 
immersed into distilled water with 0.2 µg/ml ethidium bromide at room 





Gene transcripts levels were determined using RT-PCR method.  A total reaction 
volume of 50 µl (Table 2.3) containing Sensiscript reverse transcriptase and 
HotStarTaq DNA polymerase, 400 µM dNTP, 1X reaction buffer, 0.6 µM of 
genetic specific primers, and 1 µg of template RNA were amplified in a Pχ2 
programmable thermal cycler (Thermo Hybraid) (Table 2.4).  To ensure that only 
RNA was amplified, a negative control in which the RT enzyme was omitted was 
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performed for each sample.  After amplification, the PCR products were 
separated by electrophoresis in a 2% agarose gel, stained with ethidium bromide 
(0.5 g/ml) and visualised under UV light.  
 
Table 2.3     Components for one-step RT-PCR reaction 
 
Component Volume/reaction μl Final concentration 
RNase-free water 
5x Qiagen OneStep RT-PCR buffer 
dNTP Mix 
Haptoglobin Primer forward 

















Total 50  
 
 







Reverse transcription: 30 50
Initial PCR activation step:  15 95




Final extension: 10 72
 
 
2.2.18 Statistical analysis  
 
Statistical significance was evaluated using the Student’s t-test or ANOVA 
analysis for comparison of the concentrations among benign, borderline tumour, 
early and late stage ovarian cancers.  For survival analysis, the Pearson’s χ2 test 
was used to compare the relationship between serum haptoglobin level with 
demographic and clinical data.  The univariate Kaplan-Meier analysis was used 
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to estimate the probability of survival and differences in survival rates were 
assessed by the log-rank test.  Multivariate analysis of prognostic factors was 
estimated using the Cox regression model.  Correlation studies were conducted 
using the Pearson’s correlation analysis to evaluate any relationship in the levels 
of proteins of interest in this study.  Receiver operating characteristic (ROC) 
curves were performed to assess the diagnostic performance of biomarkers in 
cyst fluid using split-point analysis based on previous study (Zhang et al., 2004).  
Thresholds for each biomarker were set to minimise the false positive and false 
negative ratios.  All statistical analyses were performed using SPSS 13.0 

















Chapter 3: SELDI-TOF based identification of 
differentially expressed cyst fluid protein 




Proteins derived from ovarian tumour cells can be detected in the cyst fluid 
(Hazelton et al., 1999; Furuya et al., 2000; Ott et al., 2003).  It is possible that 
rapid cellular turnover during malignant transformation could contribute to a large 
array of proteins which may be deregulated in the carcinogenic process.  Such 
tumour-derived proteins could play an important role in the growth of ovarian 
epithelial neoplasms.  By studying proteins secreted by these tumour cells into 
the cyst fluid, potential tumour markers that are being differentially expressed 
could be of use to discriminate benign cysts from EOC.   
 
Proteomics is a high-throughput technology which has the capability to identify 
hundreds of protein molecules present in the patient’s serum, biofluids and 
tissues.  The proteinChip platform technology SELDI-TOF, is a recent technology 
that has been invaluable in the discovery of new biomarkers and also in 
establishing differential protein profiles in various pathological states including 
cancers (Cheung et al., 2004; Yang et al., 2005; Engwegen et al., 2007).  In this 
regard, serum proteomic patterns have been utilised with a very high diagnostic 
power in ovarian cancer (Petricoin et al, 2002).  In addition, SELDI-TOF based 
identification of protein markers has been reported to be the major technique in 
biomarker detection for EOC (Ye et al., 2003; Moshkovskii et al., 2005).   
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In this study, a comprehensive investigation using SELDI-TOF, SDS-PAGE, 
MALDI-TOF alongwith the traditional immunological validation methods was 
conducted with a view to characterise novel proteins that may be differentially 
expressed in such tumours.  The hypothesis1 of the thesis “Differentially 
expressed proteins may be present in cyst fluid from benign and malignant 
ovarian tumours and could be identified using a combination of SELDI-TOF 
based proteomics methods and traditional immunological techniques” was 
examined in this chapter.  
 
3.2 Protein profiling using SELDI-TOF technology 
 
Aim.  To identify differentially expressed proteins in cyst fluid from benign and 
malignant ovarian tumours.  
 
Investigation.  Differences in protein profiles using the SELDI-TOF technique are 
represented as unique peaks or peaks with differential intensity within the 
Ciphergen spectra in diseases when compared with controls.  Detection of these 
protein peaks could be carried out either manually or with the help of Ciphergen 
ProteinChip software version 3.0.1 (Ciphergen Biosystems Inc).  The signature 
protein profiles of interest could be further fractionated using gel-based methods 
and identified by MALDI TOF-TOF/MS.  Sample preparation for hydrophilic NP20 
ProteinChip arrays as well as optimised machine settings for data acquisition 
from SELDI-TOF was described in section 2.2.4. 
 
Results and Interpretation.  The discriminating pattern formed by a small subset 
of proteins or peptides among the entire repertoire of thousands of proteins 
present in cyst fluid samples could distinguish malignant from benign ovarian 
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tumours.  Using Ciphergen’s Biomarker Program, it revealed that the protein 
profiles in benign and malignant cyst fluid samples shared many similarities 
among their hydrophilic proteins.  Figure 3.1 A illustrates the representative 
SELDI-TOF profiles ranging from 5 kDa—20 kDa according to the m/z ratio.  A 
major difference was observed from the 17.5 kDa peak in cyst fluid obtained from 
late stage ovarian cancers.  This particular peak was greatly diminished or absent 
in the benign tumours of the ovary (Figure 3.1 A; 3.1 B and 3.1C).  The 
normalised 17.5 kDa protein peak intensities in cyst fluid from benign, borderline 
tumour, early and late stage ovarian cancer is given in Table 3-1.  It was 
observed that this peak of high intensity was present in 9 out of 10 late stage 
ovarian cancers.  In contrast, it was not detected or was present with very low 
intensities in the majority of benign ovarian tumours.  Moreover, statistical 
analysis using ANOVA showed that the peak intensities for this 17.5 kDa protein 
were significantly higher in late stage ovarian cancer when compared with those 
from benign ovarian tumours (P<0.01).  Hence, the 17.5 kDa protein possessed 
the ability to differentiate malignant from benign ovarian tumours.  However, the 
identity of this protein could not be ascertained using the SELDI-TOF technique.  
In this regard, we utilised the conventional SDS-PAGE method to separate this 




























































Figure 3.1     SELDI-TOF protein profile analysis 
A     Cyst fluid protein profiles are demonstrated between 5-20kDa according to 
m/z ratio using NP20 protein chips.  Arrows indicate the position of the 17.5 kDa 
peak observed in ovarian carcinomas which was less frequently observed in 
benign tumours. 
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Figure 3.1 B     The identified protein peak at 17.5 kDa is indicated in the gel 



















Figure 3.1 C     The 17.5 kDa protein peak (circled) which has the ability to 
distinguish the malignant from the benign ovarian tumours is shown using 
Ciphergen Biomarker Wizard software 
 
Table 3.1     Normalised 17.5 kDa protein peak intensities in cyst fluid from 
benign and malignant ovarian tumours 
 
Benign Early or borderline Late 
Sample No. Intensity Sample No. Intensity Sample No. Intensity
1 0.9 10 2.4 11 2.5 
2 ND 20 1.6 13 ND 
3 0.6 26 1.6 14 7.3 
4 0.9 27 0.9 15 5.2 
5 3.9 74 1.4 16 2.9 
6 2.7 25 1.1 17 4.6 
7 0.7 31 1.7 18 2.1 
8 ND   32 2.7 
9 1.0   46 6.8 
21 2.9   49 4.3 
 





3.3 Protein fractionation and identification using SDS-
PAGE and MALDI TOF-TOF/MS 
 
3.3.1 Optimisation of protein precipitation methods for SDS-PAGE 
Aim.  Protein samples commonly contain substances that interfere with 
downstream applications.  There are several strategies for removing these 
substances, of which protein precipitation is one of the easiest methods utilised in 
the purification and concentration of proteins.  Protein precipitation is generally 
induced by addition of a salt, an organic solvent or by altering the pH of the 
solution (Rothstein, 1994).  Several precipitation methods were tested in order to 
precipitate proteins optimally from cyst fluid in this study.  
 
Investigation.  Cyst fluid samples were collected from patients presenting with 
benign and malignant ovarian tumours after obtaining informed consent as 
approved by the ethics committee of the National University Hospital (section 
2.1.1.1).  Proteins were precipitated using three different methods including i) 
acetone, ii) chloroform/ methanol and iii) ammonium sulphate precipitation 
(section 2.2.1.1).  After quantification using Bradford assay (section 2.2.3), ten 
micrograms of protein was separated by 12% SDS-PAGE followed by 
visualisation using silver stain (section 2.2.5).  Band intensity was detected 
visually or with the aid of Quantity One® software (Bio-Rad Laboratories).  
 
Results and interpretation.  Cyst fluid proteins separated by SDS-PAGE and 
observed by silver stain method is given in Figure 3.2.  It was observed that the 
proteins extracted using acetone had a better band recovery when compared 
with the other two precipitation methods.  Therefore, this method of precipitation 







Figure 3.2     SDS-PAGE (12%) of cyst fluid proteins using three 
precipitation methods  
Equal amount of cyst fluid proteins (10 µg) from representative benign and 
malignant epithelial ovarian tumours were loaded into each well.  Three 







3.3.2 Protein fractionation and identification using SDS-PAGE and MALDI TOF-
TOF/MS 
Aim.  The SELDI-TOF protein profiles are displayed according to their m/z ratio.  
Proteins with a single charge are separated based on their molecular weight.  As 
mentioned in section 3.2, the presence of one candidate marker with the 
molecular weight approximately 17.5 kDa is indicated (Figure 3.1).  Since the 
identity of this singly charged protein cannot be determined using the SELDI-TOF 
technique, conventional SDS-PAGE and MALDI TOF-TOF/MS methods were 
performed to separate and identify the target protein based on the molecular 
weight similarity.  
 
Investigation.  We utilised SDS-PAGE to separate the protein mixtures and 
isolate the corresponding protein bands between 15-20 kDa.  SDS-PAGE 
separates proteins according to their size.  Considering the molecular weight of 
the target protein, 15% SDS-PAGE was selected due to its ability to recover low 
molecular weight proteins.  Cyst fluid proteins from benign and malignant 
epithelial ovarian tumours were prepared using acetone precipitation method 
(section 2.2.1.1) and silver stain (Bio-Rad Laboratory) was used to visualise the 
protein bands.  Proteins of interest were detected either visually or with the aid of 
software (Bio-Rad Laboratory).  The target gel band from SDS-PAGE (Figure 3.3) 
was excised and subjected to alkylation, reduction and protein digestion prior to 
identification by MALDI TOF-TOF/MS (section 2.2.9.2 and section 2.2.9.3).   
 
Results.  Figure 3.3 indicated that the protein bands between 15 kDa to 20 kDa 
were predominantly present in cyst fluids from late stage ovarian cancer samples 
when compared with benign ovarian tumours.  Peptide mass fingerprinting using 
MALDI TOF/MS (section 2.2.9.2) followed by MASCOT search (section 2.2.9.4) 
identified the target protein as haptoglobin-α2 subunit.  The matched peptide 
 108
peaks were highlighted with arrows from the MASCOT search results (Figure 3.4 
A).  The sequence of matched peptides was noted to have 74% homology to that 
of haptolgobin-α2 subunit (Figure 3.4 B).  These results were significant with the p 
value being <0.05.  The peptides with peak of high intensity were selected for 
MS/MS analysis.  A summary of the sequence information is shown in Figure 3.4 
C while the selected peptide sequences ascertained by MS/MS analysis are 
depicted in Figure 3.5.  
 
Interpretations.  Proteins in conventional SDS-PAGE are separated according to 
the molecular weight.  The specific protein with molecular weight of 15-20 kDa 
identified in SDS-PAGE corresponded appropriately with that in the SELDI-TOF.  
This protein was observed to be significantly upregulated in late stage ovarian 
cancers (Figure 3.1 and 3.3).  Using the MALDI TOF-TOF/MS technique it was 
noted the protein band was identified as haptoglobin-α2 subunit.  The 
identification also demonstrated a very high sequence coverage (74%) and 
Mowse scores (325), indicating the accurate determination of this protein.  
However, using SDS-PAGE, protein resolution was limited since a number of 
proteins share the similar molecular weights and comigrate to the same position 
in the gels (Figure 3.3).  Since not all tryptic peptides from the selected protein 
spots were used for MS/MS analysis, the MS-based identification provided only 
an indication of haptolgobin-α2 subunit.  Alternative techniques are therefore 











Figure 3.3     One-dimensional gel electrophoresis of representative cyst 
fluid proteins  
Representative protein samples were obtained from benign ovarian tumour, 
borderline ovarian tumour, early stage and late stage ovarian cancers.  The 
protein band indicated between 15-20 kDa was the corresponding unique protein 






















VNDSGNDVTD IADDGQPPPK CIAHGYVEHS VRYQCKNYYK LRTQGDGVYT  
LNNEKQWINK AVGDKLPECE ADDGQPPPKC IAHGYVEHSV RYQCKNYYKL  
RTQGDGVYTL NNEKQWINKA VGDKLPECEA VGKPKNPANP VQ 
 
C 
Observed    Mr(expt)     Start    End    Ions   Peptide 
1439.72       1438.71        60   -    72     106   TEGDGVYTLNDKK 
1580.85       1579.84        58   -    71     17     LRTEGDGVYTLNDK 
1708.91       1707.90        117 -   131     49    LRTEGDGVYTLNNEK 
1857.98       1856.97        137 -   153     29    AVGDKLPECEAVCGKPK 
 
 
Figure 3.4     Mass spectrum generated by the 15~20 kDa protein band from 
SDS-PAGE using MALDI TOF/MS 
A: PMF from the 15~20 kDa protein band.  Arrows at the mass spectrum peaks 
represent peptides from haptoglobin-α2 subunit.  B: Sequence of human 
haptoglobin-α2 subunit (NCBI database accession No. 701184A) and the 
matched peptide sequence (bold).  Sequence coverage: 74%.  C: The peptide 
sequence from four most intense peaks observed in the mass spectra using 























































Figure 3.5     Representative CID generated MS/MS spectrum of the amino 
acid peptide sequence  
Amino acid sequence of TEGDGVYTLNNEK [(M+H)+ m/z 1439.88] and 
LRTEGDGVYTLND [(M+H)+ m/z 1581.02] from haptoglobin-α2 subunit  are 
shown.  Only b-, y- and a-type fragment ions are produced that can be used to 
confirm the amino acid assignments. 
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3.4  Validation of haptoglobin-α2 subunit using PS20 
immunocapture proteinChip analysis 
 
Aim.  In previous section, we assumed the protein band between 15-20 kDa in 
SDS-PAGE to be the corresponding protein peak in SELDI-TOF experiment 
based on the similarity of molecular weight (Figure 3.1 and 3.3).  In this section, 
immunocapture proteinChip experiment was utilised to further confirm that the 
predominantly present protein peak in Figure 3.1 was haptoglobin subunit.  
 
Investigation.  PS20 proteinChip is used to covalently immobilised biomolecules 
for the subsequent capture of proteins from complex biological samples and well 
suited for antibody-antigen interaction study (ProteinChip System Users Guide, 
Ciphergen).  Immunocapture experiments were performed with this proteinChip 
preincubated with rabbit anti-human haptoglobin antibody.  Experiment procedure 
control was carried out using proteinChip preincubated with TNF-α antibody.  
Purified haptoglobin antigen was used as internal positive control and IgG as 
negative control.  Cyst fluid proteins from selected benign and malignant tumours 
were analysed and data acquisition was carried out as described in section 2.2.4. 
 
Results and interpretation.  Results from this procedure indicated that malignant 
ovarian tumour had the same specific protein peak with the molecular weight 
around 17.5 kDa corresponding to haptoglobin-α2 subunit, which was also 
observed in the positive control.  Hence, this experiment provided confirmatory 
evidence that the predominantly present 17.5 kDa protein peak in late stage 
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Figure 3.6     Immunocapture experiments using PS20 proteinChip 
The immunocapture experiments were performed with PS20 proteinChips 
preincubated with anti-haptoglobin antibody to provide additional evidence 
confirming the presence of 17.5 kDa peak observed in Figure 3.1 to be 
haptoglobin-α2 subunit.  Haptoglobin antigen and Bovine IgG were used as the 
internal positive and negative control.  Cyst fluid protein from late stage ovarian 
cancer and benign tumour were exposed to the antibody-coated arrays.  TNF-
alpha and Bovine IgG were used in chips preincubated with TNF-alpha antibody 
as procedure control. 
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3.5 Validation of haptoglobin-α2 subunit as potential 
protein markers in EOC using conventional immunologic 
methods 
 
3.5.1 Validation using Western blotting analysis 
Aim.  In order to provide additional evidence, traditional immunological method 
Western blotting was used to validate the aberrant expression of haptoglobin-α2 
subunit in cyst fluid from benign and malignant ovarian tumours.  
 
Investigation.  Cyst fluid proteins from benign and malignant ovarian tumours 
were subjected to 15% SDS-PAGE as described earlier (section 2.2.5).  
Polyclonal rabbit anti-human haptoglobin antibody was used for Western blotting 
analysis (section 2.2.10).  Band intensities from different groups were measured 
using Quantity One® software (Bio-Rad Laboratories) 
 
Results and interpretation.  Results from the blotting procedure indicated the 
presence of different subunits of haptoglobin in cyst fluid from epithelial ovarian 
tumours as shown in Figure 3.7.  Based on the molecular weight, the 
corresponding subunits identified were β (40 kDa), α2 (17.5 kDa) and α1 (9 kDa) 
subunits.  The haptoglobin-α2 subunit was the protein of interest identified from 
SELDI-TOF and SDS-PAGE procedures.  Combined with immunocapture result, 
this data provided confirmatory evidence that haptoglobin-α2 subunit was 
elevated in cyst fluid from EOC when compared with benign disease.  It was also 
observed that the intensities of other haptoglobin subunits were increased in cyst 




Figure 3.7     Confirmation of haptoglobin using Western blotting analysis  
Confirmation of haptoglobin was performed using polyclonal rabbit anti-human 
haptoglobin antibody to detect the different subunits of this protein.  Equal 
amounts of protein (10 µg) from benign, borderline ovarian tumour, early stage 
and late stage ovarian cancer were loaded into the 15% SDS-PAGE.  Based on 
the molecular weight, the corresponding subunits identified were β (40 kDa); α2 
(17.5 kDa) and α1 (9 kDa).  High intensity bands were distinctly present in 
samples from early and late stage ovarian cancers when compared with benign 
















3.5.2 Generation of polyclonal antibody and quantitative analysis of 
haptoglobin-α subunit in cyst fluid using in-house established ELISA method 
Aim.  The aberrant distribution of haptoglobin-α subunit in benign and malignant 
ovarian tumours has been verified using semi-quantitative methods such as 
SELDI-TOF, SDS-PAGE and Western blotting (section 3.2, 3.3, 3.5.1).  In order 
to obtain the absolute quantity of this protein of interest in cyst fluid, we proposed 
to develop the in-house sandwich ELISA method using two antibodies, one of 
which should bind haptoglobin-α subunit specifically.  So far there is no 
commercially available antibody specifically against haptoglobin-α subunit.  
Therefore, a polyclonal rabbit anti-human haptoglobin-α subunit antibody was to 
be generated.  
 
Investigation.  The polyclonal rabbit anti-human haptoglobin-α antibody was 
generated as described in section 2.2.11.  Goat anti-human haptoglobin antibody 
(Biodesign) and the generated antibody were used in this ELISA experiment as 
described in section 2.2.12.  The precision of the detection method for 
haptoglobin-α subunit antigen was evaluated using intra-and inter-assay 
coefficients of variation (CV).  The intra-assay coefficient of variation was 
revealed by choosing three haptoglobin-α subunit antigen-positive cyst fluid 
samples by parallel determination of 8 wells simultaneously each.  The inter-
assay coefficient of variation was demonstrated by determination of the above 
samples for 5 consecutive days.  
 
Results and interpretation.  The CVs were 4.5% and 13.2% for the intra-assay 
and inter-assays respectively, which reached the requirement for intra and inter-
assay CVs for diagnostic kits (Chen et al., 1999).  Comparison of the mean of 
haptoglobin-α subunit levels in benign subjects and those presenting with early 
and late stage cancers was analysed using the ANOVA analysis.  A significant 
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difference between the three groups of patients was observed as indicated in 
Table 3.2 and Figure 3.8.  
 
Table 3.2     Mean concentration of haptoglobin-α subunit in benign and 
malignant ovarian tumours by the ELISA procedure 
 
Haptoglobin-α subunit (μg/ml)Group 
No. Mean P 
Late Cancer 17 216.3 <0.01 
Early and 
borderline 11 137.9  
Benign 





Figure 3.8     Concentrations distribution of cyst fluid haptoglobin-α subunit  
The concentrations of cyst fluid haptoglobin-α subunit obtained from 17 patients 
with EOC, 11 borderline tumour and 35 benign ovarian tumours were 
demonstrated.  The haptoglobin-α subunit levels were significantly higher in 







SELDI-TOF mass spectrometry technology offers a powerful and sensitive way to 
study post-translational protein profiles.  Previous study (Yang et al., 2005) 
already showed the effectiveness using SELDI-TOF coupled with gel based 
fractionation and MS based identification methods in identification of brain 
derived neurotrophic factor to be a novel functional protein in development of 
hepatocellular carcinoma.  In this study, by proteinChip technique, we monitored 
an upregulated cyst fluid proteins in malignant when compared with benign 
ovarian tumours, indicating that this protein might be closely related to tumour 
pathogenesis and had the potential to be a candidate biomarker for this insidious 
cancer.  We then identified this protein from malignant cyst fluid using SDS-
PAGE and MS to be haptoglobin-α2 subunit.  Using specific immunocapture 
experiment and antibody generated against this subunit, the expression pattern 
of haptoglobin-α subunit was confirmed.  Hence, our study suggests that the 
technical triads starting with (1) SELDI-TOF proteinChip technology, (2) SDS-
PAGE to separate proteins of interest based on molecular weight, followed by (3) 
in-gel digestion of selected protein bands, (4) identification of proteins using 
MALDI TOF-TOF tandem MS and (5) series of validation methods including 
immunocapture proteinChip, Western blotting and ELISA methods are ideal 
models in searching for potential protein markers for EOC.  The upregulated 







Chapter 4: 2-DE based identification of 
differentially expressed cyst fluid protein 




In the preceding chapter, the identification of haptoglobin-α2 subunit as a 
potential biomarker for EOC using SELDI-TOF based methods was described.  
This technique, however, is only suitable for the recovery of relatively low 
molecular weight proteins (Petricoin et al., 2004).  Hence, SELDI-TOF-based 
method used in the investigation limits the ability to isolate suitable protein 
biomarkers which may be identified by alternative methods.  In this regard, 2-DE 
was chosen to be a complementary technique to the SELDI-TOF with a view to 
identify other protein biomarkers of interest for the diagnosis or prognosis of 
ovarian cancer.  
 
2-DE consisting of IEF and SDS-PAGE eables the separation of complex protein 
mixtures according to pI and molecular weight.  It can resolve more than 5000 
proteins simultaneously and is suitable for both high and low molecular weight 
proteins (Gorg et al., 2004).  Moreover, the 2-DE technique has the capability to 
identify proteins that have undergone post translational modification including 
phosphorylation, glycosylation or limited proteolysis.  The modified proteins in 2-
DE gels can be readily located as they appear as distinct spot trains in the 
horizontal and/or vertical axis of the gel (Gorg et al., 2004).  In this context, it has 
been reported that differential expression of haptoglobin precursor, transferrin, 
cSHMT, Tbx3 and RhoGDI identified using 2-DE occurred in serum, plasma and  
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tissues from ovarian tumour patients (Jones et al., 2002; Ahmed et al., 2004; 
Lomnytska et al., 2006).  
 
Based on this premise, a comprehensive study using 2-DE coupled with MALDI-
TOF and traditional immunological validation methods was performed in a bid to 
further characterise alternative biomarkers.  Attempts were made to verify the 
hypothesis 1 “Differentially expressed proteins may be present in cyst fluid from 
benign and malignant ovarian tumours and could be identified using 2-DE and 
traditional immunological technology”.  
 
4.2 Protein sample preparation prior to 2-DE 
 
Aim.  Several high abundance proteins such as albumin and immunoglobin G in 
human serum may dominate the protein profile and mask potential low 
abundance biomarkers.  In human plasma, albumin accounts for 57–71% (w/w) 
of the total protein and is present at concentrations of 35–50 mg/ml, while the 
potential protein markers are always present in µg or pg ranges (Anderson et al., 
2002).  Moreover, uneven distribution of protein concentrations in serum could 
result in horizontal or vertical smears on the 2-DE, which poses a difficulty in 
image analysis (Magnani et al., 2004).  One approach to facilitate biomarker 
discovery would be to prefractionate body fluids using antibody chelating columns 
to remove high abundance proteins, thereby increasing the potential for analysing 
and detecting useful biomolecules. 
 
Investigation.  Protein composition in cyst fluid was studied using SDS-PAGE 
(section 2.2.5).  In order to remove the high abundance protein albumin, cyst fluid 
samples were subjected to affinity column purification using Aurum Serum 
Protein Mini kit (Bio-Rad laboratories; section 2.2.8.1).  To evaluate if albumin 
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was successfully removed in the samples, an aliquot of fractionated and 
unfractionated cyst fluid (10 µl) were subjected to SDS-PAGE and 2-DE (section 
2.2.5 and section 2.2.8) followed by visualisation with silver stain (Biorad 
laboratory). 
 
Results and interpretation.  As shown in Figure 4.1 and 4.2, using SDS-PAGE 
and MALDI TOF-TOF/MS it was observed that albumin comprised the major 
portion of cyst fluid proteins.  Figure 4.3 indicated that the fractionated cyst fluid 
sample in which the albumin was substantially removed had a better resolution of 
the protein bands when compared with the unfractionated samples.  Silver 
staining of 2-DE from albumin depleted samples also revealed the presence of 
additional protein spots with low molecular weight which could be readily 
identified and characterised (Figure 4.4).  Therefore, this Aurum Serum Protein 
Mini column provides a simple, rapid and effective method for depletion of 










Figure 4.1    Identification of the high abundance protein in cyst fluid as 
albumin 
The protein band indicated in the left panel (arrowed) was subjected to MALDI 
TOF/MS analysis.  Mass spectrum analysis generated by this high abundance 
protein using MALDI TOF/MS is shown in the right panel.  Arrows at the mass 
spectral peaks represent peptides from albumin.  
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MS/MS Fragmentation of DDNPNLPR (score 41) 
 
 
Figure 4.2     Representative CID generated MS/MS spectrum of the amino 
acid peptide sequence  
Amino acid sequences of YLYEIAR [(M+H)+ m/z 927.51] and DDNPNLPR 
[(M+H)+ m/z 940.47] from albumin are shown.  Only b-, y- and a-type fragment 











Figure 4.3     SDS-PAGE analysis of representative cyst fluid protein sample 
before and after albumin depletion using the anti-albumin antibody 
chelating column 
Unfractionated cyst fluid (proteins without albumin depletion), the fractionated 
cyst fluid (proteins following Aurum Serum Protein Mini column purification) and 
bound fraction (proteins recovered from the membrane) are indicated 
respectively.  It was observed that the albumin depleted samples of cyst fluid 








Figure 4.4     2-DE analysis of representative cyst fluid protein sample before and after albumin depletion 
Cyst fluid proteins were analysed using pH three to ten IPG strip for the first dimension and 4-20% gradient SDS-PAGE for the second 
dimension after silver staining.  Arrows showed the effectiveness of albumin depletion and the presence of additional protein spots in the low 
molecular weight regions were also highlighted as circles. 
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4.3 Identification of differentially expressed proteins in 
cyst fluid using 2-DE based proteomics methods 
 
4.3.1 Cyst fluid protein profiles from benign and malignant epithelial ovarian 
tumours using 2-DE 
Aim.  To examine the protein profiles and detect differentially expressed proteins 
in cyst fluid from EOCs using 2-DE 
 
Investigation.  For 2-DE analysis, cyst fluids from benign (n=10), borderline 
tumours (n=7), early (n=3) and late stage (n=12) EOCs were analysed in triplicate 
as mentioned in section 2.2.8.  Following removal of high abundance proteins 
including albumin, the cyst fluid samples were subjected to quantification using 
the RC DC protein assay (Bio-Rad laboratories).  Briefly, for the 2-DE procedure, 
100 µg of cyst fluid protein was mixed with 185 µl of rehydration buffer, subjected 
to electrophoresis in IPG strips of 11 cm at a pH of 4–7 for the first dimensional 
separation and to a 4-20% tris-HCl criterion gel (Bio-Rad Laboratories) for the 
second dimensional separation.  Protein spots were visualised by silver staining 
and spot detection, quantification and matching were performed using the 
PDQuest version 7.2 software package (Bio-Rad Laboratories).  
 
Results and interpretation.  Representative cyst fluid protein profiles from benign, 
borderline tumour, early and late stage ovarian cancers performed by this 
procedure are presented in Figure 4.5.  An average of 160-180 spots for each 
sample was detected in the gels at the pH range 4-7 (Figure 4.5).  It was 
observed that four regions of significant and consistent up-regulated spots with 
an intensity change of more than two-fold were detected with the PDQuest 
software (illustrated in Figure 4.5 and 4.6) from malignant EOC cases when 
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compared with benign tumours.  As indicated in Figure 4.6, representative 
samples of up-regulated spots in region A could be observed in two early, four 
borderline and seven late stage ovarian cancers; two early, two borderline and 
five late ovarian cancer were noted for spots in region B; one early, two 
borderline and five late ovarian cancer for region C and one early, three 
borderline and six late ovarian cancer for region D after computing for volume 
intensity difference between benign and malignant ovarian tumours.  Data from 
this 2-DE technique also indicated the presence of isoforms for the above 
proteins as indicated by multiple protein spots with different molecular mass and 
pIs, suggesting possible co- or post-translational modifications.  It was also 
observed that a significant heterogeneity in protein patterns occurred in these 
cyst fluid samples.  All significant protein spots which were reproducible by the 2-
DE technique were excised from the gels and subjected to MALDI TOF-TOF/MS 





Figure 4.5     Representative silver-stained 2-DE of cyst fluid protein profiles 
from benign, borderline tumours as well as early and late stage ovarian 
cancers  
50ng of protein was used for each experiment and the staing time for each 
sample was identical.  The differences in spot intensities could be visually 
appreciated and identified using PDQuest software.  Four areas were identified 
and the consistent spot changes observed were represented as circles.  
Molecular weight markers were indicated on the left (in kDa) and the 









Figure 4.6     Elevated expression of protein spots in cyst fluid from 
malignant compared to benign ovarian tumours  
Image analysis was performed using PDQuest software.  Results from two 
benign; two borderline tumours; two early and two late stage ovarian cancers are 
presented.  These are representative of ten benign tumours, seven borderline 











4.3.2 Identification of differentially expressed proteins in malignant ovarian 
tumours using MALDI TOF-TOF/MS 
Aim.  To identify the differential protein spots in 2-DE from malignant cyst fluid 
mentioned in section 4.3.1 
 
Investigation.  The differentially expressed protein spots in 2-DE gels (Figures 4.7) 
from malignant ovarian cyst fluids were excised and the corresponding peptides 
were eluted by in-gel digestion.  MALDI TOF-TOF/MS was employed for 
identification of these protein spots (section 2.2.9)  
 
Results and interpretation.  MALDI TOF-TOF/MS (section 2.2.9.2) followed by 
MASCOT search (section 2.2.9.4) identified the proteins of interest circled in 
Figure 4.5 as ceruloplasmin and haptoglobin.  Matched peptide peaks from 
MASCOT search are highlighted (Figure 4.8 and 4.10, arrows).  The sequence of 
matched peptides has 28% and 45% homology to that of ceruloplasmin and 
haptoglobin respectively.  A summary of the peptide sequence information is 
shown in Figure 4.8 B and 4.10 B while the representative peptide sequences 
ascertained by MS/MS analysis are depicted in Figure 4.9 and 4.11.  Other 
proteins identified from the selected spots with their matched peptides, sequence 
coverage, MOWSE score, theoretical molecular weight and pI are listed in Table 
4.1.  Ceruloplasmin and haptoglobin were further analysed by Western blotting, 
since they were consistently and significantly altered in cyst fluid from EOC when 
compared with benign ovarian tumours.  Identification of candidate markers in the 
60 kDa-120 kDa molecular weight regions provides evidence for hypothesis 1 in 
which it was proposed that 2-DE could be a complementary method to SELDI-








Figure 4.7     A representative map of silver-stained 2-DE profile obtained 
from cyst fluid of EOC.   













Figure 4.8     Identification of ceruloplasmin using MALDI TOF-TOF/MS  
A: Mass spectrum generated by the protein No 1 using MALDI-TOF/MS.  Arrows 
at the peaks of mass spectra represent peptides from ceruloplasmin 
B: The peptide sequence from the most intense peaks observed in the mass 













MS/MS Fragmentation of QYTDSTFR (ion score 33) 
 
 
Figure 4.9     Representative CID generated MS/MS spectrum of the amino 
acid peptide sequence  
Amino acid sequence of EYTDASFTNR [(M+H)+ m/z 1203.55] and QYTDSTFR 
[(M+H)+ m/z 1017.48] from ceruloplasmin are shown.  Only b-, y- and a-type 





Figure 4.10   Identification of haptoglobin using MALDI TOF-TOF/MS  
A: Mass spectrum generated by the protein spot No 9 using MALDI-TOF/MS.  
Arrows at the mass spectrum peaks represent peptides from haptoglobin.   
B: The peptide sequence from seven most intense peaks observed in the mass 









MS/MS Fragmentation of DYAEVGR 
 
 
MS/MS Fragmentation of GSFPWQAK 
 
 
Figure 4.11   Representative CID generated MS/MS spectrum of the amino 
acid peptide sequence  
Amino acid peptide sequence of DYAEVGR [(M+H)+ m/z 809.37] and 
GSFPWQAK [(M+H)+ m/z 920.48] from haptoglobin are shown.  Only b-, y- and 
a-type fragment ions are produced that can be used to confirm the amino acid 
assignments. 
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Table 4.1     Proteins identified using 2-DE with MALDI TOF-TOF/MS and database search in cyst fluid from EOC  
 
Spot 






MOWSE score Protein coverage (%) 
Theoretical 
MW/pI 
1 Ceruloplasmin gi|1620909 3 188 12 116.197/5.43
2 Ceruloplasmin gi|1620909 7 415 28 116.197/5.43
3 Alpha1-Antitrypsin gi|1942629  4 270 46 44.280/5.37 
4 Chain A, Human Serum Albumin gi|4389275 3 190 19 68.425/5.67 
5 Vitamin D-Binding Protein gi|21730555 3 89 21 56.34/5.87 
6 Chain A, Human Serum Albumin gi|4389275 4 231 23 68.425/5.67 
7 Serum albumin precursor gi|6013427  8 536 33 71.176/5.91 
8 Transferrin gi|4557871 9 959 40 79.310/6.68 
9 HP protein gi|47124562  7 516 45 31.647/8.48 
10 HP protein gi|47124562  4 229 38 31.647/8.48 
11 HP protein gi|47124562  5 213 56 31.647/8.48 
12 IgG kappa chain gi|4176418  2 133 47 23.726/7.85 
13 Proapo-A-I protein gi|178777  7 527 65 30.745/5.55 
14 Hp2-alpha gi|296653  4 210 21 15.945/5.57 
15 Apolipoprotein gi|27065339  5 190 41 11.291/6.58 
16 Transthyretin gi|55669576  3 191 60 12.835/5.33 
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4.4 Validation of differentially expressed proteins in cyst 
fluid using conventional immunologic methods and RT-
PCR 
 
4.4.1 Validation of protein identification using 2-DE followed by Western blotting 
analysis 
Aim.  To validate ceruloplasmin and haptoglobin identified from 2-DE and MALDI 
TOF-TOF/MS techniques 
 
Investigation.  Cyst fluid from malignant ovarian tumours was selected in this 
investigation.  2-DE and Western blotting analyses were performed as described 
previously (section 2.2.10).  Rabbit anti-human ceruloplasmin and haptoglobin 
polyclonal antibodies (Dakocytomation) were used in this validation experiment 
(section 2.1.2.1).  Protein spots of interest were identified according to pI and 
molecular weight of proteins in the parent 2-DE gel using PDQuest software.   
 
Results and interpretation.  Ceruloplasmin and haptoglobin identified using MS 
was confirmed by 2-DE and Western blotting analysis.  The polyclonal antibodies 
used in this technique enabled detection of the corresponding protein spots at the 
position where they were excised from 2-DE for subsequent identification using 
MALDI TOF-TOF/MS (Figure 4.12).  Validation using the 2-DE followed by 
Western blotting analysis therefore provides further evidence for the proteomics 








Figure 4.12   Confirmation of identification of ceruloplasmin and 
haptoglobin using 2-DE followed by Western blotting analysis 
Representative cyst fluid 2-DE protein profiles using silver stain (left) and 
Western blotting analysis of ceruloplasmin and haptoglobin (right) from serous 
ovarian cancer using 4-20% precast gel.  Comparing relative position of protein 
spots in 2-DE and Western blotting using PDQuest software could confirm the 






4.4.2 Validation of differentially expressed proteins in cyst fluid from benign and 
malignant ovarian tumours using SDS-PAGE and Western blotting analysis 
Aim.  To validate differentially expressed ceruloplasmin and haptoglobin in cyst 
fluid using SDS-PAGE and Western blotting methods 
 
Investigation.  Cyst fluid proteins from benign and malignant ovarian tumours 
were subjected to 15% SDS-PAGE as described earlier (section 2.2.5).  
Polyclonal rabbit anti-human antibodies were used for Western blotting analysis 
(section 2.2.10).  Ceruloplasmin was analysed using native gel electrophoresis 
without application of DTT and SDS, and high temperature was also avoided to 
prevent fragmentation of this high molecular weight protein (section 2.2.6).  Band 
intensities from Western blotting were measured using Quantity One® software 
(Bio-Rad Laboratories) 
 
Results and interpretation.  The antibody used in this experiment could detect the 
different subunits of ceruloplasmin and haptoglobin.  For ceruloplasmin, previous 
studies indicated that this protein may undergo proteolytic fragmentation and 
result in segments with different molecular weight (Kingston et al., 1977).  Hence, 
in this experiment, ceruloplasmin was analysed by native gel electrophoresis in 
order to facilitate the comparison of intensity difference between the benign and 
malignant ovarian tumours.  It was observed that ceruloplasmin antibody 
produced a major band corresponding to the molecular weight of 130 kDa (Figure 
4.13).  On the other hand, the haptoglobin antibody revealed three subunits of 
this acute phase reactant with molecular weights of 40 kDa, 17.5 kDa and 9 kDa 
as mentioned previously (section 3.5.1; Figure 4.13).  Moreover, the intensities of 
both proteins in cyst fluid were significantly higher in late stage ovarian cancer 





Figure 4.13   Western blotting analysis of ceruloplasmin and haptoglobin in cyst fluid from benign, borderline tumour, early and late 
stage ovarian cancers  
The intensities of both proteins were significantly elevated in cyst fluid from late stage ovarian cancer when compared with benign tumours 
(*P<0.01). 
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4.4.3 Validation of differentially expressed proteins in tissues from benign and 
malignant ovarian tumours using Western blotting analysis 
Aim.  To explore the aberrant expression of ceruloplasmin and haptoglobin in the 
ovarian tumour tissues  
 
Investigation.  Haematoxylin and eosin (H & E) staining was conducted to 
visualise sections containing the malignant ovarian cancer cells (section 2.2.16).  
For Western blotting analysis, the tissue sections were carefully selected 
following consultation with the histopathologist wherein the cancer cells 
accounted for the major portion of the tissue.  The samples used were placed in 
lysis buffer (section 2.1.2.3) followed by homogenisation.  Following 
centrifugation, the supernatants were collected and used for the subsequent 
experiments.  
 
Results and interpretation.  H & E staining from representative serous and 
mucinous ovarian tumours is indicated in Figure 4.14.  It was observed that 
cancer cells were localised to form “cancer loci” with high nucleus to cytoplasm 
ratio.  The neoplastic cells had large and irregular nuclei compared with para-
cancerous interstitial cells and those from benign ovarian tumours.  Samples from 
early stage ovarian cancer were not included in this study because of paucity of 
material.  Our data revealed that significant up-regulation of ceruloplasmin 
(P<0.01) and haptoglobin (P<0.01) could be observed in ovarian cancer tissues 
when compared with those from benign tumours (Figure 4.15).  Moreover, as 
indicated in Figure 4.16, a significant positive correlation existed between the 
levels of these two proteins in cyst fluid and in the corresponding ovarian tumour 
tissues.  The positive correlation between tissue and cyst fluid levels of 
ceruloplasmin and haptoglobin therefore provides evidence that alteration of both 
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Figure 4.14   H & E staining of representative benign and malignant ovarian 
tumours 
A serous cancer; B mucinous cancer; C benign serous tumour; D benign 
mucinous tumour.  For tissue selection, the neoplastic cells accounted for the 
major portion of the tissue sections.  As indicated, the malignant cells possessed 
the typical characteristics of large and irregular nuclei compared with those from 















Figure 4.15   Differential expressions of ceruloplasmin and haptoglobin in 
benign and malignant ovarian tumour tissues  
A  Differentially expressed ceruloplasmin and haptoglobin in tissues from benign 
and malignant ovarian tumours detected by Western blotting analysis.  B  The 
expression of ceruloplasmin and haptoglobin was significantly higher in ovarian 
cancer tissue compared with those from benign ovarian tumours.  The bars 
represent the mean ± SEM of densities of gel bands determined from ovarian 






















Figure 4.16   Correlations of haptoglobin and ceruloplasmin expression in 
cyst fluid and tissue  
Single regression analysis of band intensities in ovarian tumour tissues and cyst 
fluids is demostrated.  Significant correlations were observed between levels of 



















4.4.4 Immunohistochemical localisation of ceruloplasmin and haptoglobin in 
benign and malignant ovarian tumours 
Aim.  To localise the presence of cerulopasmin and haptoglobin in ovarian 
tumour tissue sections by the immunohistochemical technique 
 
Investigation.  Immunohistochemical experiments were carried out in wax-
embedded and frozen tissue sections.  Samples were embedded in wax or 
subjected to frozen section after collection and H & E staining was performed.  
Sections used were carefully selected after consultation with the histopathologist.  
Polyclonal rabbit anti-human ceruloplasmin and haptoglobin antibodies were 
used in this study (section 2.1.2.1).  
 
Results and interpretation.  In accordance with results from the Western blotting 
procedure, immunohistochemical analysis also indicated intense staining of 
ceruloplasmin and haptoglobin in the cytoplasm of ovarian cancer cells obtained 
from late stage ovarian cancers when compared with those from benign ovarian 
tumours (Figure 4.17).  Cellular staining was mostly cytoplasmic with the majority 
of the staining being observed in “cancer loci”.  Strong staining for haptoglobin 
was evident in areas with stroma and vascular spaces as well as in the ovarian 
vessels.  Coupled with the Western blotting data in section 4.4.2 and 4.4.3, it is 
reasonable to suggest that levels of ceruloplasmin and haptoglobin were up-
regulated in both cyst fluid and tissue levels from the malignant tumours.  
Elevation in these two proteins in cyst fluids and tissues could be indicative of the 







Figure 4.17   Differential expressions of ceruloplasmin and haptoglobin in 
ovarian tumour tissue samples examined by immunohistochemistry.   
Ceruloplasmin was expressed predominantly in late stage ovarian cancer (A) 
compared with benign ovarian tumours (B).  Haptoglobin was expressed in both 
late stage ovarian cancer (C serous, D mucinous) and benign ovarian tumour (E 
serous, F mucinous).  The expression level was higher in ovarian cancer cells 
when compared with those from benign tumours.  More intense staining was 
evident in areas with cancer cells as well as in the vascular spaces.  Original 
magnification ×200 
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4.4.5 Quantitative measurements of ceruloplasmin and haptoglobin in cyst fluid 
from benign and malignant ovarian tumours using in-house ELISA method 
Aim.  Using Western blotting and immunohistochemistry studies we have 
evaluated the relative expression levels of ceruloplasmin and haptoglobin in 
benign and malignant cyst fluid as well as in tumour tissues.  The in-house ELISA 
methods were employed to quantify these two proteins in cyst fluid.   
 
Investigation.  Cyst fluid samples from 47 benign ovarian tumours, 13 borderline 
tumours, 10 early stage and 20 late stage ovarian cancers were used in this 
study.  For ceruloplasmin, the 96-well microplates were coated with cyst fluid 
antigen directly and a rabbit anti-human ceruloplasmin antibody (Dakocytomation) 
was used to detect its concentration.  For haptoglobin, instead, a sandwich 
ELISA method was developed using two antibodies specific to haptoglobin 
(section 2.2.12).  Briefly, cyst fluid samples were diluted 100 times for 
haptoglobin and undiluted samples were used for ceruloplasmin measurements.  
Purified ceruloplasmin and haptoglobin (Sigma grade) were used as standards.  
Standard curves were obtained by serial dilution of the corresponding purified 
proteins.   
 
Results and interpretation.  Tetrameric protein haptoglobin has three phenotypes 
Hp 1-1, 2-1, and 2-2 (Tseng et al., 2004a).  All the phenotypes are composed of 
different combinations of β, α2 and α1 subunits.  Results from western blotting 
analysis showed that the two antibodies used for the in-house sandwich ELISA 
method possessed the capacity of binding both alpha and beta subunits (Figure 
3.7 and 4.18 and 4.12).  Based on this finding, the ELISA method used in this 
study measured the total serum haptoglobin concentrations.  The intra- and inter- 
assay CVs were computed by using three samples of different concentrations 8 
times on the same day and on 5 consecutive days, respectively.  The CVs were 
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4.8% and 15.3% for the intra-assay and inter-assays for ceruloplasmin 
measurements while it was 3.8% and 14.2% for haptoglobin, respectively.  A 
representative standard curve for haptoglobin is given in Figure 4.19.  
Comparison of the mean of haptoglobin or ceruloplasmin levels in benign 
subjects and those presenting with early and late stage cancer were analysed 
using the ANOVA analysis.  The concentration of haptoglobin in cyst fluid from 
early (4.44±0.61 mg/ml) and late stage (5.96±0.56 mg/ml) ovarian cancer was 
significant higher when compared with benign ovarian tumours (1.54±0.30 mg/ml, 
P<0.01).  No significant difference in ceruloplasmin concentrations was 
discernible between early, late stage ovarian cancers (0.89±0.36; 1.11±0.18 
μg/ml respectively) and benign ovarian tumours (0.65±0.11 μg/ml; Table 4.2 and 







































































































Figure 4.18   Western blotting analysis showing binding capacity of goat 








Figure 4.19   Representative standard curve obtained from a serial dilution 
of purified haptoglobin. 
 
 
Table 4.2     Mean concentrations of ceruloplasmin and haptoglobin in cyst 
fluids from benign and malignant ovarian tumours by the ELISA method 
 
Haptoglobin level       Ceruloplasmin level Group 
No. Mean (mg/ml) P Mean (μg/ml) P 
Late cancer 20 5.96±0.56 <0.01 1.11±0.18 =0.134  
Early and 
borderline 23 4.44±0.61 <0.01 0.89±0.36    









Figure 4.20   Concentration distribution of cyst fluid ceruloplasmin and 
haptoglobin 
Cyst fluid ceruloplasmin and haptoglobin concentrations obtained from 20 
patients with EOC, 23 with early and borderline and in 47 benign ovarian tumours.  
The haptoglobin levels were significantly higher in patients with early and late 
stage ovarian cancers when compared with those from benign tumours (*P<0.01).  
There was no significant difference between early, late stage ovarian cancer and 
benign ovarian tumours for ceruloplasmin (P=0.134). 
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4.4.6 Validation of ceruloplasmin and haptoglobin mRNA expression in ovarian 
cancer cell lines using RT-PCR 
Aim.  Expression of haptolgobin and ceruloplasmin proteins were evaluated in 
cyst fluid and tissue samples from benign and malignant ovarian tumour patients.  
The RT-PCR was conducted to examine the mRNA expression of these 
biomolecules in three ovarian cancer cell lines.  
 
Investigation.  Three ovarian cancer cell lines were obtained from ATCC and 
cultured until a density of about 80% confluence.  Total RNA was extracted 
(section 2.2.2 and section 2.2.17) from approximately 5X106 cells followed by 
quantitative and qualitative measurements (section 2.2.17).  Optimal PCR 
conditions for each gene was determined in preliminary experiments so that the 
number of cycles selected was within the linear range of amplification and optimal 
annealing temperatures were determined for each gene (Agarwal et al., 2001).  
Primer pairs used for the amplification of the individual gene are listed in Table 
4.3.  The conditions for RT-PCR reaction in this experiment is illustrated in Table 
4.4. 
 
Table 4.3     Primer pairs used for the amplification for individual gene 
 
Target proteins  Sense Anti-Sense 
Amplified 
bps 














Results and interpretation.  Denaturing formaldehyde agarose gel electrophoresis 
revealed the presence of 18S rRNA and 28S rRNA bands, which indicated the 
integrity of total RNA in these experiments (Figure 4.21).  An intense mRNA 
expression for haptoglobin occurred in the three ovarian cancer cell lines (Figure 
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4.22), which provided confirmatory evidence that the tumour cells might possess 
the capacity to synthesise haptoglobin.  However, ceruloplasmin mRNA 
expression was not observed in these cell lines. 
 
 Table 4.4     RT-PCR reaction condition 
 
Step Time Temperature (oC) 
Reverse transcription: 30 min 50 
Initial PCR activation step 15 min 95 
   
Three-step cycling (35-40 cycles)   
Denaturation 45 sec 94 
Annealing 45 sec variable 
Extension 1 min 72 
   





Figure 4.21   Analysis of integrity of total RNA from ovarian cancer cells 
using denaturing formaldehyde agarose gel electrophoresis   














Figure 4.22   Analysis of mRNA expression of haptoglobin in ovarian cancer 
cell lines by RT–PCR   
A fragment of 197 base pairs was amplified from the total RNA isolated from 
ovarian cancer cell lines.  RT control was conducted without Sensiscript reverse 


























The progression from early to late malignant ovarian cancer is accompanied by 
genetic alterations and changes in protein levels which are of critical importance 
since altered protein expression is a hallmark of neoplasia.  Therefore, proteins 
secreted by ovarian cancer cells into cyst fluid may prove to be useful markers for 
intra-operative discrimination of malignant from benign ovarian tumours.  They 
may also provide a rich source of potential tumour markers which are more 
difficult to be isolated and identified in blood where there are a number of 
abundant proteins. 
 
In this regard, the discovery of sensitive and specific serum biomarkers for the 
diagnosis and prognosis of ovarian cancer remains a daunting challenge.  The 
large dynamic range between the least and most abundant of protein constituents 
found in biological fluids is a difficult hurdle to overcome.  The current study 
approaches this problem by removing the most abundant circulating protein, 
albumin from cyst fluid samples which make up more than 70% of total serum 
protein by mass.  The immunoaffinity-depleted cyst fluid samples from patients 
with ovarian cancer and benign samples were then subjected to 2-DE.  2-DE 
coupled with MS is a key separation technique in proteome analysis due to its 
advantage of simultaneous separation and display of many proteins at a time with 
good reproducibility (Gorg et al., 2004), while MS is a powerful tool for mining 
with high sensitivity and speed of analysis for the 2-DE proteome.  This study 
demonstrated for the first time the presence of differentially expressed 
ceruloplasmin and haptoglobin in cyst fluid from ovarian cancers when compared 
with benign ovarian tumours.   
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Another interesting observation is that relative quantitative Western blotting using 
SDS-PAGE demonstrated significant higher intensities of ceruloplasmin and 
haptoglobin in cyst fluid and tissues from patients with ovarian cancer.  
Localisation of ceruloplasmin and haptoglobin by immunohistochemistry also 
indicated enhanced staining of both proteins in ovarian cancer cells from the 
tissue sections.  Moreover, measurements of haptoglobin concentration in cyst 
fluid using the in-house sandwich ELISA method indicated elevation of 
haptoglobin in cyst fluid from malignant ovarian tumours.  Therefore, it seems 
plausible to suggest that elevated cyst fluid haptoglobin levels could be derived 
from the malignant tumour cells, although the circulating molecules may also 
contribute to this elevation.   
 
In conclusion, using conventional 2-DE based proteomics methods combined 
with immunological validation procedures, this study indicates the differential 
expression of ceruloplasmin and haptoglobin in cyst fluid from benign and 
malignant ovarian tumours.  Identification of high molecular weight proteins 
including ceruloplasmin and haptoglboin-β subunit using 2-DE indicates that this 
high throughput technology could serve as a complementary method to SELDI-
TOF in identifying candidate protein markers for EOC.  It is noteworthy that 
haptoglobin may be a useful marker for diagnosis and prognostication of 








Chapter 5: Investigations on haptoglobin as a 




Significant differences in survival rates between early and advanced EOCs has 
been the focus of research to identify markers for EOC that can be of diagnostic 
or prognostic value.  Owing to the paucity of symptoms and their insidious onset, 
most ovarian cancer patients present with advanced stage of the disease, the 
five-year survival rate being a mere 30% often due to a failure in early diagnosis 
(Menon, 2004).  Although CA-125 is by far the most useful biomarker for ovarian 
cancer, it is only limited in evaluations of therapeutic effectiveness in patients 
diagnosed with EOC and also in detection of recurrent disease during post-
treatment surveillance (Meyer et al., 2000).  Moreover, CA-125 is not a specific 
biomarker for ovarian cancer due to its elevation in women with other benign 
gynaecologic conditions such as ovarian cysts, endometriosis and uterine fibroids 
(Mogensen, 1992; Cannistra, 1993; Mackey et al., 1995).  On the other hand, 
prognosis of ovarian cancer is largely dependent on the stage and histologic 
grade on presentation.  Patients with well-differentiated tumours based on 
histologic grade tend to have a better survival rate compared to those with poorly-
differentiated tumours (Swenerton et al., 1985).  The current management of 
patients with ovarian cancer involves optimal cytoreductive surgery followed by 
chemotherapy.  Despite an initial favourable reaction to the therapy, most 
patients however, appear to have a relapse within five years after management of 
the tumours (Ozols, 2005).  The present study therefore focuses on the 
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evaluation of clinical significance of haptoglobin as a biomarker identified from 
the cyst fluid of EOC.   
 
Data from this research revealed that haptoglobin was differentially expressed in 
samples from benign and malignant ovarian tumours.  The applicability of this 
biomolecule needs to be further evaluated in our group of patients attending the 
Gynaecologic Oncology Clinic at the National University of Hospital, Singapore.  
Two important clinical evaluations were conducted to address this issue.   Firstly, 
the  hypothesis 2 “Similar protein expression patterns may also observed in 
serum from benign and malignant ovarian tumours and they may have potentials 
to be diagnostic and prognostic markers” was examined by measurements of 
haptoglobin concentration in sera from patients with EOCs.  Secondly, we 
explored the hypothesis 3 in which “an intra-operative assay using cyst fluid could 
be developed so as to differentiate malignant from benign ovarian tumours at the 
time of surgery”.  In this regard, a simple, portable and rapid intra-operative 
diagnostic kit which could diagnose malignant ovarian tumours in the operation 
was developed.   
 
5.2 Pre-operative diagnostic and prognostic significance 
of haptoglobin in sera of patients with epithelial ovarian 
tumours 
 
Aim.  The development of non-invasive diagnostic and prognostic strategies for 
ovarian cancer detection has been the Holy Grail for several decades.  The 
commonly employed techniques involve serum marker measurement using 
ELISA which is a reliable, sensitive and widely acceptable method for the 
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identification and monitoring of cancer.  In this study, the clinical significance of 
serum haptoglobin levels was evaluated in EOC.  
 
Investigation.  Blood samples from benign and malignant ovarian tumours were 
collected during surgery without intra-operative spillage (section 2.2.1.2).  The 
total haptoglobin levels were quantified using the sandwich ELISA technique with 
two polyclonal antibodies against this protein (section 2.2.12).  The diagnostic 
potential of serum haptoglobin was evaluated by the ROC curve analysis and 
compared to the conventional biomarker CA-125.  This analysis represents the 
standard procedure in evaluating the performance of putative diagnostic 
biomarkers (Shapiro, 1999).   
 
Moreover, the overall cancer-specific survival was defined to be from the date of 
blood sampling to the date of death due to malignancy.  Univariate and 
multivariate analyses were performed to estimate the probability of survival and 
the differences in survival rates.  In order to evaluate the acute phase reactions in 
the patients with EOC, serum concentrations of CRP were also determined by 
specific ELISA kits (Chemicon International) in accordance with the 
manufacturer’s instructions.  In addition, thirteen EOC patients who were treated 
with combination therapy consisting of carboplatin (AUC 5) and taxol (175 mg/m2 
body weight) following surgery were included in this study.  Blood samples were 
taken prior to surgery and after six cycles of chemotherapy with a view to assess 
serum haptoglobin concentrations in evaluating therapeutic effectiveness for 
these patients.   
 
Results.  Data from this study indicated that serum haptoglobin concentrations 
were significantly higher in late stage ovarian cancer patients (4.6±0.6 mg/ml) 
when compared with benign ovarian tumour and healthy controls (3.12±0.5 
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mg/ml, 1.5±0.5 mg/ml respectively; P<0.05, P<0.01).  Moreover, a significant 
difference was observed in haptoglobin levels between early stage cancer 
(3.6±0.5 mg/ml) when compared with healthy controls (P<0.01, Figure 5.1).  This 
observation appears to be in agreement with previous reports (Warwas et al., 
1981; Dobryszycka et al., 1999).  
 
Since CRP is a serological marker that can be used to investigate the association 
between inflammation and risk of cancer, the levels of this acute phase reactant 
were measured in our patients.  CRP concentrations were observed to be 
significantly elevated in both early and late stage EOCs (13.9±3.0µg/ml; 
12.7±2.7µg/ml respectively) when compared with normals as well as benign 
tumours (1.28±0.4µg/ml; 2.67±0.9µg/ml, P<0.01).  The distribution of haptoglobin 
and CRP levels in benign, early and late EOC as well as in normal women is 
presented in the boxplot which is bounded by the 75th and 25th percentiles (Figure 
5.1).  Moreover, a significant elevation in serum haptoglobin and CRP levels was 
observed in early and late stage EOC when compared with those from normals 
and benign tumours as illustrated in Figure 5.1.  
 
The diagnostic potential of serum haptoglobin was evaluated using ROC analysis 
and compared to the conventional ovarian cancer marker CA-125.  Area under 
the curve (AUC) was computed to test the inherent capacity of a biomarker for 
discriminating between diseased and non-diseased subjects (Hanley et al., 1982).  
Using this parameter, it was observed that the AUC for haptoglobin and CA-125 
was 0.741 and 0.758 respectively (Figure 5.2).  The relatively low AUC for 










Figure 5.1     Concentration distribution of serum haptoglobin and CRP  
Serum haptoglobin and CRP concentrations obtained from 66 patients with EOC, 
60 benign ovarian tumours and 10 healthy controls.  Serum levels of haptoglobin 
and CRP were significantly higher in patients with early and/or late stage of 






Figure 5.2     Evaluation of diagnostic potential of haptoglobin using ROC 
curve analysis 
The diagnostic potential of serum haptoglobin from epithelial ovarian tumours 
was evaluated using ROC curve analysis and compared to the conventional 











The association of haptoglobin levels with clinicopathologic variables including 
age, FIGO stage, tumour type, Grade and pathology is given in Table 5.1.  In this 
study, we have used a cut-off value of 4 mg/ml of concentration for haptoglobin 
since this value corresponds to a better diagnostic accuracy in our series of 
patients.  A cut-off value of 4 mg/ml minimises the false positive and negative 
rates in the differentiation of normal and benign cases from the malignant ovarian 
tumours.  As indicated in the ROC curve, the largest value of the sum of 
sensitivity and specificity could be achieved by adding a series of sensitivity and 
specificity at different cut off coordinate points at 4.0mg/ml (Figure 5.3).  
Accordingly, following this criteria, the ovarian cancer patients were divided into 
two groups based on haptoglobin concentrations.  The tumour staging/grading 
according to the International Federation of Gynecology and Obstetrics (FIGO) 
classification is known to be the most important prognostic factor for ovarian 
cancer.  In this study, we noted a significant association between the serum 
haptoglobin level and FIGO stage at diagnosis (P<0.05, Table 5.1).  However, no 
significant association was observed between the serum haptoglobin level and 
age, histology, or tumour grade at diagnosis (P>0.05).   
 
In addition, tumour haptoglobin expression levels were also examined for the 
overall survival rates using the Kaplan-Meier analysis with log-rank statistics for 
determining significance.  The mean follow-up time for the entire cohort of 66 
patients was 37.7 months (range, 4-100 months).  Using the 4 mg/ml haptoglobin 
concentration as a cut-off point mentioned earlier, the median and mean survival 
time of patients with enhanced serum haptoglobin levels were observed to be 
significantly less when compared to those with low serum levels for this acute 
phase reactant protein (38 versus 79, and 46.7 versus 84.7 months; P = 0.048).  
Kaplan-Meier survival curves generated for high versus low concentrations of 
haptoglobin are illustrated in Figure 5.4.  It is noteworthy that significantly 
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elevated haptoglobin concentrations were associated with poor outcome for 
survival in our women with EOC (Figure 5.4, P = 0.048).  
 
Using the Cox proportional hazards model, multivariate survival analysis of 66 
patients we observed enhanced haptoglobin levels (relative risk, 5.054; 95% 
confidence interval, 1.11-22.98) and tumour stage at diagnosis (relative risk, 5.99; 
95% confidence interval, 1.24-29.0) which appeared to be significant predictor 
variables of overall survival in these patients.  In contrast however, age, tumour 
type, histology and grade at diagnosis were not significantly correlated with 
survival rates as illustrated in Table 5.2.  
 
Haptoglobin levels in sera from 13 patients who were subjected to chemotherapy 
were also measured in order to determine whether chemotherapeutic treatment 
had any effect on the expression of this acute phase reactant protein. Its 
concentration was significantly reduced after six cycles of chemotherapeutic 
treatment (2.2 ±0.8 mg/ml) when compared with those before treatment (5.2±0.7 
mg/ml; P<0.001). This result is in accordance with a previous study (Ahmed et al., 
2005), indicating a role for haptoglobin in monitoring patients undergoing 
chemotherapy.  
 
Interpretation.  It is envisaged that inflammation could serve as a potential 
contributory factor in the development of a variety of cancers.  CRP is a 
serological marker of inflammation that could be utilised to investigate the 
association between inflammation and risk of cancer (Helzlsouer et al., 2006).  It 
is noteworthy that in a similar manner to that of haptoglobin, serum CRP levels 
were also significantly elevated in early and late stage ovarian cancer.  Moreover, 
a significant correlation existed between CRP and haptoglobin levels (r2=0.22, 
P<0.001; Figure 5.5) indicating that inflammation occurs in the early and late 
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stages of ovarian cancer development.  Based on this observation, it seems 
plausible to suggest that CRP could serve as an adjunct to haptoglobin in the 
evaluation of ovarian cancers.  Since haptoglobin is among the most abundant 
glycoprotein secreted by the liver and circulating hepatic haptoglobin accounts for 
the major elevation of this protein in the serum of ovarian cancer patients (Ahmed 
et al., 2005),  it is reasonable to suggest that enhanced hepatic synthesis of this 
protein occurs due to an acute phase response in these ovarian cancer patients.  
 
Haptoglobin levels in sera from 13 patients who were subjected to chemotherapy 
were also measured in order to determine whether chemotherapeutic treatment 
had any effect on the expression of this acute phase reactant protein.  Its 
concentration was significantly reduced after six cycles of chemotherapeutic 
treatment (2.2 ±0.8 mg/ml) when compared with those before treatment (5.2±0.7 
mg/ml; P<0.001).  This result is in accordance with a previous study (Ahmed et 
al., 2005), indicating a role for haptoglobin in monitoring patients undergoing 
chemotherapy.  
 
Using the immunohistochemical technique described earlier (section 4.4.4) strong 
intensity of staining for haptoglobin was observed in the ovarian cancer cells and 
blood vessels suggesting that other extrahepatic sources may also contribute to 
its elevation in the blood of EOC patients.  Moreover, the enhanced haptoglobin 
concentrations in cyst fluid may be reflective of its biosynthesis from malignant 
ovarian tumours.  It has been reported that a substantial portion of the 
synthesised haptoglobin occurs as a single polypeptide precursor (Misumi et al, 
1983).  It is also noteworthy that circulating levels of this acute phase reactant 
could be the result of increased intrahepatic synthesis. 
 
 165
Our retrospective analysis therefore provides evidence that circulating 
haptoglobin levels could be a useful independent prognostic indicator in patients 
with EOC.  Overall, our data suggests that lower haptoglobin levels in pre-
operative sera are associated with better survival outcome.   
 
Table 5.1     Association of serum haptoglobin levels with clinicopathologic 
variables  
 
Variable  n       Haptoglobin concentration P* 
                                                   Low (<4mg/ml)   High (>4mg/ml)    
Age  
 <52  31  13  18  0.691  
 ≥52  35  13  22   
Tumour type  
 Benign  60  41  19  <0.001  
 Malignant 66  26  40   
FIGO stage 
 Early (I/II) 19  11  8  <0.05   
 Late (III/IV) 47  15  32  
Histology 
 Serous  27  11  16  0.254 
 Mucinous 20  8  12 
 Endometrioid 11  5  6 
 Clear cell 6  0  6 
 No record 2 
Differentiation 
 Well  24  8  16  0.918  
 Moderate 14  5  9 
 Poor  23  9  14 
 No record 5  




Table 5.2     Multivariate survival analysis by Cox regression 
 
 
Variables   Hazard ratio (95% CI)   P  
Age    1.032 (0.357—2.981)   0.954 
FIGO stage   5.99   (1.237—29.005)  0.026 
Histology   0.839 (0.522—1.346)  0.466 
Grade    1.162 (0.457—3.035)   0.896 







Figure 5.3     Determining suitable serum haptoglobin cut-off value for 
prognosis analysis using ROC curves analysis 
Using different cut off coordinate points a series of sensitivity and specificity 
would be generated.  It was noted that at the point of 4.0mg/ml the greatest value 
of the sum of sensitivity and specificity could be achieved. 
 
 
    
 
Figure 5.4     Univariate survival analysis of EOCs  
Overall survival of 66 patients with EOC in relation to haptoglobin level was 
indicated.  A cut-off value of 4 mg/ml was used to divide the patient into two 










Figure 5.5     Single regression analysis between haptoglobin and CRP  
Haptoglobin was significantly correlated to C-reactive protein (P <0.001).  The 
central straight line corresponds to the best-fit linear regression line.  The two 
curved lines surrounding the best-fit line define the 95% confidence interval of the 
regression line.  The graphs also show the prediction interval (the curves defining 













5.3 Development of a novel intra-operative diagnostic kit 
for detection of ovarian malignancy using cyst fluid 
 
Aim.  Regular pelvic examinations and CA-125 biomarker measurements 
followed by radiological diagnosis on an individualised basis have been the 
current practice for detection of ovarian cancer.  However, the impact of 
screening on mortality from ovarian cancer remains to be a daunting challenge.  
In contrast, the impact of accurate staging and appropriate surgical intervention 
for all stages of EOC on patient survival is clear since the mortality risk is twice 
for patients who do not undergo surgery (Engelen et al., 2006).  
 
The study by Engelen et al (2006) showed that inappropriate surgical 
management of the patient adversely affects the patient’s chances of survival. 
Appropriate surgical management is largely dependent on the intra-operative 
diagnosis of benignity or malignancy of the ovarian cyst, making correct intra-
operative diagnosis critical to proper patient management.  Moreover, an ovarian 
malignancy is unexpectedly encountered in up to one percent of cases 
undergoing laparoscopy (Wenzl et al., 1996; Muzii et al., 2005).  Neither an 
elevated serum CA-125 level, nor the presence of an ovarian cyst identified by 
clinical examination and ultrasonography, accurately predicts the occurrence of 
an ovarian malignancy (van Nagell et al., 2000).  Frozen section of ovarian cyst 
tissue is the currently used method for intra-operative diagnosis, but it is 
expensive and resource intensive and requires the services of a trained 
pathologist or gynaecologic oncologist.  Frozen section diagnosis of ovarian 
tumours has also been reported to be most problematic in terms of its accuracy 
(Boriboonhirunsarn et al., 2004).  In addition, such services are not available in 
many developing countries.  A better alternative to this method would clearly be 
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very useful, and this was the rationale for developing this intra-operative 
diagnostic kit.  
 
We envisaged the possibility of using biological materials obtained at surgery to 
identify specific protein biomarkers which could be utilised in the diagnosis of 
EOC for subsequent triage of frozen section.  These may include tissue, ascitic 
and ovarian cyst fluids.  It is noteworthy that the cyst fluid represents a suitable, 
evenly diluted and consistent source of intra-operative biological material which 
could be readily examined in the operating theatre for the presence of biomarkers 
of interest.  Using ovarian cyst fluid it has been observed that differences in 
hormone levels, such as LH and FSH  (Chudecka-Glaz et al., 2004; Rzepka-
Gorska et al., 2004), potential tumour markers including tissue polypeptide 
specific antigen and soluble interleukin-2 receptor-alpha (Sedlaczek et al., 2002) 
and differences in proteomic profiles occurred between benign and malignant 
ovarian cysts (Ott et al., 2003).  However, none of the above mentioned markers 
could be utilised clinically to discriminate between benign and malignant ovarian 
cysts. 
 
Data from this study indicated that haptoglobin levels were significantly lower in 
benign when compared with borderline, early and late stage EOCs (P<0.01).  We 
hypothesised that a rapid intra-operative detection assay could be developed 
using this protein as an adjunct to the frozen section technique for identification of 
malignancy.    
 
Investigation.  A systematic strategy to identify unique biomarkers within the cyst 
fluid was employed resulting in the identification and characterisation of 
haptoglobin in cyst fluid from EOC as described earlier (chapters 3 and 4).  
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Workflow of preliminary studies 
  
 
To determine the effectiveness of an accurate and rapid method for detection of 
malignancy in ovarian tumours, the cyst fluid haptoglobin binding assay was 
conducted in a low pH environment using a commercial PHASE RANGE 
haptoglobin assay kit (Tridelta Development Ltd; section 2.2.13).  This semi-
quantitative method permits the determination of this acute phase reactant readily 
in the operating theatre.  Pearson’s correlation analysis was also performed to 
evaluate the correlation between the levels of haptoglobin between the PHASE 
RANGE assay and the ELISA technique.  The diagnostic accuracy of this 
biomolecule together with other clinicopathologic variables such as ultrasound 
and CA-125 was evaluated using the ROC curve analysis to differentiate 
malignant from benign ovarian tumours.  
 
Using this strategy, a diagnostic device was developed for the rapid intra-
operative haptoglobin detection.  In the first phase of this study we designed a 
point-of-care device which could contain the dye binding assay reagents within it.  
This device must fulfil the following criteria: it must be easy to perform by the 
SELDI-TOF protein profiling of cyst fluid samples from benign and malignant ovarian cysts
Gel electrophoresis to identify differentially expressed proteins 
Mass spectrometry identification of differentially expressed protein 
Western blotting and SELDI-immunocapture to confirm identity of protein 
Development of sandwich ELISA method for haptoglobin assay 
Testing commercial dye assay method for haptoglobin 
Testing efficacy of the assay in stored cyst fluid samples 
Development of a diagnostic kit for rapid intra-operative haptoglobin 
detection 













nurse in the operating theatre; it must contain the appropriate amount of the 
reagents used in the dye binding assay and finally it must be small, inexpensive 
and readily portable unit which can be stored conveniently in the refrigerator. 
 
Results and interpretation.  The colour reactions obtained at 5-minute time point 
for the PHASE RANGE assays using cyst fluid from benign and malignant 
ovarian tumours are illustrated in Figure 5.6.  As indicated in Figure 5.7, a good 
correlation was observed between the PHASE RANGE haptoglobin assay colour 
intensity and levels of haptoglogin measured by the ELISA technique, with a 
Pearson’s correlation coefficient r square value of 0.79.  Measurements of cyst 
fluid haptoglobin by the 5-minute colour reaction using the PHASE RANGE assay 
would be potentially useful in the differentiation of benign from EOCs.   
 
Comparison of frozen section with final pathological diagnosis was made and the 
misdiagnosed cases were highlighted in Table 5.3.  It was envisaged that this 
rapid assay could accurately detect the two misdiagnosed borderline tumours as 
indicated in Table 5.3.  ROC curves for haptolgobin, ultrasound and CA-125 were 
then conducted to examine the ability of these parameters to differentiate 
malignant from benign ovarian tumours.  It showed that haptoglobin had an 
enhanced predictive performance when combined with CA-125 and ultrasound 
parameters giving an AUC of 0.946 with a 95% confidence interval of 0.900-
0.992 (Figure 5.8).  Moreover, a combination of the three parameters in our 
patients was observed to have a sensitivity of 88.4%, a specificity of 91.5%, a 
PPV of 90.5%, and a NPV of 89.6% in detection of ovarian cancers.  
 
This rapid assay method could therefore be used in established oncology centres 
to triage for frozen section or trigger appropriate intraoperative subspecialist 






Figure 5.6     Representative picture of the haptoglobin dye binding assay  
showing standards, benign ovarian tumours, early and late stage ovarian 
cancer samples   
A1: blank; A2-A6: Standards (0, 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml); C1-
C10: benign ovarian tumours; E1-E7: early and borderline ovarian tumour; G1-
G10: late stage ovarian cancer.  
 
 
Table 5.3     Cases with disagreement between frozen section and final 
paraffin diagnosis  
 
ID Pathological diagnosis Frozen section Colour reaction 
59 Mucinous borderline tumour Mucinous cystadenoma Positive 
128 Mucinous adenocarcinoma Mucinous borderline Negative 
133 Serous adenocarcinoma Borderline Positive 
161 Serous adenocarcinoma Serous borderline Negative 
166 Serous adenocarcinoma  Serous borderline Negative 
182 Mucinous borderline Mucinous cystic tumour Positive 
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Haptoglobin level = -0.02 + 0.16 * Haptoglobin level (ELISA) 
 
Figure 5.7     Single regression analysis between haptoglobin levels 
measured by ELISA and the PHASE RANGE assays 
Haptoglobin levels from ELISA was significantly correlated with that of the 



















Source of the Curve
ROC Curve
 
Figure 5.8     ROC curve of ultrasound, CA-125 and haptoglobin assay 
Haptoglobin enhanced the diagnostic value of ultrasound and CA-125 (AUC 
0.946, 95% CI 0.900-0.992).  Combination of all three parameters gave a 
sensitivity of 88.4%, a specificity of 91.5%, a PPV of 90.5%, and a NPV of 89.6% 
for ovarian malignancy.  
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Development of diagnostic kit: (Confidential) 
A prototype of the diagnostic kit which applies the principle of Phase Range 
Haptoglobin assay into real time testing of intra-operative levels of haptoglobin in 
cyst fluid has been developed.  As indicated in Figure 5.9, the device comprises 
an assembly of two parts: the top portion having four extruding, reagent-
containing plastic bubbles and the bottom part having reagent-passage channels 
engraved on a plastic base.  The technical details of this diagnostic kit are as 
follows: 
a) 100 μl of diluted haemoglobin solution, 50 μl of substrate and 90 μl of 
chromogen from a commercial PHASE RANGE Haptoglobin assay kit (Tridelta 
Development Ltd) will be injected into bubbles B2, B3 and B4 from the injection 
holes on the base, sealed properly and stored at 4 °C.  
b) In the operating theatre, the nurse will press bubble B2 to allow diluted 
haemoglobin solution to flow into the empty bubble B1, apply 7.5 μl of cyst fluid 
from patient into bubble B1 through the application hole, press bubble B3 to 
release substrate into chromogen in bubble B4, and finally press bubble B4 to 
allow substrate-chromogen mixture flowing into bubble B1.  This will be followed 
by incubation for 5 min at room temperature.  
c) Haptoglobin present in the cyst fluid will bind with haemoglobin and at low 
pH the peroxidase activity of the bound haemoglobin will be preserved.  Addition 
substrate and chromogen will result in a colorimetric reaction which can be 
determined either visually or by the ELISA reader at 630 nm.  Preservation of the 
peroxidase activity of haemoglobin is directly proportional to the amount of 
haptoglobin present in the cyst fluid.  
d) The blue coloration which develops after 5 min will be recorded and 
compared with a standard cut-off colour scheme to differentiate malignant from 

































In this chapter, clinical application of the identified protein biomarker haptoglobin 
from SELDI-TOF and 2-DE based methods was validated in sera and cyst fluid 
from EOCs.  It was observed that levels of haptoglobin were significantly higher 
in malignant when compared with benign ovarian tumours.  Prognostic analysis 
using uni- and multivariate analyses indicated that circulating haptoglobin levels 
could be a useful independent prognostic indicator in patients presenting with 
EOCs.  Moreover, a haptoglobin assay was also evaluated for its usefulness to 
triage malignant from benign ovarian cysts.  It is envisaged that this newly 
developed PHASE RANGE assay device could complement the frozen section 
technique and could therefore be used in established oncology centres to triage 
for frozen section or trigger appropriate intraoperative subspecialist consult and 
ensure best practice care.  More studies are in progress to conduct multicentre 
trials in South East Asia with a view to establish a potential role for haptoglobin in 













Chapter 6: General Discussion 
 
Investigations on proteomics-based identification of biomarkers were conducted 
in ovarian cyst fluid.  This fluid represents an ideal source for biomarkers in that it 
is constantly in contact with the epithelial cells forming the cyst wall, so the 
protein composition changes happening in ovarian epithelial cells as they 
become malignant will be reflected in the cyst fluid in the undiluted form.  
Therefore, cyst fluid was regarded as a suitable and consistent source of 
biomarker identification as well as intra-operative biological material that could be 
readily examined in the operating theatre.   
 
We hypothesised that a comprehensive analysis of cyst fluid proteins using a 
combination of high throughput technologies including SELDI-TOF and 2-DE 
might provide a sequence-based network for the mining of potential polypeptides 
which could serve as diagnostic and prognostic targets.   
 
Based on this premise, the main objective of this work is to identify differentially 
expressed protein markers in the cyst fluid from patients presenting with benign 
and malignant ovarian tumours.  The diagnostic and/or prognostic potential of 
these biomarkers was further evaluated in the clinical setting.  As detailed in 
chapters 3 and 4, the possibility of identification of differentially expressed 
proteins in cyst fluid using SELDI-TOF and 2-DE based methods was examined.  
The diagnostic and prognostic implications of identified biomarkers within the field 







The aim of this thesis was to identify potential diagnostic and/or prognostic 
protein markers using the cyst fluid as a model.  A combination of two 
proteomics-based methods SELDI-TOF and 2-DE were utilised in this study in 
searching complimentary biomarkers.  I hypothesised that 1) differential disease 
related proteins may be present in cyst fluid from benign and malignant ovarian 
tumours and could be identified using a combination of SELDI-TOF, 2-DE and 
conventional immunological techniques; 2) Similar protein patterns may also be 
observed in sera from benign and malignant ovarian tumours and they may have 
potential roles as diagnostic and/or prognostic markers; 3) An intra-operative 
diagnostic assay may be developed using cyst fluid to enable the differentiation 
between malignant and benign ovarian tumours at the time of surgery. 
 
6.2 Research findings 
 
The expression profile of proteins in cyst fluid from patients presenting with 
benign and malignant epithelial ovarian tumours was examined using different 
proteomics-based technologies including SELDI-TOF and 2-DE.  As indicated in 
chapter 3, a protein peak with molecular weight around 17.5 kDa was present 
with higher intensities in EOCs when compared with controls using SELDI-TOF 
(section 3.2).  This protein was purified using SDS-PAGE and identified as 
haptoglobin-α2 subunit by MALDI TOF-TOF/MS (section 3.3).  Using 2-DE as a 
complementary method, the differentially expressed protein spots were 
highlighted and identified as two acute phase proteins namely, haptoglobin and 
ceruloplasmin (section 4.3).  Further validation of these putative biomarkers using 
variable immunologic techniques including Western blotting, 
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immunohistochemistry and ELISA confirmed our findings that differential 
expression of haptoglobin occurred in ovarian cancer (section 4.4).   
 
Our data therefore consistently demonstrated that haptoglobin was 
overexpressed in malignant ovarian tumour samples including cyst fluid, tissue 
and serum samples.  Serum haptoglobin levels were significantly elevated in 
ovarian cancer patients with advanced-stage disease or poor performance status 
(section 5.2).  Moreover, a simple and rapid intra-operative diagnostic kit using 
cyst fluid was developed for detection of patients presenting with malignant 
ovarian tumours (section 5.3).  A preliminary study using this PHASE RANGE 
assay on 90 ovarian tumour samples indicated an effective diagnostic power 
capable of differentiating malignant from benign ovarian tumours.  It showed that 
haptoglobin had an enhanced predictive performance when combined with CA-
125 and ultrasound parameters giving 88.4% sensitivity and 91.5% specificity 
with a PPV of 90.5% and NPV of 89.6% for EOCs.  
 
The molecular mechanisms underlying carcinogenesis and metastasis of EOCs 
remain obscure at present.  It is noteworthy that the two molecules identified in 
this study could provide us knowledge to better understand the pathological 
processes involved in the progression of EOCs.  Data from this study have 
demonstrated for the first time the presence of haptoglobin which has the 
potential to serve as a marker in cyst fluid from patients presenting with EOC.  
The basic haptoglobin molecule is a tetrameric protein with two α/β dimers.  The 
β chains are identical in all haptoglobin types and the polymorphisms of 
haptoglobin arise from differences in the α chains (Gerner-Smidt et al., 1978).  
Although the biological functions of haptoglobin are not well understood, recent 
data suggest that this glycoprotein possesses specific physiological activity 
distinct from its role as a haemoglobin scavenger following haemolysis, thereby 
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preventing iron loss, renal damage and tissue destruction (Wassell, 2000).  
Haptoglobin is also a potent antioxidant which protects low density lipoprotein 
from copper induced oxidation thereby having a role in cellular resistance to 
oxidative stress (Tseng et al., 2004b).  In addition, this acute phase protein has 
been shown to be involved in the regulation of epidermal cell transformation (Xie 
et al., 2000), immune suppression in cancer(Oh et al., 1987; Oh et al., 1990) and 
as an angiogenic factor in systemic vasculitis (Cid et al 1993).  Moreover, 
haptoglobin was reported to be a natural inhibitor of collagen degradation and 
locally expressed by fibroblasts in the arterial wall (Smeets et al., 2002).  This 
glycoprotein could therefore serve an important role in cell migration and arterial 
restructuring.  This collagen turnover is an important feature in many 
physiological processes like growth and wound healing and enhanced collagen 
degradation is causally related to severe tissue destruction and malfunction as 
evidenced by known pathophysiological processes such as arthritis and cancer 
(Westermarck et al., 1999).  The importance of haptoglobin in extracellular matrix 
degradation and cell migration suggests a role for this polypeptide in the 
aetiology of cancer.   
 
Elevation of haptoglobin in sera and ascites of ovarian cancer have also been 
reported in previous studies using the ELISA method (Dobryszycka et al., 1991; 
Elg et al., 1993).  Recently, proteomics-based approaches have been utilised to 
discover and identify novel proteins as potential diagnostic biomarkers.  Ye and 
coworkers have shown that haptoglobin α-subunit as potential serum biomarker 
in ovarian cancer with a sensitivity of 95% and a specificity of 91% combined with 
CA-125 (Ye et al., 2003).  Another recent study found that haptoglobin-1 
precursor as a novel circulating biomarker of ovarian cancer (Ahmed et al., 2004).  
Nevertheless, in this study, we provide the evidence that pre-operative serum 
levels of haptoglobin could serve as an independent prognostic factor in patients 
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presenting with EOC (Zhao et al., 2007).  We also developed a rapid intra-
operative diagnostic kit, a device that could complement the frozen section 
technique and differentiate malignant from benign ovarian tumours in operating 
theatre (section 5.3).   
 
In addition to haptoglobin, ceruloplamsin was also noted to be differentially 
expressed in ovarian cyst fluid and tissues from EOCs using semi-quantitative 
analysis.  However, in this study, no significant difference of cyst fluid 
ceruloplasmin concentrations was discernible between early, late stage ovarian 
cancers and in benign ovarian tumours using ELISA method (section 4.4.5), 
which limited its usage as a useful biomarker in clinical settings.  
 
6.3 Significance of this study 
 
Prognostic significance of circulating haptoglobin levels 
In this study we demonstrated for the first time the differential expression and 
secretion of haptoglobin and ceruloplasmin in cyst fluid from EOCs using 
complementary proteomics-based methods.  Our retrospective analysis 
demonstrated that circulating haptoglobin levels therefore could be a useful 
independent prognostic indicator in patients with EOC.  It is noteworthy that 
significantly elevated haptoglobin concentrations were associated with poor 
outcome for survival in our patients.  Early recognition of a profile with high 
haptoglobin levels could therefore identify patients with an increased risk of poor 





Intra-operative diagnosis of EOC with a diagnostic kit using cyst fluid 
The initial evaluation using a simple and rapid intra-operative diagnostic kit on 90 
ovarian tumour samples indicated an effective diagnostic power capable of 
differentiating malignant from benign ovarian tumours based on differential cyst 
fluid haptoglobin levels.  This kit is both easy for nurses in the operating theatre 
to use, and also give the colorimetric result that can be easily interpreted.  We 
have also designed a portable device (Figure 5.9) which could be safely stored 
and easily transported to other countries so that this kit could be applied in other 
hospitals upon satisfactory results from further validation studies.  This finding 
has potential clinical significance in that it could be performed as an adjunct to 
frozen section and be utilised to triage women requiring frozen section or sub-
specialist consult, so that these services are more cost-efficient.   
 
6.4 Limitations and future directions 
 
Identification of low abundant proteins using more sensitive proteomics based 
methods  
Cellular proteins that are overexpressed by the malignant cells and released into 
the bloodstream during cancer development are ideal biomarkers and they can 
be used alone or in combination with other established tumour markers for 
diagnosis and prognosis of cancers.  These markers are usually present in serum 
at relatively low concentrations of 1–10 ng/ml in the normal state (Erika, 2004).  
In this study, however, we are not able to identify such low abundant biomarkers 
in serum other than haptoglobin.  It is possible to speculate that low abundance 
proteins may be diluted or degraded after being released into the circulation.  In 
this regard, growth factors and cytokines are a group of molecules and have 
been shown to play important roles in the development and growth of various 
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kinds of cancers (Aaronson, 1991; Cross et al., 1991) and it has been proposed 
that EOC may be a cytokine propelled disease (Malik et al., 1991).  Our 
preliminary results have revealed that a novel proinflammatory cytokine—
Interleukin 22 (IL-22) was differentially expressed in benign and malignant 
ovarian tumours (Figure 6.1).  A more detailed study of the various cytokines and 
growth factors could therefore provide a panel of sensitive and specific candidate 
protein markers for EOCs.  More sensitive technologies such as 2D-DIGE, ICAT, 
iTRAQ and antibody-based protein arrays should therefore be employed to detect 
minute quantities of such proteins from the patient proteome. Moreover, pooled-
sample testing has proved to be an effective strategy to increase the power and 
reduce the cost of monitoring populations for low-prevalence diseases (Ogata et 
al., 2007). This strategy may provide stability in protein detection and also reduce 
inter-sample variations.   
 
Validation of clinical significance of haptoglobin in a multi-centre study 
It is envisaged that several criteria have to be met before biomarkers can be 
utilised for clinical practice, such as preclinical evaluation, assay development 
and clinical validation, retrospective analysis and prospective screening (Pepe et 
al., 2001; Barker, 2003).   Based on these preliminary findings, validation of the 
results are therefore necessary for conducting prospective, well-controlled clinical 
trials with a larger sample size and stringent standards for all procedures.  
Considering the varied protocols employed by the different research centres, 
more comprehensive standardisation procedures are required in order to achieve 
reliable and reproducible results.  This problem could be circumvented by multi-
institutional teamwork, through participation in large collaborative oncology 
groups, which may advance both analytical and clinical validation by creating 
standards and experimental designs in a bid to use the limited patient samples 
and resources most effectively (Ludwig et al., 2005).  The gynaecological 
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oncology centres in the Asian countries have indicated their interest to participate 
in this multi-centre collaborative effort.  The initiation of the Ovarian Cancer 
Research Group or Consortium in our centre will further enhance our efforts to 
contribute towards biomarker discovery in ovarian cancer research.  This 
collaborative effort is the first of its kind in Asia and efforts are being made initially 
to include centres from Indonesia and Malaysia where there is an increasing 




Figure 6.1     Differential expression of IL-22 in ovarian tumour tissue 
IL-22 is highly expressed in invasive ovarian cancer (A) compared with benign 
ovarian tumour (C) using immunofluorescent method, corresponding H & E 








6.5 Conclusion  
 
The main aim of this study is to identify differentially expressed biomarkers in cyst 
fluids from benign and malignant ovarian tumours.  In order to facilitate the 
biomarker identification, two complementary proteomics based methods including 
SELDI-TOF and 2-DE were utilised.  Data from this study provides strong 
evidence that the differential disease related protein haptoglobin was present in 
cyst fluid and serum from ovarian tumour patients with diagnostic and prognostic 
potentials, which could be explored using combination of proteomics-based 
methods.  Circulating haptoglobin identified could have potential significance as a 
prognostic marker for EOCs.  Moreover, the diagnostic kit developed in this study 
based on differential cyst fluid haptoglobin levels might be used intra-operatively 
to differentiate malignant from benign ovarian tumours so as to triage for frozen 
section or trigger appropriate intraoperative subspecialist consult and ensure best 
practice care.  Thus, this thesis suggests that proteomics-based identified 
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